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Abstract 
Cognitive deficits are a core disabling feature of schizophrenia, yet remain inadequately treated 
by current pharmacological or behavioural therapies. The non-competitive NMDAR antagonist 
ketamine can pharmacologically induce cognitive deficits in both rodents and humans, 
presenting a novel translational approach for examining mechanisms underlying cognitive 
deficits associated with schizophrenia (CDS). Nicotine can improve working memory in rodents 
and in smokers with schizophrenia where heavy tobacco use may reflect self-medication to 
ameliorate CDS. The roles of the two main subtypes of nAChRs, the α7 and α4β2, in mediating 
cognitive improvement have yet to be determined. Cohorts of male hooded-Lister rats were 
trained in the Odour Span Task (OST) until demonstrating asymptotic performance and then 
exposed to a sub-anaesthetic dose of ketamine or vehicle daily for 5 consecutive days. This sub-
chronic regimen produced a replicable, dose-dependent impairment in OST performance that 
was not restored following anti-psychotic treatment. Nicotine, α7 and α4β2 nAChR-selective 
agonists improved performance in ketamine-treated animals, with nicotine and one α4β2 agonist 
also improving the performance of control subjects. These data indicate the α4β2 nAChR as the 
main receptor subtype mediating the effect of nicotine on the OST in control animals, with a 
lesser role for the α7 nAChR. The α7 nAChR however was shown to have a role in improving 
the performance of ketamine-treated animals, as demonstrated by the enhancing effect of 
allosteric modulator PNU-120596 and Compound T on OST performance; an effect that was 
blocked by the α7 nAChR antagonist methyllycaconitine. When administered locally into the 
medial prefrontal cortex (mPFC), nicotine improved, and muscimol impaired OST performance; 
suggesting the mPFC as the neural site of action in the OST. Complementary data using an in-
vitro electrophysiological gamma frequency model of network oscillations indicated an 
enhancing effect of nicotine on normal gamma frequency oscillations in the rat mPFC and is 
proposed as a potential mechanism behind the behavioural data. Collectively, these results 
provide further impetus for targeting nAChRs in the treatment of CDS.  
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Chapter 1 
General Introduction 
 2 
1.1 An overview of the Schizophrenia Syndrome 
Schizophrenia is a debilitating disorder affecting approximately 1% of the population. It is 
a multi-faceted disease with wide ranging symptoms that comprise positive (auditory 
hallucinations, disorganised and deluded thoughts), negative (flattening of affect, apathy 
and anhedonia), and cognitive (attention and memory) (Diagram adapted from American 
Psychiatric Association, 2000). Significant and disruptive to everyday living, these deficits 
result in many patients being unable to cope in the community or hold down a long-term 
job, despite available anti-psychotic medication. This has an impact socially and 
economically for patient and wider community alike; the cognitive problems in particular 
demonstrate a very serious unmet clinical need. The real problem is that schizophrenia is 
not one disorder but rather an umbrella term for a whole syndrome of disorders that rarely 
present in exactly the same way in any two patients. This means that the task of finding 
safe, efficacious medication to treat all symptoms in all patients is a challenge akin to 
finding the proverbial needle in the largest of haystacks. 
 
1.1.1 Clinical symptoms and diagnosis 
In the late 19
th
 and early 20
th
 century, German psychiatrist Emil Kraepelin challenged the 
traditional methods of diagnosis for mental illnesses (For review see Kendler and 
Jablensky, 2010). He called for a novel classification according to a common pattern of 
symptoms; a syndrome, rather than diagnosis through similarities in major symptoms 
(Kraepelin, 1893, 1919). Kraepelin recognised that elements of mental illness such as 
mania, depression or cognitive deficits could be present in various different psychiatric 
disorders, but that it was the pattern in which they occur that allows their distinction into 
separate syndromes (Kraepelin, 1893, 1919). Through this method, Kraepelin divided the 
varied classes of functional psychoses into two groups. The first, ‘manic depressive 
insanity’, was described as a long-term disorder in which the patient had many episodes of 
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illness but was also fully functional for significant periods of time (Kraepelin, 1893, 1919). 
The second, ‘dementia praecox’ was a term initially coined by Morel, and in contrast 
included hebephrenia, as described by Hecker in 1971, catatonia, as described by 
Kahlbaum, and dementia paranoids. These classifications formed the early diagnostic 
criteria for schizophrenia and indeed the basis of modern psychiatric diagnosis as we know 
it today (Hecker, 1871; Kahlbaum, 1863; Kraepelin, 1893, 1919; Morel, 1860). In contrast 
to Kraepelin, who very much believed psychoses to be an organic disease of the brain, 
Bleuler in 1911 described ‘the schizophrenias’ in psychological terms as much as in 
neuropathological terms. He coined the now widely used term ‘schizophrenia’, meaning 
‘split mind’, to describe loosened associations between various brain functions leading to 
impaired cognitive, emotional and volitional processes (Bleuler, 1911, 1950). His 
diagnostic criteria focused upon negative symptoms such as thought disorder, autism and 
ambivalence, and to some extent ignored the positive criteria set out by Kraepelin which 
included hallucinations and delusions. When translated into English in 1950, Bleuler’s 
ideas significantly influenced the first two editions of the Diagnostic and Statistical Manual 
(DSMI and DSMII) (Andreasen, 1989). This changed with the development of DSMIII 
with the introduction of Kurt Schneiders’ ‘first rank symptoms’ (table 1.1). He outlined 
specific symptoms such as the idea that thoughts were being broadcast or inserted from a 
third party. He proposed that the nature of such symptoms offered a direct, accurate 
diagnosis of schizophrenia because they were unique to the disorder. This has now been 
shown to be incorrect as many of the described symptoms are present in other 
neuropsychiatric disorders. Despite this, Schneiderian symptoms have formed the core of 
diagnostic criteria from the DSMIII to present day (table 1.2). Until clear knowledge of 
what causes schizophrenia or any reliable biomarkers are available, diagnosis will remain a 
significant challenge. 
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1.1.2  Causes of schizophrenia: Genetic or environmental? 
The spectrum of disorders that make up the schizophrenia syndrome are thought to be the 
result of both genetic and environmental factors. The neurodevelopmental hypothesis is the 
predominant theory explaining the cause of schizophrenia. This hypothesis stipulates that a 
person with a genetic predisposition to schizophrenia who is additionally exposed to 
environmental insults in-utero or during early childhood may have neurodevelopmental 
errors. This may result in altered neuronal development and expression of a schizophrenic 
phenotype (Fatemi and Folsom, 2009).   
Support for this comes from a longitudinal Finnish adoption study by Wynne et al (2006) 
where both mothers with a psychiatric diagnosis and control mothers, who had given up a 
child for adoption, were recruited. The respective adoptees and their adoptive families were 
also recruited. The psychiatric history of the biological mother was taken as a measure of 
genetic risk for development of a schizophrenia spectrum disorder. Based upon an 
independent psychiatric assessment, high risk adoptees were further split between risk of a 
broad schizophrenia spectrum disorder diagnosis and a narrow diagnosis of schizophrenia. 
Adoptive families were observed and assessed for several days using the Global Family 
Rating scales. Adoptees were followed up at 12 and 21 years for evidence of psychiatric 
disorder development. It emerged that adoptees that had low genetic risk and a normal 
family environment were least likely to develop a schizophrenia spectrum disorder (2.9%). 
Less likely was the discovery that, when either reared in a severely deviant environment or 
categorized as having high genetic risk, adoptees were only moderately more likely to 
develop a psychiatric disorder (9.3% and 6.4% respectively). However, when a high genetic 
risk was combined with a deviant environment this risk greatly increased to 40% (Wynne et 
al, 2006).  
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Table 1.1: Schneider’s first rank symptoms  (Lieberman, 2006) 
Symptoms 
Three special forms of auditory 
hallucinations 
Description 
1. Hearing one’s thoughts spoken aloud. 
2. Hearing voices referring to 
himself/herself, made in the third person. 
3. Auditory hallucinations in the form of a 
running commentary on one’s activity. 
Thought withdrawal, insertion, and 
interruption 
 
Thought broadcasting One’s thoughts are broadcast to others. 
Somatic hallucinations Somatic passivity, in which the patient is the 
passive and reluctant recipient of externally-
imposed bodily functions. 
Delusional perception A normal perception followed by a 
delusional and highly personalized 
interpretation. 
Ideas of passivity Feelings, impulses, or motor activity are 
experienced, influenced, or controlled by 
external agents. 
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Table 1.2: DSM-IV-TR criteria for schizophrenia (American Psychiatric Association, 
2000) 
Diagnosis of schizophrenia 
A. Two or more of the following symptoms present for one month: 
1. Delusions. 
2. Hallucinations. 
3. Disorganized speech. 
4. Grossly disorganized behaviour or catatonic behaviour. 
5. Negative symptoms (i.e., affective flattening, alogia, avolition). 
B. Decline in social and/or occupational functioning since the onset of the illness. 
C. Continuous signs of illness for at least six months with at least one month of active 
symptoms. 
Criteria for subtypes of schizophrenia 
A. Paranoid type schizophrenia 
1. Characterized by a preoccupation with one or more delusions or frequent 
auditory hallucinations. 
2. Paranoid type schizophrenia is characterized by the absence of prominent 
disorganization of speech, disorganized or catatonic behaviour, and flat or 
inappropriate affect. 
B. Disorganized type schizophrenia 
1. Prominent disorganized speech, disorganized behaviour, and flat or 
inappropriate affect. 
C. Catatonic type schizophrenia is characterized by at least two of the following: 
1. Motoric immobility. 
2. Excessive motor activity. 
3. Extreme negativism or mutism. 
4. Peculiar voluntary movements such as bizarre posturing. 
5. Echolalia or echopraxia. 
D. Undifferentiated type schizophrenia 
1. Meets criteria for schizophrenia, but it cannot be characterized as 
paranoid, disorganized, or catatonic type. 
E. Residual type schizophrenia 
1. Characterized by the absence of prominent delusions, disorganized speech 
and grossly disorganized or catatonic behaviour and continued negative 
symptoms or two or more attenutated positive symptoms. 
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Logically, this would demonstrate an active contribution of environment to the 
development of schizophrenia: In line with this, the scientific community are now 
exploring the idea that what triggers schizophrenia in one individual over another may be 
the result of epigenetic modifications that ‘switch on’ a relevant gene in a susceptible 
individual in response to environmental experiences. This may also explain why it is 
unusual for there to be a 100% concordance rate for diagnosis of schizophrenia in 
monozygotic twins and also why so many candidate genes have been associated with an 
increased risk of schizophrenia (Harrison and Weinberger, 2005; Walsh et al, 2008).  
DISC1 (Disrupted In Schizophrenia 1), located on chromosome 1, is one such gene. 
Expressed in the brain, DISC1 is likely to play a role in neurite outgrowth, neuronal 
migration, synaptogenesis, and glutamatergic neurotransmission. Single nucleotide 
polymorphisms (SNPs) in DISC1 have been associated with increased likelihood of 
developing both schizophrenia and severe affective disorder (Hodgkinson et al, 2004). 
Other susceptibility genes for schizophrenia include neuregulin1 (NRG1) and (ErbB4) 
which, like DISC1, are involved in various aspects of pre- and postnatal neurodevelopment 
(Jaaro-Peled et al, 2009). Another promising candidate gene for schizophrenia 
susceptibility is dystobrevin-binding protein 1 (DTNBP1) which encodes dysbindin, a 
synaptic protein involved in excitatory synaptic neurotransmission (Allen et al, 2008; 
Karlsgodt et al, 2011). The gene encoding reelin is also associated with schizophrenia but 
instead of being involved in direct neurotransmission, this protein is involved in synaptic 
formation and CNS plasticity and is reduced in the brains of patients with schizophrenia. 
Alternatively, catechol-o methyl transferase (COMT) is an enzyme associated with the 
breakdown of catecholamine neurotransmitters including dopamine (Glatt et al, 2003). 
COMT polymorphisms at the Val158Met locus have been associated with an increased risk 
of susceptibility to schizophrenia but there is significant variation in the literature as to 
whether this is a true susceptibility gene (For review see Harrison et al, 2005).  Other genes 
have also been linked to an increased susceptibility to schizophrenia, with the general 
consensus being that is it highly unlikely that we will ever find a single genetic ‘cause’ of 
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schizophrenia. Instead it is likely that research will continue to uncover further 
susceptibility genes which serve to increase the likelihood of developing schizophrenia. 
1.1.3 Treatment 
As a result of the hugely varied nature of the schizophrenia syndrome and the relative 
scarcity of knowledge we have on its cause, treatment is still, as it was in the 1950’s, 
focused on resolving symptoms. The development of chlorpromazine in the 1950’s 
revolutionised the treatment of schizophrenia when doctors noted its calming yet non-
sedating properties. Through blockade of dopamine (DA) D2 receptors, chlorpromazine 
allowed control of the disabling positive symptoms in approximately 70% of patients, 
enabling the large majority of patients previously requiring long-term hospital care to return 
to the community (Delay et al, 1952)  
 
Despite this, not all of the outcomes of chlorpromazine and other ‘typical’ first generation 
antipsychotic (FGA) treatments, such as haloperidol, were beneficial; severe extra-
pyramidal side effects (EPS) and tardive dyskinesia were common and on occasion, could 
be as disabling as the original symptoms. This, in addition to the fact that FGA treatment 
had little or no effect on the negative and cognitive symptoms, meant the search continued 
for more efficacious medication with fewer side effects. Progress was hampered by the 
belief that signs of catalepsy (indicative of EPS) signified antipsychotic properties. It was 
not until 1989 with the discovery of tricyclic antipsychotic (TCA) clozapine, that this myth 
was dispelled: Clozapine has higher efficacy than any of its predecessors, especially in 
treatment resistant patients, and almost no evidence of EPS (Bonham and Abbott, 2008; 
Hippius, 1989; Kane et al, 1988). This is thought to be as a result of lower occupancy of, 
and fast dissociation from, DA D2 receptors in the basal ganglia; an area responsible for 
control of motor function (Bonham et al, 2008; Kapur and Seeman, 2001). Other side 
effects however soon became apparent, with severe agranulocytosis (depletion of white 
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blood cells) leading to the deaths of eight people during the early 1970s and resulting in 
clozapine being removed from the U.S Food and Drug Administration (FDA) approved 
drugs list for a number of years (Crilly, 2007). Further ‘atypical’ second generation 
antipsychotics (SGAs) such as olanzapine, quetiapine and risperidone were developed and 
prescribed subsequent to the initial fall-out in favour of clozapine. These SGAs effectively 
reduced positive symptoms but did not induce EPS. This was found to be the result of fast 
dissociation from D2 receptors and lower receptor occupancy in the striatal regions (~60%) 
with SGAs as opposed to over 80% with FGAs (Kapur et al, 2001). Some SGAs such as 
risperidone and olanzapine are modestly more effective in treating negative symptoms 
(Leucht et al, 1999). However, although this may be a primary effect through activation of 
5-hydroxytryptamine (serotonin, 5-HT)2 and D4 receptors; it could also be because SGAs 
offer a significantly reduced likelihood of EPS which may reduce any related dysphoria. 
Indeed, Kapur et al (2001) demonstrated that the atypical antipsychotic effect of SGAs is 
dependent upon appropriate D2 receptor occupancy and not, for example, on the level of 5-
HT receptor occupancy. Additionally, it is also the dissociation from the D2 receptor and 
not the 5-HT2 or D4 receptor which most accurately predicts atypicality of SGAs (Kapur et 
al, 2001).  
Whilst an improvement on typical FGAs, SGAs are not a cure for schizophrenia and there 
is still a significant need for more efficacious medication which can treat all aspects of this 
disorder. This is the case despite more than two decades of research since the arrival of 
SGAs. 
There have been some promising starts such as the Eli Lilly metabotropic glutamate 
receptor (mGluR)2/3 agonist LY404039. LY404039 was found to be as effective as 
olanzapine in the first Phase II clinical trial, leading to widespread excitement in the field 
(Patil et al, 2007b). This would have been the first antipsychotic agent to work on a 
pathway that did not involve direct blockade of DA D2 receptors. Unfortunately, the 
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second trial failed as placebo was found to be as effective as the active compound and thus 
enthusiasm surrounding this project has since waned (Kinon et al, 2011).  
As pharmacotherapy alone does not currently provide adequate treatment, it is often 
combined with psychological therapies. Psychosocial education is one of these and aims to 
better inform patients and their families about schizophrenia and the various treatments and 
drugs which are available. This has advantages in that it can improve compliance; if a 
patient understands why a medication might not work for several weeks, they may 
persevere in taking it for the full time-course despite side effects. This may account for the 
correlation of this therapy with decreased relapse and reducing hospital re-admission rates 
(Mari and Streiner, 1994; Pilling et al, 2002). Cognitive behavioural therapy (CBT) and 
cognitive remediation courses are also used with patients: Cognitive remediation leads to 
some short term improvements in various impaired cognitive functions (d'Amato et al, 
2011; Demily and Franck, 2008; Grynszpan et al, 2011; Pfammatter et al, 2006). This is 
important as scores for attention, working memory and social cognition are approximately 
one standard deviation below the mean score for healthy controls, and are currently 
considered the most debilitating aspect of this disorder (Pfammatter et al, 2006).  CBT is 
designed to help patients rationally analyse their disease symptoms and examine different 
ways in which they can respond to them. This can help to reduce the severity of symptoms 
and help with coping strategies (Pilling et al, 2002; Turkington et al, 2008). Both CBT and 
cognitive remediation have been shown to have some efficacy in combination with 
pharmacotherapy for the treatment of positive symptoms, though there is significant 
variability within the literature (For review see Demily and Franck, 2008; Pfammatter et al, 
2006; Rector and Beck, 2001). Indeed, Wykes et al (2011) carried out a meta-analysis 
encmpasing over 100 different studies and over 2000 patients. They found that although 
there was a significant effect of CBT and cognitive remediation, these effects were small 
and transient, disappearing upon follow-up assessment. This highlights the idea that 
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although there is some evidence that these techniques are useful, care must be taken when 
interpreting their ‘real-life’ value (Wykes et al, 2011). 
The question that therefore remains is whether the search for a single so-called ‘super-drug’ 
which aims to cater for all aspects of the disorder is hampering vital research in this field, and 
whether we should instead be exploring symptom based treatment? Some strategies such as 
concurrently prescribing anti-depressants to combat negative symptoms and antipsychotics to 
combat positive symptoms are being employed (Siris et al, 2001). However, this strategy is 
not fully effective as it doesn’t provide any relief for the cognitive deficits which remain a 
significant unmet clinical need within this disorder. 
1.1.4 The TURNS and MATRICS initiative 
The MATRICS (Measurement and Treatment Research to Improve Cognition in 
Schizophrenia) initiative was born of the need to develop a common method to assess the 
efficacy of novel pharmacological and behavioural treatments for cognitive deficits in 
schizophrenia (www.MATRICS.ucla.edu ; Green and Nuechterlein, 2004; Marder and 
Fenton, 2004). This involved the identification of the most important areas of cognitive 
impairment in schizophrenia, the best way of measuring these features and the current best 
pharmacological treatment targets. MATRICS also aimed to determine the best experimental 
design and in order to satisfy the FDA requirements, additionally aimed to identify secondary 
measures of improvement. The resulting MATRICS Consensus Cognitive Battery (MCCB) 
(table 1.3) was the collaborative effort between the National Institute of Mental Health, 
academia, the pharmaceutical industry and various regulatory bodies (Harvey, 2006; 
Nuechterlein et al, 2008).  
The TURNS (Treatment Units for Research in Neurocognition in Schizophrenia) project aims 
to utilise the MCCB in a collection of treatment trials to investigate the seven areas of 
cognition which are impaired in patients with schizophrenia (www.TURNS.ucla.edu, table 
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1.4a and 1.4b). All of these studies will employ randomised double-blind testing, concurrent 
treatment with anti-psychotics and longer term treatment with compounds that are usually 
employed in cognition clinical trials. These trials will also utilise the whole, 90 minute long, 
MATRICS test battery (Harvey, 2006).    
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Table 1.3: MATRICS assessment battery  
Verbal memory Hopkins Verbal Learning – revised 
Visual memory Brief Visual Memory Test – revised 
Working memory University of Maryland letter-number sequencing; Wechsler 
Memory Scale, Third Edition, spatial working memory 
Processing speed Trail-Making Test, part A; Brief Assessment of Cognition 
in Schizophrenia, symbol coding; animal naming 
Problem solving Neuropsychological Assessment Battery Mazes 
Vigilance Continuous Performance Test, identical pairs version 
Social cognition MSCEIT Subtests 
Table 1.4A: Secondary measures: To be used in TURNS 
Performance-based everyday living skills UCSD performance-based skills assessment 
Self/observer-rated neuropsychological ability Schizophrenia Cognition Rating Scale 
 
 
 
Table 1.4B: Identified cognitive domains impaired in schizophrenia (Nuechterlein et al, 
2004) 
 
1 Working memory 
2 Attention 
3 Visual learning and memory 
4 Verbal learning and memory 
5 Speed of processing 
6 Social cognition 
7 Reasoning and problem solving 
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1.2 The prefrontal cortex 
The prefrontal cortex (PFC) is of great interest with respect to schizophrenia, as there is 
demonstrable evidence that a malfunction in this region is responsible for CDS.  
The mammalian PFC is divided into 3 main sub-regions; the orbital, medial, and lateral. In 
primates it is emotional behaviours which are guided by the orbital and medial regions, 
while the lateral region provides executive control of behaviour and reasoning as well as 
speech. This structure-function relationship is different in rats, with the functioning of the 
medial prefrontal cortex (mPFC) in rats thought to be analogous to the dorsolateral 
prefrontal cortex (DLPFC) in primates (Vertes, 2004, 2006). 
 
Initially defined by cytoarchitectonic features alone, the PFC was originally characterised 
as an area that is granulated. PFC definition has since evolved to include definition by 
connection to the mediodorsal thalamic nucleus (MD) and reciprocosity of these 
connections as well as input from the ventral mesencehaplon via dopaminergic fibres 
(Goldman-Rakic and Porrino, 1985; Gorelova and Yang, 1997; K Brodmann, 1909; Ray 
and Price, 1992; Rose and Woolsey, 1948; Uylings and van Eden, 1990; Williams and 
Goldman-Rakic, 1998). These evolving definitions resulted in a continuing debate as to 
whether the rat has a comparable PFC to humans and ultimately whether rodents represent 
a translational model. It is now however largely accepted that although structurally 
different, so-called class-common functions are largely the same and therefore reasonably 
representative of each other, and thus rodents are suitable test models. 
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1.2.1 Primate vs Rat PFC: Structure 
 
Rats have a frontal area that is earlier along the evolutionary path, and is less differentiated 
and segregated than is found in primates. Therefore whether rats have a PFC and 
particularly a region within the brain that is consistent with that of the DLPFC in primates 
has been questioned. Through analysis of cytoarchitectonic characteristics, it was initially 
thought that the PFC was unique to humans and primates, as only they possess a DLPFC 
with a well developed internal granular layer IV. 
 
Revolutionary work by Rose, Wooley and Akert instead demonstrated dense innervations 
to anterior and ventral parts of the rat brain from the MD; suggestive of an agranular, non-
primate, functional homologue of the primate PFC in the rat (Akert and Hartmann-von 
Monakow, 1980; Rose et al, 1948). However, Rose and Wooley’s original assumption that 
the MD was the only nucleus with thalamocortical projections to the PFC has since been 
shown to be incorrect: The PFC also connects to other thalamic nuclei such as the 
intralaminar, midline and anterior thalamic nuclei (Berendse and Groenewegen, 1991; 
Dermon and Barbas, 1994; Shibata and Kato, 1993). This meant that defining the rodent 
PFC through thalamic connections alone was no longer accurate. Uylings and Van Eden 
(1990) therefore employed a system of using strong reciprocal connections from the MD to 
define the PFC. This allowed inclusion of the frontal region 2 (Fr2) and dorsal anterior 
cingulate (ACd); regions previously classified as premotor regions and disputed by some as 
not strongly enough connected to the MD to warrant inclusion (Uylings et al, 1990). This 
dispute is critical as exclusion of these regions would mean there are no cortical areas in 
rats that are comparable to the primate DLPFC. However, as there are more prefrontal than 
pre-motor connections, these regions are now generally accepted as PFC regions and the 
pattern of connectivity of the MD in the rat is considered comparable to that in non-human 
primates. Supporting this is the parallel basal ganglia-thalamocortical circuitry present in 
both primates and rats. Many regions project to the basal ganglia but very few receive 
 17 
reciprocal connections. The PFC receives the majority of input from the basal ganglia 
mediated mainly by the medial, laminar and anterior thalamic nuclei. The resulting 
functionally segregated, basal ganglia-thalamocortical circuits are paralleled in both 
primates and rat, leading towards a conclusion that rats have a homologous PFC to 
primates. 
 
1.2.2 Primate vs Rat PFC: Function 
Rats and humans will never of course be described as the same, but in many functional 
respects their behaviours are similar: They have the capacity to take in sensory information 
and act upon it; they can adapt to survive in their respective environments and are able to 
complete complex tasks. For example, both rats and primates use sensory information to 
identify an object.  For the human this is through excellent tri-chromatic vision, supported 
by the touch and feel of the object. The rat however has detailed tactile sensory information 
through use of whiskers and support from reasonably limited visual information. In both 
cases, the ability of the PFC to receive this information and produce appropriate 
corresponding behaviour is crucial. 
One of the most significant functions of the PFC is the initiation and organisation of 
movement. In this respect both primates and rodents are surprisingly similar. Despite clear 
differences in their abilities to manipulate objects, both species have comparable motor 
maps whereby the size of the motor representation reflects the motor ability of a body 
region (Whishaw et al, 1992a, b). However, perhaps the most significant function of the 
PFC is that described earlier; the ability to act as a control centre for managing sensory 
input and guiding resultant behaviour. This can be current on-line information or 
information from short term working memory (such as the memory of oncoming traffic 
when crossing a road). Actions mediated by the PFC are also influenced by long term 
stored memory of previous actions or events (such as almost being run over by a speeding 
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car and so being extra vigilant in future). The PFC acts to select and coordinate this 
information to generate an appropriate behaviour. This behaviour may be completely novel 
or be similar to previous behaviours (i.e. crossing the road is a very similar process each 
time, but each time is slightly different). This novel information functionally connects the 
PFC with other cortices until it becomes routine or automatic. At this point the connection 
with the PFC is reduced and taken over by other brain structures. Fuster (1998) suggests 
that this function is common to both primates and rodents, and indeed all mammalian 
species (Fuster, 1998).  
One way to investigate function is to lesion the areas in question and examine which 
behaviours are lost. A comparison of prefrontal lesions in rodents and primates in the 1970s 
demonstrated that lesions of the medial and lateral orbital regions of the rat and the 
dorsolateral and orbitofrontal regions of primates produce similar behaviours (Kolb, 1984). 
For example, dorsolateral lesions in primates produce working memory and attentional 
deficits; this is also seen in rats with lesions to the mPFC, in particular the prelimbic (PrL) 
region, (Birrell and Brown, 2000; Granon et al, 2000; Muir et al, 1996). This supports the 
theory that these regions are analogous; crucial knowledge for the development of reliable 
animal models of CDS.  
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1.3 Impaired cognition in schizophrenia 
Spearman in 1928 was the first to distinguish between general and specialised cognition 
(Spearman, 1928). Patients with schizophrenia usually have impaired general intellectual 
functioning alongside specific cognitive disabilities in attention, executive function, 
working memory and processing speed, among others. However, the differences in severity 
in these specific abilities vary greatly, perhaps determined by the severity of general 
intellectual deficits. 
Patients with schizophrenia perform consistently poorer in tests of general cognition when 
compared to healthy controls with performance being approximately one standard deviation 
below normal (Fioravanti et al, 2005; Laws, 1999; Mesholam-Gately et al, 2009). 
Cognitive abnormalities are however present before the onset of the disorder as 
demonstrated by Crow and Done (1995) in their landmark study. Beginning in 1958, they 
followed 15000 children into adulthood. Those who developed schizophrenia during 
adulthood had shown notable differences to their peers during childhood including 
behavioural problems and impaired reading ability at age 7. At age 11, IQ was 5 to 10 
points lower than expected and these children were also delayed in establishing hemisphere 
dominance, thought to be crucial to the full development of language (Crow et al, 1995, 
1996). The degree of cognitive impairment in patients with schizophrenia is central to the 
disorder and is a key predictor of functional outcome (For review see Harvey, 2009) 
There are also physical abnormalities present in patients with schizophrenia. These include 
neurological soft signs such as poor sensory integration and motor coordination along with 
ocular abnormalities: Patients with schizophrenia can blink up to 80 times per minute 
compared to the average adult blinking rate of 12 times per minute (Varambally et al, 
2012). Patients also show brain structure differences consisting of small changes in 
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ventricular size and reduced cortical grey matter volume (De Peri et al, 2012; Lawrie and 
Abukmeil, 1998; Selemon et al, 2002).  
1.3.1 Working memory  
Working memory is a form of short term memory that allows the use of currently relevant 
information to make a decision but that is forgotten once that information is no longer 
relevant. In the context of experimental research Dudchenko defines working memory in 
the rat as ‘short term memory for an object, stimulus, or location that is used within a 
testing session, but not typically between sessions’ (Dudchenko, 2004). Working or ‘on-
line’ memory has long since been described as an ‘executive process’ as it enables selection 
of appropriate responses and behaviour, and their subsequent coordination. This process 
also allows the brain to discard information which is no longer relevant, such as how many 
cars were coming down the road when you crossed it last week. 
In order to test spatial working memory in animals, Olten and Samuelson developed the 
radial arm maze (RAM) in 1976. This task and several variations are still among the most 
widely used for testing working memory today. The original RAM had 8 radial arms, some 
of which contained food pellets. Rats were able to retrieve food pellets without revisiting a 
previously visited arm (Olton and Samuelson, 1976). This demonstrates an ‘on-line’ 
memory for which arms had been investigated and the pellet retrieved. However, on a 
session the next day, this information is no longer relevant as different arms are baited; in 
fact if animals did not ‘forget’ the information from the previous session, their performance 
may well be hampered on the current session. It is this transience of information that 
distinguishes working memory from the reference memory which is used to remember the 
rules of the task.  
There is evidence that patients with schizophrenia perform poorly in working memory tasks 
when compared to healthy controls: Forbes et al (2009) carried out a meta-analysis of 187 
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studies examining working memory in patients with schizophrenia. This revealed that 
patients had significant deficits in working memory in comparison to healthy subjects 
which could not be explained by discrepancies in IQ of test subjects (Forbes et al, 2009). 
Even prodromally, patients exhibit performance at approximately one standard deviation 
below normal in standard working memory tests (Simon et al, 2007). These deficits alone 
may constitute a poorer outcome because patients are less able to cope with their varying 
symptoms. However, patients may also have more difficulty manipulating information in a 
way that a healthy person can, such that they have difficulty in basic concentration, learning 
and reasoning along with everyday situations such as remembering the list of ingredients on 
a shopping list.  This means that working memory deficits within schizophrenia represent a 
serious, unmet clinical need which significantly affects the daily lives of patients. 
1.3.2 Causes of working memory deficits in schizophrenia 
There have been a multitude of studies examining working memory in schizophrenia but 
the exact nature or causes of these deficits are unknown. However, there is evidence that 
patients with schizophrenia have significant deficits in working memory and imaging 
studies have shown that these deficits correlate with functional changes in the DLPFC 
(MacDonald et al, 2005; Menon et al, 2001; Weinberger and Gallhofer, 1997).  The way in 
which DLPFC functioning deviates in patients depends upon the nature of the task used for 
testing: Low working memory load induces increased DLPFC activity in patients compared 
to control subjects with no poorer performance seen in patients versus controls. Conversely, 
high working memory load is associated with lowered DLPFC activity in comparison to 
controls, and patients demonstrate impaired performance on the task (Tan et al, 2007). 
In addition, studies of patients with schizophrenia have demonstrated a reduction in 
prefrontal grey matter volume and a reduction in N-acetylaspartate, a metabolite indicating 
volume and viability of neurons, in prefrontal regions (Gur et al, 2000; Hirayasu et al, 
2001; Keshavan et al, 2000).  
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On a molecular level, one of the most significant findings in patients with schizophrenia is 
a reduction in PFC messenger ribonucleic acid (mRNA) for the 67 kDa isoform of the 
gamma-aminobutyric acid (GABA) synthesizing enzyme glutamic acid decarboxylase 
(GAD67) (Volk et al, 2000). A reduction in GAD67 expression in parvalbumin (PV)+ve 
interneurons, either through N-methyl-D-aspartate receptor (NMDAR) hypofunction or a 
central deficit in GAD67 mRNA, may lead to a reduction in GABA production (Lewis et 
al, 2005; Moghaddam, 2004). Reduced GABA could then cause disinhibition of DLPFC 
pyramidal neurons, in turn inducing excess glutamate at non-NMDARs and thus disrupting 
cortical circuit function (Moghaddam, 2004). This is supported by evidence that normal 
DLPFC functioning has been shown to be essential to working memory: Rao et al (2000) 
found that application of GABA antagonist bicuculline to pyramidal cells and interneurons 
in the DLPFC of monkeys impaired their performance on a working memory task (Rao et 
al, 2000). This indicates an essential role for GABA and PV+ve interneurons in working 
memory processes. PV+ve interneurons are additionally instrumental in the generation of 
gamma frequency oscillations, which are central to working memory processes: The size 
and the synchronicity of gamma frequency oscillations have been shown to correlate with 
working memory load (Gonzalez-Burgos and Lewis, 2008; Howard et al, 2003) In patients 
with schizophrenia, Cho et al (2006) have shown that gamma frequency activity increased 
with task difficulty in control subjects but no changes were observed in patients with 
schizophrenia (Cho et al, 2006). This supports the idea that gamma frequency oscillations 
play a significant role in working memory and that this function is impaired in patients with 
schizophrenia compared to healthy controls. 
 
Therefore, although the causes of working memory deficits in schizophrenia have yet to be 
fully delineated, there is likely to be significant involvement of aberrant gamma frequency 
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oscillations arising from an impairment in GABA-mediated regulation of pyramidal cell 
networks. 
1.3.3 Network oscillations as neural correlates of working memory 
Neural oscillations allow communication of information between different brain regions. 
Oscillations exist in different frequency bands such as beta (15-30 Hz), gamma (30-80hz), 
theta (4-12hz) and delta (1-4hz) (Whittington et al, 2000). These different frequency band 
oscillations act as parallel communication channels for different networks, coordinating 
different but sometimes related, information (Benchenane et al, 2011). Fast oscillations 
such as gamma and beta function to enhance the neuronal representation of sensory stimuli, 
resulting in enhanced activity of neuronal groups communicating behaviourally relevant 
information (Womelsdorf and Fries, 2007). Beta has been implicated in long-range 
synchronisation with long transmission delays where as there is evidence for gamma 
oscillations in shorter range synchronisation (Kopell et al, 2000). Theta frequency network 
oscillations also have been shown to be essential to spatial working memory tasks and can 
function to coordinate communication between the hippocampus and the prefrontal cortex 
(Jones and Wilson, 2005). 
Mechanistically, it is widely accepted that inhibitory interneurons have a significant role in 
the generation of gamma frequency oscillations, with the firing ability of pyramidal 
neurons being strictly controlled by the level of inhibitory input (Cardin et al, 2009; Sohal 
et al, 2009). This means that only in a state of synchronous inhibition, there exists a 
window of low inhibitory conductance which allows the cell to fire. The active contribution 
of pyramidal cells to this process has not as yet been fully delineated: Gamma frequency 
oscillations can be generated with the passive involvement of pyramidal cells, the 
interneuron gamma (ING) mechanism, or by the pyramidal interneuron gamma (PING) 
mechanism (Traub and Whittington, 2010; Whittington et al, 2000). In the case of ING, 
inhibitory interneurons are activated through the binding of glutamate to mGluRs. This 
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initiates firing of localised interneurons which become more synchronised, which in turn 
entrains more interneurons. This ultimately results in the generation of inhibitory 
postsynaptic potentials (IPSPs) which allows synchronous firing to occur following release 
from inhibition (Cobb et al, 1995; Whittington et al, 2000). In contrast, the PING 
mechanism dictates that pyramidal neurons drive the oscillation through the generation of 
excitatory post-synaptic potentials (EPSPs) in neighbouring pyramidal cells but also 
interneurons: Activation of sufficient inhibitory interneurons initiates widespread 
inhibition, thus coordinating the synchronous firing of pyramidal cells following cessation 
of inhibition (Traub et al, 2010; Whittington et al, 2000). 
Gamma frequency oscillations can be examined in-vivo, in-vitro and clinically through 
electro-encephalography (EEG) and magneto-encephalography (MEG). This translatable 
way of examining neural networks means that findings pre-clinically are more likely to 
translate to meaningful results for patients and ultimately increase the likelihood of 
developing novel efficacious compounds for the treatment of CDS.  
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1.4 Smoking and schizophrenia  
The prevalence of smoking in patients with schizophrenia far outweighs that in the normal 
population at a ratio of approximately 80:20% (Morisano et al, 2009). This, in addition to 
reports that cessation rates in patients are approximately half that of the normal population, 
led researchers to conclude that patients may be self-medicating with the psychoactive 
ingredient in tobacco, nicotine (Lasser et al, 2000). Nicotine may be used as self- 
medication as it has been shown to increase hepatic clearance of antipsychotic medications 
through the induction of metabolising enzyme CYP1A2 (Andrade, 2012; Bozikas et al, 
2004). By smoking, patients may therefore be able to reduce side effects such as 
neuroleptic-induced parkinsonism (Chambers, 2009). In addition, nicotine has been shown 
to improve cognition and sensory gating in patients with schizophrenia (Barr et al, 2008; 
Chen et al, 2011; Jacobsen et al, 2004). On a molecular level, the self-medication 
hypothesis is supported by studies showing that patients have reduced nicotinic 
acetylcholine receptor (nAChR) expression and that nicotine administration paradoxically 
increases nAChR presence (Durany et al, 2000; Leonard et al, 2000). Sallette et al (2005) 
propose that this is because nicotine can act intracellularly in a similar way to a chaperone 
protein, promoting proper folding and assembly of nAChR subunits. This means that the 
fraction of functional nAChRs on the cell surface is increased (Sallette et al, 2005)  
Contrary to the self-medication hypothesis, the addiction vulnerability hypothesis proposes 
that patients with schizophrenia have inherent genetic factors and brain reward pathway 
abnormalities which predispose them to smoking. This means that patients compulsively 
smoke despite the negative consequences associated with smoking tobacco. This is not to 
say that there are not some positive effects associated with smoking, but this hypothesis 
proposes that they are secondary to a nicotine addiction (Chambers, 2009).  
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1.4.1 Nicotine and memory 
Nicotine has been shown to improve working memory in both compromised and non-
compromised animals. Levin et al (1997) trained rats in the 16 arm RAM whereby the aim 
is for the rat to collect food rewards from baited arms without revisiting a previously 
sampled arm. Rats that were administered nicotine prior to the task demonstrated 
significantly improved working memory performance. In addition,  a low dose of nicotinic 
antagonist mecamylamine impaired performance in the task, which was attenuated by co-
administration of nicotine  (Levin et al, 1997). Normal, uncompromised animals also 
demonstrate improved performance following nicotine administration in the Odour Span 
Task (OST), a non-spatial working memory task where animals are required to select a 
novel odour from a series of previously sampled odours. As with the study by Levin and 
colleagues, animals also demonstrated significantly impaired performance following 
mecamylamine administration (Rushforth et al, 2010).  
 
Clinically, the vast majority of patients with schizophrenia smoke and thus many of the 
studies examining the effect of nicotine on memory, are in patients who have abstained 
from smoking: Wing et al (2011) examined smoking abstinent patients and found their 
level of working memory impairment correlated with a decrease in circulating levels of 
nicotine (Wing et al, 2011). In addition, Smith et al (2006) examined the effect of nicotine 
on attention, verbal memory, and visual-spatial memory in abstinent smokers. They found 
that nicotine improved attention and visual-spatial memory: This may provide evidence of a 
role for nicotine in memory (Smith et al, 2006). However, these results are not conclusive 
as treatment with nicotine may in fact be negating the effects of withdrawal as opposed to 
enhancing cognition. Mechanistically, Tsukeda et al (2005) used positron emission 
topography (PET) to demonstrate that nicotine is able to reduce the abnormally increased 
level of prefrontal DA D1 receptor binding in monkeys sub-chronically treated with 
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NMDAR antagonist MK-801. They correlate these findings with results demonstrating that 
nicotine was also able to restore working memory performance following MK-801-induced 
impairment (Tsukada et al, 2005). Couey et al (2007) put forward that nicotine 
administration increases GABA output onto pyramidal neurons, which increases the 
threshold at which they fire. If there is a lot of activity, i.e. under the strain of a particularly 
demanding task, then this action could function to improve the signal to noise ratio, thus 
enhancing performance.  However, this could also lead to poorer performance if the 
threshold of neuron firing was increased but the level of input remained the same. This 
could account for why nicotine can cause impairments in control subjects where nicotine 
enhances performance in impaired individuals (Couey et al, 2007). This mechanism is 
supported by Newhouse et al (2004) who propose that nicotine is only effective in a 
situation where a task is highly demanding or the subject is impaired. In the case of normal 
functioning or a simple task, nicotine may cause impairments (Newhouse et al, 2004b). 
 
Therefore, whether patients with schizophrenia smoke as a result of vulnerability to 
addiction or to improve cognition or both, it is likely that there is a role for nAChRs in 
mediating cognition and thus nAChRs represent a viable target for the development of 
novel compounds for the treatment of CDS. 
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1.4.2 The nicotinic acetylcholine receptors: α7 and α4β2 
Nicotinic acetylcholine receptors are part of the cholinergic receptor system which also 
incorporates the muscarinic acetylcholine receptors (mAChRs). The mAChRs are G-protein 
coupled and found in both the central and parasympathetic nervous systems (Eglen, 2006). 
The nAChRs are ionotropic, binding both endogenous acetylcholine and exogenous ligands 
such as nicotine which results in the opening of the ion channel; allowing the flow of 
cations through the receptor. Structurally, nAChRs are pentameric, consisting of five 
transmembrane subunits surrounding a central ionic pore. There are 17 currently known 
subunits that make up the receptor which may be homomeric or heteromeric and mostly 
formed of α and β subunits (Figure 1.1). By far the most common nAChRs present in the 
brain are the homomeric α7 nAChR, consisting of five α7 subunits, and the heteromeric 
α4β2 nAChR consisting of α4(2/3) and β2(3/2) subunits (Figure 1.2).  (Albuquerque et al, 
2009).  
The α4β2 nAChRs are the most widely distributed nAChRs in the brain and have been 
shown to have a significant role in modulating neurotransmitter output (Albuquerque et al, 
2009). They exist in two forms consisting of either two α subunits and three β subunits or 
three α subunits and two β subunits. The α4(2)β2(3) form has been shown to have a very high 
affinity for nicotine although α4 containing nAChRs are all classed as high affinity 
receptors (Wu and Lukas, 2011). Mechanistically, ligand binding to the α4β2 nAChR leads 
to the influx of sodium ions and low levels of calcium ions along with potassium ion efflux, 
causing depolarisation. This induces calcium ion influx through voltage gated calcium 
channels which then triggers vesicular neurotransmitter release (Tsuneki et al, 2000).  
In contrast, the α7 nAChR is a low affinity nAChR which is highly permeable to calcium. 
These nAChRs are preferentially localised to elicit direct calcium-induced-calcium release 
(CICR) from intracellular stores: α7 nAChRs are predominantly located on ryanodine-
sensitive nerve terminals where ligands binding to the α7 nAChR induces CICR. This in  
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Figure 1.1 The α4β2 nicotinic acetylcholine receptor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1 Nicotinic acetylcholine receptors are pentameric structures consisting of 5 
subunits. These receptors can be heteromeric, consisting of two or more different subunits as 
depicted above. Alternatively, they may be homomeric , consisting of 5 of the same subunits 
as in the case of the α7 nAChR (Adapted from Mroziewicz and Tyndale, 2010) 
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Figure 1.2 Nicotinic acetylcholine receptor subtypes and their neuroanatomical location. 
 
 
 
  
Figure 1.2: Nicotinic acetylecholine receptors are present throughout the brain. The most 
ubiquitous receptors are the α4β2 nAChR and the α7 nAChR which have also been implicated 
as having a role in cognition (Adapted from Taly et al, 2009) 
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turn activates extracellular signal-regulated kinase-1/2 (ERK1/2)-dependent pathways, 
phosphorylating synapsin-1 which induces vesicle binding to the synaptic membrane and 
neurotransmitter release (Dickinson et al, 2008). Like α4β2 nAChRs, α7 nAChRs are also 
present in most regions of the central nervous system (CNS), but where as α4β2 nAChRs 
are localised in the PFC, α7 nAChRs predominate in the hippocampus; located on 
cholinergic and non-cholinergic presynaptic terminals (Albuquerque et al, 1997; Alkondon 
et al, 1999).  
 
Both α7 and α4β2 nAChRs have been shown to improve working memory: Pre-clinically, 
Lippiello et al have shown that α4β2 agonist metanicotine was able to improve passive 
avoidance retention following scopolamine-induced amnesia as well as improving working 
and reference memory in the 8-arm RAM (Lippiello et al, 1996). Chan et al (2007) 
examined both α4β2 and α7 agonists on the RAM and found that both were able to improve 
working memory function and that both α7 antagonist methyllycaconitine and α4β2 
antagonist dihydro-beta-erythroidine (DHβE) impaired working memory (Chan et al, 
2007). Further support for nicotine improving working memory comes from Castner et al 
(2007) who found that AZD0328, which is a selective α7 nAChR agonist, significantly 
improved working memory performance in rhesus macaques following acute 
administration (Castner et al, 2011). The role of α7 nAChRs in working memory is 
supported by Young et al (2007) who also found that α7 knockout (KO) mice were 
impaired in the OST; a measure of non-spatial working memory (Young et al, 2007b). 
Finally, Buccafusco and Terry (2009) demonstrated that partial α7 nAChR agonist 3-(2,4-
dimethoxybenzylidine) anabaseine (DMXBA) was able to fully reverse a ketamine-induced 
deficit in a computer assisted-delayed response task in monkeys (Buccafusco and Terry, 
2009). Clinically, DMXBA has been shown to improve working memory in a Phase II 
clinical trial (Freedman et al, 2008). In addition, Dunbar et al (2011) found that selective  
α4β2 nAChR agonist TC-1734 improved attention and memory in older subjects with age-
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associated memory impairment (Dunbar et al, 2011). This demonstrates a key role for 
nAChRs in working memory and indicates that they are likely to have a significant role in 
mediating the effect of nicotine on cognition.   
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1.5 Assessing working memory in the rat 
Working memory is distinct from other forms of memory in that it requires active 
maintenance, is subject to interference and with respect to working memory tasks in 
rodents, must be forgotten between trials in order to prevent interference with future trails. 
Working memory provides a representation of available stimuli, be that arms visited in the 
RAM or odours previously sampled in the OST, that can be used to guide behaviour. 
Dudchenko (2004) defines working memory in a rodent as ‘a short term memory for an 
object, stimulus or location that is used within a testing session, but not typically between 
sessions’ (Dudchenko, 2004).  
Access to translatable cognitive preclinical tasks that can be used in conjunction with 
disease models is essential in the development of novel compounds to treat CDS. This 
poses various problems in that several of the tasks used to measure human memory are 
difficult to replicate in the rat: Verbal working memory tasks being the most obvious but 
complex tasks such as the n-back task as carried out in humans are also difficult to replicate 
in rats. These tasks must therefore be adapted to be species relevant. However in some 
cases, researchers have done the reverse and adapted a rodent task for humans: There is 
now a computerised virtual reality version of the RAM, which has been used to 
demonstrate that patients with schizophrenia exhibit working memory errors consistent 
with studies examining RAM performance in animal models of schizophrenia (Spieker et 
al, 2012).  
The most commonly used tasks in rodents involve maze-based spatial working memory or 
delayed alternation tasks, although the use of non-spatial tasks such as the OST are 
becoming more popular.  
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1.5.1 Maze tasks: Radial Arm Maze, Morris Water Maze and T-Maze 
The RAM was developed by Olten and Samuelson in 1979 and consists of a central 
platform with 8 arms radiating from it. Olten and colleagues found that rats placed on the 
central platform would rapidly learn to retrieve a food reward from the end of each arm 
without revisiting a previously sampled arm (Olton et al, 1976). Since then there have been 
many variations on the task including increasing the number of arms to 12 or even as many 
as 24 (Buresova and Bures, 1982; Cook et al, 1985). Another factor introduced was delay: 
Bolhuis et al (1986) demonstrated that it took a delay of 60 minutes between trials to 
significantly impair performance on the RAM and a 120 minute delay for animals to 
perform at chance levels (Bolhuis et al, 1986). The Morris Water Maze (MWM) requires 
rats to find a submerged platform in a pool of water. In the working memory version of the 
task, which may also include delays between the first and second trial, the platform location 
remains the same for trials on the same day but is different between days (Steele and 
Morris, 1999).  
Although both the RAM and MWM are spatial working memory tasks, the behaviours 
observed on each may be quite different: Ormerod et al (2002) tested rats in both tasks and 
found that rats took almost twice as many trials to learn the RAM versus MWM, and that 
scopolamine administration impaired working memory only in the RAM (Ormerod and 
Beninger, 2002). This is potentially because the motivating factors for completing the tasks 
are different; in the MWM, rats are averse to water and must find the platform to escape 
where as in the RAM, unless very hungry, the possibility of missing a food reward is not 
especially aversive. Additionally, there are few strategic options available in the MWM: 
Rats must use extra-maze spatial cues to determine orientation. Conversely in the RAM, 
rats may ‘microsample’ entryways to each platform or scent-mark areas previously 
investigated meaning that the cognitive map and brain regions employed by rats to solve 
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each task may be significantly different. This must be carefully considered before inferring 
structure-function relationships (Hodges, 1996).  
 
Hodges et al (1991) exemplify this, demonstrating that animals with damaged connections 
to the hippocampus and cortex were impaired in both the MWM and RAM compared to 
control subjects: This is in contrast to hippocampal lesions which impaired performance in 
the MWM to a greater extent than in the RAM (Hodges et al, 1991; Jarrard, 1993). 
Buresova et al (1982) provide a solution to this problem with the development of a 
submerged RAM. This required rats to swim to the end of a maze arm for the opportunity 
to sit on a submerged platform for 20 seconds. After 20 seconds, this platform would 
collapse requiring the rat to swim to a new arm for relief. In the same way as the RAM, rats 
were measured on their ability to remember which arm had been visited (Buresova et al, 
1985). This task prevents potential confound such as ‘microsamples’ and scent-marking 
meaning task navigation is achieved as a result of a visuo-spatial construct. However, the 
anxiogenic and aversive nature of the task may have its own confounding effects on 
working memory. 
 
Delayed alternation using the T-maze encompasses the natural curiosity of the rat for 
novelty. The rat is placed in the long arm of the ‘T’ and must make a decision about which 
arm to enter. On the next trial, following a varying delay, the animal is rewarded for 
entering the alternate arm to one previously explored. This task is very sensitive to 
hippocampal lesions; animals perform at chance levels with only a 15 second delay 
(Dudchenko et al, 2000).  Again, this illustrates how different each spatial memory task is 
and that knowledge of both strategy and corresponding neural correlates are vital for the 
interpretation of findings.   
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Ultimately however, these studies illustrate that findings in one spatial working memory 
task may not extrapolate to others, as the motivation and strategies employed to complete 
the task may be very different. Thus, each task may provide useful but different information 
regarding brain structure-function relationships which must be considered with initial task 
selection. 
1.5.2 Delayed Match-to-Sample and Non-Match-to-Sample Tasks: The N-Back, Paired 
Associate Learning, Novel Object Recognition and the Odour Span Task 
The n-back task is commonly used in humans, not least because it can be combined with 
imaging to provide a more accurate indication of structure-function relationships. In the 
human version, subjects are asked to respond to a letter when it matches the presented letter 
(0-back), the previous letter (1-back) or the penultimate letter (2-back). In rats, a series of 
lever presentations are used in place of letters and rats must respond to the previously 
presented lever or the penultimate lever from a random sequence of lever presses. Ko et al 
(2009) have shown that this version of the task is sensitive to impairments by both 
amphetamine and MK-801, but that performance was not restored by SKF-38393 (D1, D5 
partial agonist) or nicotine. The authors put forward that this may be as a result of 
interference from the continuing pattern of lever presentations and that nicotine may in fact 
improve attending to each novel presentation, causing previous presentations to be 
forgotten more quickly (Ko and Evenden, 2009). However, the logarithmic dose range used 
(0.1, 0.3 and 1mg/kg) may miss out a therapeutic dose between the 0.3 and 1mg/kg dose 
which has been shown to improve performance in other non-spatial working memory tasks 
(Rushforth et al, 2010). 
Paired Associate Learning (PAL) in humans requires subjects to examine five boxes on a 
computer screen and remember the contents; one of these sample objects is then displayed 
and the subject must match it to the correct box (Sahakian et al, 1988). In the rodent 
version of the task, rats are trained to respond to an object displayed at a correct response 
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location in the presence of another object at an incorrect location on a touchscreen. The 
objects displayed may be the same (same paired associate learning, sPAL) i.e. two flowers 
located at space one and three, where only the flower at space one is rewarded, or different 
(different paired associate learning, dPAL), such as a correct spider at space one, an 
incorrect aeroplane at space two followed by a correct flower at space two (Talpos et al, 
2009). Talpos et al (2009) demonstrated that hippocampal impairments, using local 
administration of compounds such as MK-801 could be induced in the dPAL task only, 
attributing this factor to the more difficult nature of the task. The significant advantage of 
this task is that it is fully automated meaning that multiple animals can be tested in parallel 
and the measurable outcomes are fully objective. In addition, this is similar to the PAL used 
in humans and may therefore prove useful in the development of novel compounds which 
are efficacious in man. 
The OST is a complex task that involves increasing amounts of information which must 
remain active in working memory in order to successfully complete the task. Developed by 
Dudchenko et al (2000), the OST works by initially presenting a bowl of woodchip 
containing a food reward, scented by a household spice such as coriander (A+); this bowl is 
presented at a numbered location where the rat must dig in the bowl and retrieve the food 
reward. On the next trial, a second baited bowl, containing a different odour such as garlic, 
is introduced at another numbered location (B+) and the, now unbaited, first bowl (A-) is 
also moved to a new location: The animal must investigate both bowls and dig in only the 
bowl with the novel scent. This continues with additional bowls for each trial until the 
animal makes a mistake or reaches 15 bowls. When the animal makes a mistake, it is 
removed from the board and the number of correct bowls identified minus the first (which 
has no memory requirement) gives a span score (figure 2.3). A spatial version of the OST 
can also be employed where the location of the bowl is instead the relevant factor. In the 
paper first describing this task by Dudchenko (2000), one experiment induced neurotoxic 
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hippocampal lesions in rats previously trained in the OST. These animals demonstrated no 
impairment on the normal OST task but were substantially impaired on the spatial version 
of the task. This indicates a role for the hippocampus in spatial working memory but also 
alludes to the involvement of other brain regions in mediating this task (Dudchenko et al, 
2000). Since then, various groups have picked up this task, demonstrating that performance 
can be enhanced with nicotinic agonists and that it is sensitive to impairment with NMDAR 
antagonists such as MK-801 (Galizio et al, 2012; Rushforth et al, 2010).   
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1.6 Pharmacological models of cognitive impairment in schizophrenia 
The aim for any animal model of a disorder is to have face, construct and predictive 
validity. This means the model should induce similar symptoms, have similar molecular 
pathology and respond in the same way to treatment as the original disease, respectively. 
The best way to do this is to replicate the underlying cause of the original disease but this 
becomes difficult when the origin of the disorder is unknown. This is particularly the case 
with syndromes such as schizophrenia where there are numerous disorders under the 
umbrella term of schizophrenia which often present slightly and sometimes significantly 
different from patient to patient.  As a result, current models do not serve as the complete 
animal equivalent but are instead largely fragmented; examining only for certain aspects of 
the disorder. The main pharmacological models of schizophrenia have arisen from the two 
main hypotheses of schizophrenia; the DA hypothesis and the glutamate hypothesis. The 
first, hypothesising abnormal dopaminergic tone, is evidenced by studies showing that 
psychotic symptoms can be induced by amphetamine in healthy subjects, that patients 
release more DA following amphetamine than controls and that all successful antipsychotic 
drugs antagonise the D2 receptor (Abi-Dargham et al, 2009; Breier et al, 1997; Carlsson 
and Lindqvist, 1963; Morland, 2000). However, whilst amphetamine administration models 
are able to model positive symptoms and antipsychotics can treat them, the negative and 
cognitive aspects of the disorder remain unaccounted for. Conversely, treatment with 
NMDAR antagonists such as ketamine, MK-801 or phencyclidine (PCP) models, not only 
positive symptoms but negative and cognitive symptoms as well (Figure 1.3). In healthy 
subjects, NMDAR antagonists induce a syndrome indistinguishable from a psychotic 
episode as well as significant cognitive impairments. Additionally, ketamine has been 
shown to exacerbate psychosis and cognitive impairments in patients with schizophrenia 
(Krystal et al, 1994b).  
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Figure 1.3 Mechanism of ketamine action. 
  
Figure 1.3: Hypofunction or blockade of NMDA receptors on GABAergic interneurnons 
reduces the output of GABA onto pyramidal neurons. This in turn causes disinhibition of 
pyramidal cells, effectively enhancing glutamate output onto non-NMDA receptors such as 
AMPA and kainate (Krystal et al, 2003). 
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1.6.1 Dopaminergic models  
The modified DA hypothesis indicates that there is hyperactivity of the mesolimbic DA 
neurons which is reported to account for the positive symptoms of schizophrenia and a 
hypoactivity of frontal mesocortical DA neurons that accounts for negative symptoms of 
schizophrenia (Dworkin and Opler, 1992; Seeman, 1987). Support for this comes from 
current treatments: All current successful antipsychotics antagonise the D2 receptor and 
their efficacy correlates with the degree of antagonism at this receptor (Sharp et al, 1987). 
In addition, animals given DA agonist amphetamine show increased striatal and nucleus 
accumbens DA levels, behaviorally exhibiting hyperlocomotion and stereotypy; an effect 
that can be blocked with antipsychotics (Leite et al, 2008; Sharp et al, 1987). Clinically, 
Abi-Dargham et al (2009) have shown that patients with schizophrenia have increased 
baseline and amphetamine-induced DA release in comparison to healthy controls (Abi-
Dargham et al, 2009). Amphetamine has also been shown to exacerbate psychotic 
symptoms in patients with schizophrenia with the severity of that response being 
proportional to the degree of DA release (Laruelle et al, 1999). Furthermore, in healthy 
controls, acute amphetamine can also induce psychotic symptoms (Curran et al, 2004). 
However, a review of DA receptor agonist apomorphine by Depatie and Lal (2001) reveals 
that this compound does not induce psychotic symptoms in healthy subjects and fails to 
exacerbate symptoms in patients with schizophrenia. 
Manipulation of DA can emulate psychotic symptoms and can induce some negative and 
cognitive symptoms such as impaired attention (Fletcher et al, 2005). However, this model 
does not effectively replicate the significant cognitive deficits which are a mainstay of this 
disorder; in particular working memory where amphetamine has been shown to have no 
effect on task performance (Shoblock et al, 2003; Stefani and Moghaddam, 2002). This 
indicates that models which manipulate DA have significant flaws as not all symptoms are 
reliably induced: This is likely to mean that the fundamental mechanisms by which these 
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deficits are induced are not likely to be the cause of schizophrenia. Despite this, models 
based on the DA hypothesis appear to be useful in terms of examining positive and some 
negative and cognitive symptoms, but also have significant shortcomings meaning other 
pharmacological manipulations may be more appropriate. 
1.6.2 Glutamatergic models 
In contrast to treatment with amphetamine, administration of non-competitive NMDAR 
antagonists such as PCP, ketamine and MK-801 to humans can induce the broad range of 
symptoms associated with schizophrenia (Jentsch and Roth, 1999; Krystal et al, 1994b). 
NMDAR antagonists are also able to induce psychosis in patients with schizophrenia 
currently in remission (Malhotra et al, 1997b; Malhotra et al, 1996). These observations 
lead to the postulation that schizophrenia may occur as a result of NDMAR hypofunction or 
the ‘hypoglutamatergic hypothesis of schizophrenia’ (Coyle, 1996). This is supported by 
evidence that patients with chronic schizophrenia demonstrate significantly lower levels of 
glutamate in the DLPFC compared to healthy controls (Ohrmann et al, 2005).  
NMDAR antagonists have been shown to model the symptoms of schizophrenia pre-
clinically (Neill et al, 2010). Acute administration of PCP prevented acquisition of the 
MWM in addition to disrupting performance on the spatial alternation task when given as a 
challenge dose following chronic PCP treatment (Stefani et al, 2002; Wass et al, 2006). 
Sub-chronic PCP also impairs cognition in the form of working memory as well as social 
interaction in rats (Seillier and Giuffrida, 2009). This effect on cognition is supported by 
McLean et al (2008) and Grayson et al (2007) who found that sub-chronic PCP was able to 
impair performance in the both the attentional set-shifting task and the NOR task. Both 
studies additionally found that this effect could be reversed by atypical anti-psychotic 
treatment (Grayson et al, 2007; McLean et al, 2008). In non-human primates repeated PCP 
administration has been shown to cause enduring working memory impairments correlating 
with enhanced DA release in the PFC; these effects were also ameliorated by atypical 
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antipsychotic clozapine (Jentsch et al, 1997). Acute ketamine has been shown to cause 
disruption in a battery of cognitive tasks in a study by Taffe and colleagues (2002) who 
administered a range of doses acutely before testing in the tasks(Taffe et al, 2002). 
Additionally, Featherstone et al (2012) have demonstrated that sub-chronic ketamine can 
induce significant cognitive deficits in mice (Featherstone et al, 2012a). Becker et al (2003) 
support this finding, having also shown that sub-chronic administration of ketamine 
induces cognitive deficits in rats which are still present 4 weeks following final drug 
exposure (Becker et al, 2003a). Furthermore, in another study, Becker and Grecksch (2004) 
demonstrated that sub-chronic ketamine could induce changes in the social interaction test 
that were normalised by treatment with atypical antipsychotics (Becker and Grecksch, 
2004). These findings suggest that treatment with NMDAR antagonists may provide a 
model of schizophrenia with a level of face validity for most features of the disorder; the 
main discrepancy being that acute doses of antipsychotics are able to reverse cognitive 
deficits and control positive symptoms after a single dose whereas this is not the case in the 
clinic. This means in terms of predictive validity, these models may be inclined to produce 
‘false positive’ results when translated into humans. 
Neurobiologically, chronic administration of NMDAR antagonists decreases striatal D1 
receptor expression and reduces GABAA receptors in the frontal cortex, hippocampus and 
striatum, in addition to a more widespread reduction in NMDAR binding (Beninger et al, 
2010; Choi et al, 2009). Following chronic PCP administration, basal levels of PFC DA are 
reduced but are hyper-responsive to amphetamine; replicating human findings (Jentsch et 
al, 1998). Basal PFC glutamate release is also reduced in rats treated with chronic PCP 
(Fattorini et al, 2008).  
One of the most striking changes observed in post-mortem brains of patients with 
schizophrenia is the reduction of PV+ve neurons: Bernstein et al (2007) report a 50% 
reduction in comparison to healthy controls (Bernstein et al, 2007). This finding is 
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replicated in non-human primates treated with sub-chronic PCP (Morrow et al, 2007). 
McKibben et al (2010) also demonstrate that this treatment regimen in rats reduced 
performance on a NOR task which correlates with reduced PFC PV interneurons 
(McKibben et al, 2010). This is supported by Abdul-Monim et al (2007) have shown that 
sub-chronic PCP can induce deficits in reversal learning which correlates with reduced 
density of PV+ve neurons in several regions including the PFC and hippocampus(Abdul-
Monim et al, 2007). Damgaard et al (2011) have also shown that sub-chronic PCP induced 
deficits in memory can be reversed by modulating extrasynaptic GABAA receptors 
(Damgaard et al, 2011). Behrens et al (2007) show that repeated ketamine exposure also 
leads to loss of PV expression and Braun et al (2007) demonstrate this finding in 
hippocampal PV interneurons following MK-801 exposure (Behrens et al, 2007; Braun et 
al, 2007). In this case however, no reduction was seen in PFC PV+ve neurons which may 
indicate that MK-801 administration may not have the same level of construct validity as 
PCP or ketamine administration. 
Taken together, these studies illustrate that NMDAR antagonist models of schizophrenia 
are the clear choice of current pharmacological model, although further characterisation of 
both the MK-801 and ketamine models is needed.  
 
1.6.3 Non-pharmacological models of schizophrenia 
Developmental animal models of schizophrenia induce abnormalities in CNS development 
through environmental or pharmacological manipulation during the sensitive perinatal 
period (Fone and Porkess, 2008). Rats are very social animals with a hierarchical social 
structure that is critical to their development. Social isolation of rodents by housing them 
individually from the age of weaning causes developmental abnormalities as well as 
behavioural deficits in adulthood. These include neophobia, impaired sensorimotor gating, 
social withdrawal and cognitive inflexibility which are also affected in patients with 
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schizophrenia (Lapiz et al, 2003). These behavioural changes are in addition to 
neuroanatomical and neurochemical changes such as reductions in PFC volume and 
hippocampal synaptic plasticity, hyperfunction of mesolimbic dopaminergic systems and 
hypofunction of mesocortical DA which are also present in patients with schizophrenia 
(Fone et al, 2008).  
Methylazoxymethanol (MAM) is a selective anti-mitotic compound that disrupts CNS 
neuroblast proliferation (Cattabeni and Di Luca, 1997). When given to a pregnant dam 
during gestation, the rat pups present behavioural abnormalities such as deficits in prepulse 
inhibition to startle, hyperlocomotion and working memory deficits (Moore et al, 2006). 
These rats also present neurological changes such as reduced glutamatergic transmission 
(Hradetzky et al, 2012).  
Maternal immune activation, induced by either a virus or a synthetic compound, is also able 
to induce abnormal behaviour in the adult offspring (Zuckerman and Weiner, 2005). This 
behaviour can be alleviated by antipsychotic treatments and exacerbated by NMDA 
antagonist MK-801. This model is however less well characterised and has been used less 
than either the isolation rearing or MAM developmental models. 
Neonatal ventral hippocampal (vHip) lesions, involves using the local injection of a 
neurotoxic compound such as ibotenic acid or electrolytic lesioning (Lipska, 2004). These 
lesions lead to post-puberty behavioural abnormalities including deficits in social 
interaction, hyperlocomotion and sensitivity to pharmacological challenges (Naert et al, 
2013).  
These neurodevelopmental models replicate many of the core symptoms of schizophrenia, 
many of which are seen post-puberty which is in line with the clinical timeline of this 
disorder. However, there are also alternative methods of modelling schizophrenia including 
genetic manipulations. These models modify or knock out key genes such as DISC1 and 
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COMT (as discussed on page 7), which have been linked to the development of 
schizophrenia. 
  
1.7 Aims and Objectives 
This body of work ultimately aims to establish whether neuronal nicotinic receptors 
represent viable targets for the treatment of CDS. This encompasses several objectives, 
with the initial task being the investigation of ketamine as a model of CDS in the context of 
the OST. This will involve establishing a suitable dosing regimen that will induce deficits 
in the OST using a sub-chronic, sub-anaesthetic dose of ketamine. Furthermore, it will be 
established whether those deficits are transient or long-lasting. Another objective is to 
examine if currently used antipsychotic clozapine can reverse these deficits and how this 
compares to a novel antipsychotic LY404039.  
Secondly, the self-medication hypothesis will be considered; examining whether there is a 
role for nicotine as a cognitive enhancer. Nicotine will be administered in a range of doses 
to see whether nicotine can reverse ketamine-induced deficits. We will also examine 
whether nicotine administration in this task can replicate earlier data showing that nicotine 
administration enhances OST performance in uncompromised animals (Rushforth et al, 
2010). Furthermore, the degree of improvement will be observed and the hypotheses that 
nicotine is reversing the deficit induced by sub-chronic ketamine exposure directly, or 
simply compensating for these deficits will be considered.  
Where appropriate, the nAChRs mediating this process will also be investigated through 
the use of subtype selective agonists for two of the most common nAChRs; the α7 nAChR 
and the α4β2 nAChR. The ability of both Type I and Type II α7 nAChR PAMs to enhance 
OST performance will additionally be assessed to elucidate whether reducing the activation 
point of the α7 nAChR is as effective as a direct α7 nAChR agonist. Whether these effects 
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can be blocked with a selective α7 nAChR antagonist will also be assessed. The 
contribution of the α7 nAChR in mediating the OST will be examined by assessing 
performance in the task following administration of the α7 nAChR antagonist alone.                                   
A neural correlate of working memory will also be established, with the aim of providing 
mechanistic insight into the behavioural effects of nicotine. This will be achieved by 
inducing network rhythms, which are thought to underlie working memory, in rodent PFC 
slices and examining the effect of nicotine on cortical oscillatory activity. The effect of 
both α4β2 and α7 nAChR agonists will also be examined in order to provide comparison 
points between behavioural and in-vitro data.  
 
Examining oscillatory activity in rodent PFC slices may further our understanding of the 
brain regions mediating the effects of nicotine: In order to examine the contribution of the 
PFC behaviourally, nicotine and GABA antagonist muscimol will be administered locally 
into the mPFC, with subsequent testing on the OST providing evidence for or against the 
involvement of this region, as these compounds should enhance and impair performance, 
respectively. 
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Chapter 2 
Materials and Methods 
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2.1 The Odour Span Task 
The protocol for the OST used in this task is based on the original procedures developed by 
Dudchenko et al (2000) and the further four publications using the OST in existence prior 
to the start of these experiments (Dudchenko et al, 2000; Turchi and Sarter, 2000; Young et 
al, 2007a; Young et al, 2007b; Young et al, 2009). The papers published following 
Dudchenko et al (2000) largely used the same training methods, number of scents and 
protocol with some minor changes, including use of mice instead of rats in the studies by 
Young et al (2007b,c and 2009) (Young et al, 2007a; Young et al, 2007b; Young et al, 
2009). Young et al (2007b,c and 2009)  also removed the scents cumin and garlic as the 
mice found them aversive. Dudchenko (2000) established that the OST in rats was not 
dependent on the hippocampus as hippocampectomised rats could still complete the OST 
(Dudchenko et al, 2000). Turchi and Sarter (2000) used the OST to demonstrate in rats that 
a significant role for frontal cholinergic innervations as a 60-80% reduction of AChE 
positive fibres in frontal cortical regions resulted in significant OST impairments (Turchi et 
al, 2000). Young and colleagues (2007b,c) further developed the OST in mice, 
demonstrating that mice overexpressing human caspase c, an apoptogenic protein, 
demonstrated significant impairments in the OST (Young et al, 2007b). Additionally, 
knock-out mice also demonstrated impairments in the OST but not the 5-CSRTT in 
comparison to wild-types, indicating a significant role for the α7 nAChR in mediating 
performance in the OST (Young et al, 2007a). Additionally, Young (2009) also established 
a model of Alzheimer’s disease using Tg2576 mice which over express human amyloid. 
These mice were found to be impaired on the OST and thus provide a model from which 
novel compounds for treatment of Alzheimer’s disease can be treated (Young et al, 2009). 
These studies demonstrate that the OST provides a reasonable window within which to 
examine working memory from both an impairing and enhancing perspective. 
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This task was therefore chosen for use in these studies as it was a reasonably well 
established complex task which had the potential to reflect both positive and negative 
effects of pharmacological compounds on cognition. The use of this task therefore provided 
an opportunity to develop a non-spatial working memory task for preclinical use. Also, as 
lesions of the hippocampus have previously been shown not to impair performance in the 
OST, there was potential for this task to be mediated by the PFC (Dudchenko et al, 2000). 
This means that the OST had the potential for greater translation to human subjects with 
regard to schizophrenia as impairments in working memory have been linked to this region 
(Menon et al, 2001). This task had demonstrated previous success within the lab in 
measuring the enhancing effects of nicotine on cognition in uncompromised subjects. 
2.1.1 Animals 
A total number of 132 male hooded Lister rats (Harlan, UK) were used, trained in cohorts 
of 12 or 24. Rats were aged 8 weeks and weighed 150-200g at the beginning of training. 
Animals were group housed under standard conditions (a temperature regulated room with 
a 12 hour light/dark cycle, lights on at 0700h). Rats were food restricted to 90% of free 
feeding bodyweight at approximately 8 weeks of age, for the duration of the study. Weight 
was monitored daily and amount of food was gradually increased throughout the 
experiment to allow for natural growth. Under this schedule no animals showed a weight of 
less than 85% ad libitum body weight. Ad libitum body weight was determined using a 
Harlan, UK growth chart for freely-feeding animals. Animals were permitted free access to 
water in the home cage and all testing was conducted in the light phase of the 12 hour 
light/dark cycle. All experiment was carried out in accordance with the UK Animals 
(Scientific Procedures) Act, 1986, or the guidelines set out by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) in Belgium. 
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2.1.2 Equipment 
All training and testing took place on a 93cm square platform with 5cm raised border that 
was elevated 83cm from the floor. The platform was made of wood, covered in black vinyl, 
93cm square with 5cm raised border and elevated 83cm from the floor by placing on a table 
(studies in Newcastle University) or a purpose built black plastic platform 95 cm square 
with a 5cm raised border and raised 85 cm from the floor (studies in Janssen). The bowl 
locations were evenly spaced around the platform. Once training began, the position of the 
platform and table was kept the same throughout. Opaque ceramic dishes were used to 
house the scented woodchip used for the task. The 24 following odours were used in the 
task: rosemary, mint, onion powder, oregano, cinnamon, thyme, mixed spice, Chinese-five 
spice, paprika, fenugreek, nutmeg, garlic powder, caraway seed, celery salt, tea leaves, 
ginger, cocoa powder, cumin, coffee powder, coriander, parsley, sage, dill, lemon tea. 
Odours were supermarket own brand or Schwartz™. Three grams of each odour was mixed 
with 100g of clean animal bedding and nine powdered Nestlé® Cheerio’s (added to prevent 
the rat digging in the correct bowl using scent of the food reward). Odours were replenished 
at least every two weeks to ensure the odours did not fade. 
2.1.3 Shaping and acquisition of the Non-Matching-to-Sample rule 
Rats were handled for approximately 5 minutes daily during the week prior to the start of 
training. The initial training sessions took place in a cage on top of the platform. Rats were 
trained to dig in unscented woodchip for a food reward (half a Nestlé
®
 Cheerio). A ‘dig’ 
was counted if the animal displaced any of the woodchip with a foreleg or nose (figure 2.1). 
Once reliably digging in the woodchip for the food reward, scented bowls were introduced. 
The animal dug in the first bowl, retrieved the food reward and was then removed from the 
platform. The first bowl was relocated and a second differently-scented bowl was added. 
The rat had to smell both odours and then dig in the bowl containing the novel odour. This 
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was the only bowl baited. Each rat took part in up to 10 trials per session for 3 sessions 
(time limited to 15 minutes), until they had learned the non-matching-to-sample (NMTS) 
rule. The odours used were chosen randomly each day from the 24 mentioned above using 
a random letter list. All animals were exposed to all 24 scents within the 3 sessions. In all 
sessions, the time at which they were trained or tested was pseudo-randomised with the first 
cage tested being rotated on a daily basis and then tested in cage number order i.e. cages 
4,5,6 then 1,2,3. The first animal tested in each cage was chosen randomly. 
2.1.4 Odour Span Task: Training 
In this phase, rats were introduced to the experimental platform where they underwent one 
further day of NMTS training with only two bowls at a time. From then on, the Odour Span 
Task (OST) proceeded as the NMTS task but after a correct choice was made on the second 
bowl, an additional bowl containing a novel scent was added. This meant the animal had to 
assess all three bowls and choose the third bowl. This was on the basis of scent alone as all 
bowls were relocated to prevent spatial cues aiding the choice, with bowl location 
determined through random number generation. This procedure was repeated until 10 
bowls were present or the rat had spent 15 minutes on the platform. This was the case 
despite any errors in sample choice. If a mistake was made, the animal was removed from 
the platform, the bowls relocated and the animal reintroduced. Once a correct choice was 
made, the rat was permitted to carry on to the next level. At this point, bowls were relocated 
but kept in within 3 locations of each other (a half-OST, figure 2.2). This was done so that 
the animals learned more quickly (approximately 4 sessions) that they must sniff all odours 
before making a choice, rather than attempting to dig in every bowl. Following four half-
OST sessions, animals took part in the full OST, in which bowls could be located in any of 
the 24 spaces and the task was ended once a mistake was made (figure 2.3). This continued 
for a further 9-10 sessions, until the animal’s demonstrated asymptotic performance (table 
2.1, figure 2.4). The main parameter measured in this task was the ‘span’. This was 
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determined as the number of correct, consecutively chosen bowls minus 1 (as the first bowl 
generates no memory load). Asymptotic performance was determined as achieving a span 
of over 5 in at least 2 consecutive sessions and fluctuating within a minimum of 3 spans 
over four consecutive sessions.  For example, 3-5-5-4, 5-7-5-6, and 8-8-6-8 were all 
acceptable span patterns for four sessions. 
2.1.5 Probe sessions and scent marking 
At random points during the training sessions, the reward for a correct choice was dropped 
into the bowl after a correct choice was made. In addition, trials were also carried out 
where every bowl contained a food reward. A correct choice indicated the animals were 
responding to the olfactory cues provided and not to the scent of the reward. Occasionally 
bowls and scented woodchip were replaced during the trial to ensure animals were not 
scent-marking and using this to identify the novel bowl. If a rat was visibly marking the 
bowls, these bowls were removed and replaced with a fresh bowl containing the same 
odour. 
2.1.6 Sub-chronic exposure to ketamine 
Once exhibiting stable performance, ketamine or vehicle treatment was given once daily for 
5 consecutive days. This dosing regimen is based upon that by Becker et al (2003,2004) 
who were able to demonstrate that this regimen caused impairment in the NOR, as well as 
inducing a 25% reduction in prefrontal glutamate that was present 4 weeks post ketamine 
treatment. After acute injection, animals were placed in an incubator until behaviour 
returned to normal which was usually 15-20 minutes. Behavioural effects observed 
following acute ketamine exposure at all doses include head weaving, motor impairment 
and impaired co-ordination. Animals were given two days washout before testing baseline 
and then tested once each day until demonstration of a stable performance.  
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C: Example dig 2 
A: Rat exploring the board 
prior to digging. 
B: Example dig 1 
Figure 2.1: Basic OST training 
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A: Rat moving to 
investigate the bowls 
B: Investigating, but not 
digging in, bowl 1 and 3. 
C: Investigation of bowl 2 
E: Retrieval of 
food reward 
D: Investigation of bowl 4, 
followed by digging. 
Figure 2.2: Half-OST in pictures  
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Figure 2.3: Diagram of the OST task  
Figure 2.3: Initially, the animal is presented with a bowl, scented with a household spice and 
baited with a food reward (A+). The animals must dig in the bowl and retrieve the food 
reward. He is removed from the board, the first bowl now with no food reward, A-, is 
relocated and a second bowl is added in a novel location: B+ is scented with a different odour 
and is baited. The animal must then smell both bowls and only dig in the novelly-scented 
bowl. Once retrieving the second food reward, C+ is now added to A- and B- with all bowls 
relocated. The animal must now dig only in C+ using the novel odour as a guide. This 
continues until the animal spends 10 minutes on the platform, reaches 10 or 15 bowls (training 
vs. testing), or the animal makes a mistake. At any of these points the animal is removed from 
the board and returned to the home cage (Turchi and Sarter, 2000). 
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Table 2.1: The three phases of Odour Span Task training 
Training Session Training Stages 
1-4 Learning the non-matching-to-sample rule. 
5-8 The half-OST: An easier version of the OST in which 
odours are presented in close proximity and relocated when 
a mistake is made. 
9-18 The full-OST: Bowls can now be located in any one of 24 
locations on a 93cm square platform. Locations are chosen 
using a random number generator.   
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Figure 2.4: Acquisition of the OST task   
Figure 2.4: This graph illustrates group acquisition of the OST in the 3 task phases. Session 1 
to 4 demonstrates learning the NMTS rule (green box). Sessions 5 to 8 is performance on the 
half-OST (blue box) and sessions 8 to 18 shows performance on the full OST task (purple 
box). The red line indicates the point at which animals demonstrate asymptotic performance 
and are ready for the next phase. 
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Figure 2.5: OST training and testing timeline flow diagram.  
  
Figure 2.5: This diagram illustrates an example timeline of training snd testing in the OST 
with a 5 day ketamine dosing regimen and testing 5 doses of compound plus vehicle.  
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2.1.7 Odour Span Task: Testing 
Compounds were tested in a crossover design whereby each animal received all compound 
doses, pseudo-randomised across test days. Following a drug testing day, the rats were 
rested to allow for ‘washout’ followed by retraining on the OST prior to the next test. The 
experimenter was blinded to all drug treatments except the α7 nicotinic acetylcholine 
receptor (nAChR) positive allosteric modulator (PAM) compounds as these drugs were 
tested at the same time but were visibly in solution at the highest doses. Blinding was 
carried out by a third party who labelled identical vials of the compound A, B, C, D and 
only revealed the code following the end of the experiments.  
 
2.1.8 Statistical analysis 
The odour span from each group of rats was analysed using a two-way, repeated measures 
analysis of variance (ANOVA) with dose of novel drug as the within-subject factor, and 
ketamine treatment as the between-subjects factor. A two way, repeated measures ANOVA 
was used in these cases as it allowed assessment of effect of multiple drug doses as well as 
then allowing an assessment of any interaction between this effect and prior treatment with 
ketamine or saline.  
One way ANOVAs were also carried out on individual datasets, differentiating on both 
ketamine treated and control vehicles to assess the effects on these individual groups. This 
was done so that the significance of individual doses of drug could be assessed on each 
group. This also revealed the most effective drug dose for each group of animals. 
Post- hoc analysis was carried out using Bonferroni correction for number of comparisons 
made. All data was also subject to Mauchly’s test of sphericity with a significant result 
meaning that the Greenhouse-Geisser corrected p-value was used. Both the Bonferroni  and 
Greenhouse-Geisser corrections were used as they both produce conservative values which 
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means a false-positive result in terms of significance is very unlikely. Significant was 
defined at p<0.05. All analyses were performed using SPSS for Windows (SPSS Inc., 
V19.0).  
 
2.1.9 Choice of drugs 
Ketamine was chosen for use in the odour span task as ketamine can be used in the clinic 
and thus may provide a translational model where other NMDA antagonists such as PCP 
and MK-801 cannot. Krsytal et al (1994) also state that ketamine reproduces the symptoms 
of schizophrenia more accurately than any other compound (Krystal et al, 1994). It has also 
been suggested that whilst acute ketamine treatment may most accurately reproduce the 
psychotic symptoms of schizophrenia, sub-chronic treatment may be more representative of 
cognitive deficits associated with this disorder (Morgan et al, 2009). This is supported by 
Morgan et al 2009) who have shown that long-term ketamine abuse is associated with 
impairments in working memory, episodic memory and executive function (Morgan et al, 
2009). Additionally, as few studies have been carried out with this compound, further 
validation was necessary. In terms of treatment regimen, Becker et al (2003) have shown 
that 30mg/kg dose of ketamine, given once daily for 5 days can impair latent inhibition 4 
weeks after the final ketamine treatment (Becker et al, 2003).  Keilhoff et al (2004) have 
also shown that this regimen induces changes in parvalbumin, neuronal nitric oxide 
synthase and cFOS similar to that found in patients with schizophrenia (Keilhoff et al, 
2004). This regimen was therefore also used for the OST along with a log-smaller dose of 
10mg/kg to see whether this could induce deficits in OST performance.  
Nicotine is a broad spectrum nAChR agonist and as the subject of this these was whether 
nicotinic receptors are valid targets for the treatment of cognitive deficits, it was the ideal  
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Table 2.2: Odour Span Task: Drugs 
Drug Doses Route Vehicle Notes Dose source 
Ketamine 10, 30 mg/kg i.p. 0.9% w/v NaCl  (Becker et al, 2003b) 
Nicotine (systemic) 0.025, 0.05, 0.1 
mg/kg 
i.p. 0.9% w/v NaCl pH 5-5.5 (Rushforth et al, 2010) 
Nicotine (local) 1, 2, 4 µg/side i.c. ACSF  (Hahn et al, 2003b) 
Clozapine 1, 3, 10 mg/kg i.p. 0.9% w/v NaCl Dissolved in 
0.1M HCl.  
Final pH 5.7 
Dose advised from JNJ as a 
result of in house PK data 
LY404039 0.3, 1, 3, 10 
mg/kg 
s.c. 0.9% w/v NaCl  Dose advised from JNJ as a 
result of in house PK data 
PHA-543613 0.3, 1, 3 mg/kg i.p. 0.9% w/v NaCl  (Wishka et al, 2006) 
Metanicotine 0.03, 0.1, 0.3 
mg/kg 
i.p. 0.9% w/v NaCl  (Rushforth et al, 2010) 
5-iodo-A-85380 1, 3, 6µg/kg i.p. 0.9% w/v NaCl  Unpublished in-house data 
(Doses effective in ASST) 
PNU-120596 0.03, 0.1, 0.3, 1, 
3 mg/kg 
s.c. 5% DMSO + 5% 
solutol + PBS 
Dosing = 
3ml/kg 
Sonicated 
1,3 mg/kg in 
suspension 
Dose advised from JNJ as a 
result of in house PK data 
Compound T 0.1, 0.3, 1, 3, 9 
mg/kg 
i.p. 10% cyclodextrin 
in sterile H2O + 
NaCL 
Dosing = 
5ml/kg 
Sonicated 
Dose advised from JNJ as a 
result of in house PK data 
Methyllycaconitine 2, 6 mg/kg i.p. 0.9% w/v NaCl  Dose advised from JNJ as a 
result of in house PK data 
Muscimol 1, 2 µg/side i.c. ACSF  (Stackman et al, 2012) 
  
Dosing was 1ml/kg unless otherwise stated and all values are expressed as those of the base. All 
drugs were supplied by Sigma Aldrich, UK; Tocris, UK or Johnson and Johnson, Belgium and 
pH balanced to 7 unless otherwise stated 
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compound for use in the OST. In addition, it had previously been shown in this lab to 
improve OST performance in uncompromised animals (Rushforth et al, 2010).  
Clozapine was chosen as this compound has been reported as the most effective 
antipsychotic for the treatment of cognitive deficits. In addition other pharmacological 
models of schizophrenia using NMDA antagonist such as PCP, where cognitive deficits 
have been induced, clozapine can reverse these impairments (Grayson et al, 2007). It was 
therefore important to examine whether this would be the same in a ketamine-based model.  
LY404039 was chosen as it had recently been shown in a Phase II clinical trial to be as 
effective as olanzapine in the treatment of the positive symptoms of schizophrenia. The 
effects of this compound on cognition were not reported so examining the effect of 
LY404039 on the OST aimed to further knowledge on this compound. 
PHA-543613 was chosen to investigate the α7 nAChR as it is selective for the α7 nAChR 
with good brain penetration and reported in-vitro and in-vivo activity (Acker et al, 2008; 
Wishka et al, 2006). 5-Iodo-A-85380 (5IA) and metanicotine were also chosen for their 
selectivity, but for the α4β2 nAChR (Lippiello et al, 1996). 5IA has also been shown to 
elicit dopamine release in the PFC and metanicotine has previously been demonstrated to 
improve OST performance in uncompromised animals (Livingstone et al, 2009). 
Choice of α7 allosteric modulator was done in conjunction with Janssen Pharmaceutical 
companies of Johnson and Johnson (JNJ). In order to get an indication of mechanism both 
Type I and Type II allosteric modulators were chosen. The first, PNU-120596 is the best 
characterised Type II PAM and has been shown to have cognitive-enhancing properties in-
vivo (Hurst et al, 2005; Timmermann et al, 2007).Compound T is type I PAM in 
development by JNJ and advised as a suitable compound for testing in the OST. JNJ 
conducted PK studies to ensure doses of both drugs were brain penetrant 
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MLA is a well characterised nAChR antagonist that has been shown to be selective for the 
α7 nAChR (Ward et al, 1990). Turek et al (1995) demonstrated doses of MLA which are 
brain penetrant and also confirmed that pharmacologically relevant concentrations of MLA 
are present in the brain following systemic administration (Turek et al, 1995). In addition, 
Schilstrom et al (2007) have shown that administration of MLA attenuated galantamine-
induced DA release (Schilstrom et al, 2007). MLA has also been shown by Tucci et al 
(2003) to block nicotine-induced behaviour (Tucci et al, 2003). This compound was 
therefore chosen in order to block the α7 nAChR in order to assess the contribution of this 
receptor to performance in the OST.  
Muscimol is a well characterised potent GABAA antagonist with partial antagonist activity 
at the GABAC receptor (Akhondzadeh and Stone, 1995; Johnston, 1996). Application of 
muscimol can inactivate specific brain regions when given locally and has been shown by 
Stackman et al (2012) to cause impairments in working memory (Stackman et al, 2012). 
Muscimol was therefore chosen for use in the OST in order to inactivate the PFC to 
ascertain whether this would impair OST performance, which would indicate a contribution 
of this brain region in mediating this task. 
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2.2 Surgery and local injection procedure 
2.2.1 Implanting bilateral cannulae into the medial prefrontal cortex (mPFC) 
Rats were anaesthetised and maintained under anaesthesia using isoflurane and their eyes 
coated with opthalmic ointment. They were given meloxicam (1mg/kg s.c.) before being 
mounted into a stereotaxic frame (Kopf Instruments, CA, USA) with the incisor bar set 
5mm above the interaural line. The head area was shaved, wiped with alcohol and then 
iodine solution was applied. A central incision to expose the skull was made. Topical local 
anaesthetic was applied, rubbed in using a cotton bud and left for 30 seconds to act. 
Following this, 5 small crew holes were made (two anterior, three posterior with the central 
middle posterior being the furthest back) and screws attached by 1.5 turns. Two small holes 
were drilled bilaterally using coordinates relative to bregma (AP +2.8 mm, L ±0.5 mm, V 
4.0 mm). The guide cannulae (22 gauge; Plastics One, Roanoake, Va., USA) were lowered 
to 1mm above the target sites and fixed in place using dental screws and light-fixing dental 
cement. Three sutures were put in place to secure (one anterior, two posterior). Following 
surgery, rats were given additional local anaesthetic along with 1ml saline (s.c.) to assist 
rehydration and placed in a 27ºC recovery chamber with ad libitum access to water and 
food pellets soaked in warm water. Animals were then pair housed and left to recover for 
10 days with further doses of meloxicam given for the first 5 days. Animals were weighed 
throughout and checked daily for any sign of infection or pain which was treated 
accordingly (meloxicam (Metacam) 1.5mg/kg i.o. for pain relief and enrofloxacin (Baytril) 
10mg/kg s.c. for infection prevention).  
 During the experimental process, the caps used to protect the cannulae were occasionally 
chewed by the cohabiting rat but these were easy to replace and posed no significant 
problem. This improved animal welfare in comparison to usual procedures (single housing) 
and prevented any effects that social isolation may have had on OST performance.  
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Figure 2.6: Surgical apparatus 
 
Figure 2.6: (A) Depicts the surgical apparatus used to implant bilateral cannulae into the 
mPFC of rats trained in the OST. (B) Provides further detail on the stereotaxic frame 
including ear bars, incisor bar and anaesthesia mask. 
A 
B 
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Following testing on the OST, animals were locally administered methylene blue and 
immediately culled by decapitation. Brains were removed and frozen and then sliced using 
a cryostat to verify correct cannulae placement with placements located within the PrL/ACg 
region. Four animals were removed from data analysis, two animals died before data 
collection was complete and their cannulae placements were not collected. Two animals 
had cannulae placements outside of the PrL, IL or ACg regions and were therefore removed 
from data analysis. Methylene blue distribution is representative of the distribution of drug 
approximately 5 minutes into the OST task. This means that at the start of the task, drug 
would be more localised and additionally distributed further upon completion of that task. 
This is also assuming that the distribution of methylene blue and test compounds are 
comparable and so it is possible that this may not be exactly the same as test compounds. In 
addition, only coronal slices and not horizontal slices were taken which means that the 
basis for inclusion or elimination here are as a result of vertical diffusion only. 
All animals were treated in accordance with procedures outlined by the AAALAC with 
additional advice from the in-house animal welfare and veterinary team. 
 
2.2.2 Local injection procedure 
Following the recovery period, animals were retrained and then tested on the OST to assess 
baseline. Prior to the first intracranial injection, rats were subjected to a sham handling 
procedure prior to a training session. Animals were lightly restrained and subject to a 
bilateral microinjection of saline in a volume of 0.5 µl over a 27 second period, after which 
the injection cannulae were left in place for further 60 seconds before training on the OST. 
Delivery was from a Hamilton syringe mounted in an infusion pump connected to the 
injection cannulae by polycarbon tubing. The tips of the injection cannulae (28 gauge; 
Plastics One) extended beyond the guide cannulae by 1mm.  
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Figure 2.7: Cannulae placement 
  
Figure 2.7: This shows a coronal section of the rat brain that has been adapted to 
demonstrate the location of the implanted cannulae. The overlaid section with methylyne 
blue dye demonstrates the area of the mPFC reached by local injection. 
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2.3 Gamma frequency network oscillations 
2.3.1 Preparation of the brain slices 
Male hooded Lister rats weighing 200-300g were anaesthetised with inhaled isoflurane and 
then given ketamine and xylazine (100mg/kg + 10mg/kg i.m.). Upon termination of 
respiration, animals were intracardially perfused with 50ml of modified artificial cerebral 
spinal fluid (in mM: 252 sucrose, 3 KCl, 1.25 NaH2PO4, 24 NaHCO3, 2 CaCl2, 10 glucose 
and 2 MgSO4). All animals were sacrificed in accordance with the UK Animals (Scientific 
Procedures) Act 1986. 
The brain was then removed and submerged in ACSF at a temperature of 4–5°C. 450µm 
thick coronal prefrontal cortex (PFC) slices were cut using a Leica vibroslice. Slices were 
held in a holding chamber and maintained at room temperature in oxygenated (95% O2, 5% 
CO2) ACSF. After one hour, slices were placed into an interface recording chamber and 
maintained at 31-32°C with a continuous 1.2ml/minute stream of oxygenated, humidified 
ACSF (in mM: 126 NaCl, 3 KCl, 1.25 NaH2PO4, 24 NaHCO3, 1.6 CaCl2, 10 glucose). 
2.3.2 Initiation of gamma frequency oscillations 
After a further 30 minutes in the recording chamber, gamma frequency oscillations were 
generated by simultaneous bath application of the cholinergic agonist carbachol (10µM) 
and the ionotropic glutamatergic agonist kainate (200nM). Gamma frequency activity was 
recorded extracellularly in the prelimbic (PrL) regions of the PFC (figure 2.7). Power, peak 
frequency and amplitude values of persistent gamma oscillations were taken from power 
spectra generated from a 60 second recording of PFC activity using Fourier analysis in the 
Axograph software package (Axon Instruments, Foster City, CA). Power was defined as 
the area under the peak in the power spectra between 15 and 48 Hz for  
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Figure 2.8: Location of extracellular recording 
 
  
Figure 2.8: Coronal schematic representation of the rat PFC showing subregions: Cg1 - 
anterior cingulate cortex; PrL - prelimbic cortex; IL – infralimbic cortex (Paxinos and 
Watson, 1998).  
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gamma frequency oscillations. Following application of carbachol and kainate, gamma 
oscillations increase in size; stabilising after 2 to 3 hours. Upon establishing a stable 
baseline, defined as three consecutive area readings with no more than 10% change, test 
compounds were delivered via the circulating bath artificial cerebrospinal fluid (ACSF).   
2.3.3 Measuring and recording gamma frequency oscillations 
Extracellular recording electrodes were pulled from borosilicate glass (Harvard Apparatus 
Ltd., Kent, UK) and filled with ACSF with resistance in the range of 2–5M.  Gamma 
frequency activity was recorded extracellularly in the PrL regions of the PFC. Power, peak 
frequency and amplitude values of persistent gamma oscillations were taken from power 
spectra generated from a 60 second recording of PFC activity using Fourier analysis in the 
Axograph software package (Axon Instruments, Foster City, CA). Power was defined as 
the area under the peak in the power spectra between 15 and 48 Hz for gamma frequency 
oscillations.  
2.3.4 Statistical analysis 
Analysis was carried out using Sigmaplot 11 software. Different statistical tests were used 
according to the dataset in question. This included both one way and two way ANOVA 
where appropriate, for normally distributed data with Holm-sidak post hoc analysis. Paired 
t-tests in the form of Wilcoxon Signed Rank Tests were used for data which was not 
normally distributed. For clarity, the type of analysis used is stated within each 
experimental dataset for Chapter 7. 
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Table 2.3: Electrophysiology: Drugs 
Drug Concentration Supplier 
Isoflurane  Abbott Laboratories Ltd., Kent, UK 
Ketamine 100mg/kg Ketaset, Fort Dodge Animal Health Ltd., UK 
Xylazine 10mg/kg Millpledge Veterinary, Retford, UK 
Carbachol 10µM Sigma-Aldrich, UK 
Kainate 200nM Tocris, UK 
Nicotine 1, 10µM Sigma-Aldrich, UK 
Mecamylamine 10µM Sigma-Aldrich, UK 
PHA-543613 10µM Sigma-Aldrich, UK 
5-iodo-A-85380 3µM Sigma-Aldrich, UK 
 
ACSF Ingredients (BHD-Merck UK and Sigma Aldrich, UK) 
126mM NaCl, 
3mM KCl  
1.25mM NaH2PO4     
24mM NaHCO3 
1.6mM CaCl2     
10mM glucose 
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Chapter 3 
The effect of exposure to a sub-
chronic, sub-anaesthetic 
ketamine dosing regimen on 
OST performance. 
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3.1 Introduction 
N-methyl-D-aspartate receptor (NMDAR) antagonism has long since been used to model 
cognitive deficits associated with schizophrenia (CDS). MK-801, also known as 
dizocilpine, is a non-competitive NMDAR antagonist widely used to model the symptoms 
of schizophrenia in animals that has been shown to induce psychosis and impair cognition 
(Andine et al, 1999; de Lima et al, 2005; Mandillo et al, 2003). Translation of models 
using MK-801 is however, complex as it is not licensed for clinical use due to long lasting 
effects and the ability of this compound to induce neuronal necrosis (Allen and Iversen, 
1990).  Another NMDAR antagonist commonly used to model symptoms of schizophrenia 
is phencyclidine (PCP). Luby et al (1959) first administered sub-anaesthetic doses of PCP 
to healthy volunteers in 1959: PCP induced wide-ranging symptoms similar to those 
present in patients with schizophrenia, including negative symptoms which were not 
adequately reproduced in the main pharmacological model of the time using amphetamine 
(Luby et al, 1959). Luby et al (1959) thus proposed PCP as a more viable pharmacological 
model of schizophrenia and, pre-clinically, it is still widely used today (For review see 
Neill et al, 2010). However, like MK-801, PCP is not approved for clinical use due the 
severity and longevity of its effects: PCP induces long-lasting psychosis, exacerbates 
symptoms in patients with schizophrenia and has high abuse liability (Krystal et al, 1994b). 
Ketamine is a less potent analogue of PCP which is approved for clinical use. This is 
largely because the psychotomimetic effects seen with acute, sub-anaesthetic doses of 
ketamine are transient and reversible. This means ketamine can be used to induce cognitive 
deficits in humans with a reduced risk of serious adverse psychological events and shorter 
lasting effects than PCP (Anis et al, 1983; For review see Morgan and Curran, 2006). 
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Krystal et al (1994) demonstrated that ketamine (0.1 and 0.05mg/kg) could dose-
dependently induce positive, negative and cognitive symptoms associated with 
schizophrenia in healthy subjects and proposed that these sub-anaesthetic doses of ketamine 
could induce the range of symptoms present in schizophrenia more effectively than any 
other compound (Krystal et al, 1994a). A double blind, placebo controlled study carried out 
by Malhotra et al (1997) supported this finding: Thirteen neuroleptic-free patients were 
treated acutely with sub–anaesthetic ketamine and demonstrated significantly exacerbated 
psychotic symptoms and cognitive impairment (Malhotra et al, 1997a). This suggests that 
ketamine administration has significant face validity as a model of schizophrenia and was 
therefore chosen for use in this task.  
The ability to use compounds both pre-clinically as well as in human subjects is useful in 
the development of novel targets for the treatment of CDS. Pre-clinically, Taffe et al (2002) 
demonstrated that sub-anaesthetic doses of ketamine could impair cognition in rhesus 
monkeys. Seven monkeys were trained in a neuropsychological battery including delayed 
match-to-sample and self-ordered-spatial search tasks. Treatment with ketamine induced 
impairments in both of these tasks suggesting impaired visual recognition and working 
memory. Impairments were both dose and task-difficulty dependent whereby impaired 
performance was evident following lower doses of ketamine in more difficult tasks (Taffe 
et al, 2002).   
In rats, Verma and Moghaddam (1996) have demonstrated that acute ketamine 
administration impairs performance in a spatial delayed alternation task (Verma and 
Moghaddam, 1996). Smith et al (2011) similarly found that animals treated with acute sub-
anaesthetic doses of ketamine demonstrated reduced accuracy on both the 5-Choice-Serial-
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Reaction-Time-Task (5-CSRTT) and the delayed-match-to-position task. However, the 
authors also comment that difficulties were experienced at higher ketamine doses as few 
animals completed the designated minimum number of trials (Smith et al, 2011). This is 
because ketamine can produce significant motor disturbances when given acutely, which 
can affect the ability of animals to complete a task. In addition to singular doses of 
ketamine producing only transient impairments in cognitive performance; it has been 
proposed that sub-chronic, sub-anaesthetic ketamine exposure may produce a more 
representative model of CDS.  
Sub-chronic, sub-anaesthetic treatment would reduce the confounding acute, non-cognitive 
effects of ketamine on cognitive task performance. Morgan et al (2009) also provide 
evidence that this regimen could translate into humans, demonstrating that long-term 
ketamine abuse is associated with impairments in working memory, episodic memory and 
executive function (Morgan et al, 2009). There has been limited use of sub-chronic 
ketamine in animal models but Becker et al  (2003) used a daily ketamine (30mg/kg) 
regimen for 5 days that induced significant behavioural and neurochemical impairments 
that were present 4 weeks post-treatment (Becker et al, 2003a).  
The present study therefore aimed to assess whether sub-chronic, sub-anaesthetic exposure 
to ketamine could induce significant deficits in the Odour Span Task (OST) and which dose 
of ketamine would prove most effective going forward.  
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3.2 Methods 
Male hooded-Lister rats (125-150g; Harlan UK, n=24) were trained in the OST until 
demonstration of asymptotic performance. Once trained, animals were pseudo-randomly 
assigned to treatment groups and treated with ketamine (10 or 30mg/kg i.p.) or vehicle 
daily for 5 consecutive days. Following a two day washout, animals were tested on the OST 
task to assess deficits. Initially, tests were carried out daily until performance in ketamine-
treated animals was stable. Following evidence of a consistent impairment, assessment of 
baseline performance was carried out every three days to examine the longevity of these 
effects. Animals were treated according to procedures outlined in the UK Animals 
(Scientific Procedures) Act 1986. 
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3.3 Results 
3.3.1 Sub-chronic, sub-anaesthetic ketamine treatment impaired OST performance 
A one way analysis of variance (ANOVA) revealed a significant effect of ketamine 
(F(2,23)=19.92, p<0.001) on OST task performance. Bonferonni post-hoc analysis revealed 
that administration of both the 10 and 30mg/kg doses of ketamine significantly impaired 
OST performance (p<0.01; p<0.001, respectively; Figure 1).   
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Figure 3.1: Sub-chronic, sub-anaesthetic administration of NMDA antagonist ketamine 
impaired OST performance 
  
# 
 
* 
 
S
p
a
n
 ±
 S
E
M
 
Figure 3.1: This figure demonstrates the effect of two doses of ketamine (10 and 30 
mg/kg) on span length in the OST. Both groups of animals (n=8) treated with ketamine 
exhibited significantly decreased span length when compared with the performance of 
control animals. Data shown is from the first day of testing following 2 days of ketamine 
treatment washout and is representative of the deficits present throughout the compound 
testing phase. # denotes statistical significance from vehicle treatment (p<0.01) * denotes 
statistical significance from vehicle treatment (p<0.001).. 
Ketamine mg/kg 
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3.3.2 Ketamine-induced deficits were stable and long lasting 
A two-way ANOVA revealed a significant effect of ketamine treatment over the 5 testing 
dates (F(2,70)=58.07, p<0.001). There was no significant interaction between treatment and 
day of testing, suggesting that a statistically similar effect of treatment was seen on each 
day (F(8,70)=0.28, p=0.97 n.s.). Further analysis was performed using separate one-way 
ANOVAs, examining each group of ketamine-treated animals per dose. This analysis 
revealed that both groups of animals treated with ketamine at 10 or 30mg/kg demonstrated 
impaired OST performance when compared to vehicle-treated controls, (F(1,79) = 78.98, 
P<0.001, F(1,79) = 93.68, P<0.001), respectively (figure 3.2).   
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Figure 3.2: The deficits induced by NMDA antagonist ketamine deficits were stable and 
long lasting 
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Day Post-Ketamine Treatment 
Figure 3.2: Treatment with sub-chronic ketamine at both 10 and 30 mg/kg (n=8) induced 
significant deficits in OST task performance that were still present at day 10 following the 
final ketamine exposure. * denotes statistical significance of the 10mg/kg ketamine-
treated group from the vehicle-treated group (p<0.001). # denotes statistical significance 
of the 30mg/kg ketamine-treated group from the vehicle-treated group (p<0.001). 
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3.4 Discussion 
This study demonstrates that sub-chronic exposure to ketamine at both 10 and 30mg/kg is 
effective in causing significant and lasting working memory deficits in the OST (For 
publication see Rushforth et al, 2011). This supports previous findings by Vanancio et al 
(2011) who administered ketamine (5mg/kg) for 14 days and observed impairments in the 
Novel Object Recognition (NOR) task (Venancio et al, 2011). Interestingly, in the same 
study, no effect was seen at the higher 10mg/kg dose. This is different to the findings in this 
study where the higher 30mg/kg dose was statistically no more effective than the 10mg/kg 
dose; raising the possibility that lower doses of ketamine may still produce a significant 
impairment in the OST task. Becker et al (2003) however, demonstrated that rats exposed 
to sub-chronic, sub-anaesthetic ketamine at 30mg/kg daily for 5 days demonstrated 
impaired cognitive performance 4 weeks post last exposure (Becker et al, 2003a). 
Additionally, this study also found that neurochemically, glutamate binding in the 
prefrontal cortex was decreased by 25%, potentially as a result of a reduction in PV+ve 
interneurons in the PFC (Becker et al, 2003; Behrens et al, 2007). This may explain the 
long-lasting effects of treatment with ketamine in this study and supports the theory that 
changes in OST performance may be due to a hypoglutamatergic state in the prefrontal 
cortex (PFC).  
 
Behrens et al (2008) have shown that repetitive exposure to ketamine increases levels of the 
inflammatory cytokine interleukin-6 (IL-6). IL-6 has been shown to increase cortical 
nicotinamide adenine dinucleotide phosphate- (NADPH-) oxidase levels in the PFC, in turn 
significantly enhancing brain superoxide levels. This oxidative stress has been shown by 
Behrens to cause dysfunction in parvalbumin-containing GABAergic interneurons (Behrens 
et al, 2008). Spike timing in pyramidal neurons is controlled by GABAergic activity and 
any changes in GABA could therefore affect the synchronised firing underlying gamma 
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frequency oscillations (Fisahn et al, 1998). These oscillations are known to have a role in 
information processing, encoding and retrieval and so ketamine-induced damage to 
GABAergic interneurons could affect the functioning of gamma frequency oscillations and 
ultimately lead to cognitive impairment (Cunningham et al, 2006).  
Zhang et al (2008) have shown that a reduction in GABA results in reduced power of 
gamma frequency oscillations. Animals were treated with ketamine (30mg/kg) for two days 
and sacrificed on the following day. Electrophysiological analysis of brain slices taken 
from these animals revealed a 20% reduction in GABA receptor-mediated mini inhibitory 
postsynaptic currents (mIPSCs) in comparison to vehicle-treated controls. This group also 
found a 31% reduction in the presence of glutamic acid decarboxylase 67 (GAD67), a key 
enzyme for GABA synthesis, in parvalbumin interneurons (Zhang et al, 2008). This means 
that aberrant GABA activity may be part of the mechanism surrounding cognitive deficits 
in schizophrenia. Support for this comes from post-mortem studies of patients with 
schizophrenia who show a significant reduction in GAD67 expression in GABAergic 
interneurons (Benes et al, 2007; Volk et al, 2000). In addition, Lee et al (2003) found that 
gamma frequency oscillations are reduced in schizophrenia and the degree to which this 
reduction occurs, correlates with the negative symptoms of the disease (Lee et al, 2003).   
Clinically, Morgan et al (2009) carried out a cross-sectional study examining ketamine 
abuse and cognition. Five groups were examined consisting of frequent ketamine users, 
infrequent ketamine users, abstinent users, poly-drug controls and non-users of illicit drugs. 
Subjects were examined on a variety of cognitive tasks including working memory, pattern 
recognition memory and verbal fluency. They found frequent ketamine use was associated 
with impairments in working memory, episodic memory and executive function as well as 
decreased psychological wellbeing. In contrast, infrequent or ex-users did not have 
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significant cognitive impairments but did have increased delusional and dissociative 
symptoms (Morgan et al, 2009). This study was followed up a year later, re-examining 
80% of the original subjects in the same battery of tasks. Again, cognitive deficits were 
observed mainly in frequent ketamine users whereby increases in ketamine use over the 
previous year was associated with a decline in working memory and pattern recognition 
memory (Morgan et al, 2010). This supports the use of a sub-chronic ketamine regimen in 
rats to model cognitive deficits but does raise the possibility that these effects may not be as 
long-lasting in human subjects. It is possible that the dose used in our study (10mg/kg, i.p.) 
may be higher than that those used by recreational users (0.6-2.2mg/kg, given orally) and if 
this was the case, could account for the lasting effects seen here (Shram et al, 2011). 
However, the route of administration and data collection methods are different in the study 
by Shram et al (2011) and so this cannot be stated conclusively. 
An additional finding by Morgan and colleagues (2010) was that frequent and abstinent 
ketamine users were found to have increased depression scores over the 12 months between 
the two assessments (Morgan et al, 2010). Although further work would be needed to 
confirm this effect, it is particularly interesting given the recent interest in the use of 
ketamine to treat depression (For review see Murrough, 2012). 
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3.5 Conclusions 
Administration of ketamine causes significant deficits in OST performance and may prove 
to be a clinically relevant model of cognitive deficits associated with schizophrenia. 
However, further work must be carried out to assess whether these deficits can be reversed 
as well as examining the effect of current, clinically effective antipsychotics. Further work 
also needs to be undertaken to understand the neurobiological and neurochemical 
mechanisms mediating the effects of sub-chronic, sub-anaesthetic doses of ketamine on 
cognition. 
For future work, the lower dose of ketamine (10mg/kg) will be used as this dose produced a 
significant and long-lasting deficit. This follows the National Centre for the Replacement, 
Refinement and Reduction of Animals in Research’s (NC3R’s) guidelines to reduce, refine 
and replace wherever possible in experimental work with animals. In this study the 
10mg/kg dose was observed to cause less behavioural distress than the 30mg/kg dose as 
well having a shorter recovery time.  It may also be possible that a lower dose will produce 
a deficit which is more sensitive to cognitive restoration. The next chapter examines the 
reversal of these ketamine induced deficits with nicotine and antipsychotics. 
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Chapter 4 
The effect of nicotine, 
clozapine and LY404039 
on ketamine-induced 
cognitive deficits 
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4.1 Introduction 
Tobacco smoking is undertaken by approximately 30% of the general population, a figure 
that rises to approximately 80% when you consider patients with schizophrenia alone. As 
the vast majority of patients smoke, smoking has been proposed as a form of self-
medication to ameliorate deficits in cognition (de Leon et al, 1995).  
Nicotine, the primary psychoactive agent in tobacco smoke, is well known for its cognitive-
enhancing effects. Studies with tobacco smokers have demonstrated that cognitive deficits 
induced by smoking abstinence can be restored by nicotine administration in various 
memory and attention tasks (Atzori. et al, 2008). Nicotine administration has also been 
shown to improve cognition in non-smokers but these results are not as conclusive with 
variation between studies: Foulds et al (1996) tested abstaining smokers and non-smokers 
in a 9-task cognitive battery and found that nicotine improved reaction time in both groups, 
but only enhanced performance in abstaining smokers (Foulds et al, 1996). Jubelt et al 
(2008) also tested the effect of nicotine on non-smoking patients with schizophrenia and 
non-smoking controls. In this study, nicotine treatment improved accuracy in recognising 
novel items and response speed in both groups, but a more pronounced effect was found in 
non-smokers with schizophrenia (Jubelt et al, 2008).  
Pre-clinically, Socci et al (1995) has shown that systemic nicotine improves performance in 
the Morris Water Maze (MWM) in both young and aged rats (Socci et al, 1995). Hahn et al 
(2003) have also demonstrated that local administration of nicotine into the prefrontal 
cortex (PFC) was effective in enhancing accuracy in the 5-Choice-Serial-Reaction-Time-
Task (5-CSRTT) in rats (Hahn et al, 2003a). Furthermore, previous work in our lab has 
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also demonstrated that nicotinic agonists can enhance Odour Span Task (OST) performance 
in normal animals. Uncompromised animals treated with nicotine or specific α4β2 and α7 
nicotinic acetylcholine receptor (nAChR) agonists demonstrated significantly enhanced 
performance in the OST when compared to vehicle-treated controls (Rushforth et al, 2010). 
However, it remains to be seen whether activation of nAChRs can restore ketamine-
induced deficits in the OST. 
It is also unknown whether current antipsychotic treatments can reverse ketamine-induced 
deficits in the OST. The large-scale Clinical Antipsychotic Trials of Intervention 
Effectiveness (CATIE) trial showed that atypical antipsychotics such as olanzapine, 
risperidone and quetiapine modestly improved cognition in patients with schizophrenia 
(Keefe et al, 2007).  Clozapine has also been widely studied in clinical trials focusing on 
cognitive performance and has been shown to improve attention, learning and memory 
more effectively than other atypical agents. However, these effects are modest at best and 
performance is still within the impaired range (For review see Weiss et al, 2002). As a 
result, cognitive deficits still represent a significant unmet clinical need for patients with 
schizophrenia.  
Despite the successful use of N-methyl-D-aspartate receptor (NMDAR) antagonists to model 
symptoms of schizophrenia, it is only recently that a glutamatergic drug has been tested 
with any success. LY404039 is a highly selective agonist for metabotropic glutamate 
receptors 2/3 (mGluR2/3), developed by Eli Lilly and currently in Phase II clinical trials for 
treatment of schizophrenia. Activation of mGluR2/3 functions to normalise the excessive 
glutamatergic tone characteristically found in schizophrenic patients. Patil et al (2007) 
carried out a double-blind, placebo controlled study with LY2140023 (an oral pro-drug of 
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LY404039) in patients with schizophrenia, using olanzapine as an active control. Patients 
treated with LY2140023 or olanzapine showed statistically significant improvement in both 
positive and negative symptoms when compared to placebo (Patil et al, 2007a). These 
results are encouraging but the failure of the subsequent trial due to an effect of placebo 
means that further research will be necessary to elucidate the full role for mGluR2/3 in 
terms of treatment for cognitive deficits (Kinon et al, 2011). 
The present experiments aim to assess whether nicotine and novel mGluR2/3 agonist 
LY404039 are effective in reversing ketamine-induced deficits in OST performance. This 
study will also examine the effect of clozapine on OST performance as a point of reference 
to other studies and measures of cognition. 
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4.2 Methods 
On establishing stable performance, the first cohort of hooded Lister rats (n=24) were 
pseudo-randomised into 3 groups (n=8) and treated with vehicle or ketamine (Sigma 
Aldrich, U.K. 10 or 30mg/kg i.p.) for 5 consecutive days. They were given 2 days wash 
out, then tested on the OST for 3 consecutive days and periodically after this to assess the 
stability of the ketamine-induced deficits in performance.  Following this, rats were treated 
with vehicle or acute nicotine (Sigma Aldrich, U.K. 0.025, 0.05, and 0.1 mg/kg i.p., (n=8)) 
10 minutes before testing in a within-subjects, repeated measures design. Here, each rat 
received each dose in a pseudo-randomised fashion with a day washout between each test 
day.  
The second cohort of rats (n=24) were trained in the OST until demonstrating asymptotic 
performance and then pseudo-randomised into two groups (n=12/group) and treated with 
ketamine (10mg/kg) or vehicle for 5 consecutive days after.  Once deficits were evident and 
stable, the two groups were each split in half (n=6/group) and assigned drug treatment. 
Drug treatment was with either the atypical antipsychotic clozapine (1, 3 and 10 mg/kg i.p.) 
45 minutes prior to testing on the OST, or novel mGluR2/3 agonist LY404039 (0.3, 1, 3, 10 
mg/kg s.c.) 30 minutes prior to testing.  
Both experiments were designed in a within subjects, repeated measures format in which 
each animal served as his own control, receiving all doses over a period of 3 weeks. Doses 
were randomised to ensure no effect of day. Testing occurred in a 3 day cycle examining 
baseline OST performance on day one, compounds were tested on day 2 and day 3 was a 
wash-out day with no testing or training.  
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4.3 Results 
4.3.1 Nicotine dose-dependently enhanced OST performance 
A repeated measures analysis of variance (ANOVA) revealed an overall effect of nicotine 
on OST performance (F(2,30)=14.54, p<0.001).  No significant interaction between pre-
treatment and nicotine was found (F(4,30)=0.90, p=0.48 n.s.) indicating that nicotine had 
the same effect regardless of whether subjects had previously received ketamine or vehicle 
treatment (figure 4.1). 
To examine the most effective dose on each pre-treatment group, a one way ANOVA was 
carried out on each individual dataset.  Each ANOVA demonstrated a significant effect of 
nicotine on saline, ketamine 10mg/kg and ketamine 30mg/kg pre-treatment (F(3,23)=3.42, 
p<0.05), (F(3,23)=8.89, p<0.05) and (F(3,23)=10.47, p<0.01) respectively. Bonferroni 
post-hoc analysis indicated that the 0.05mg/kg dose was only individually statistically 
significant dose in saline-pre-treated animals (p<0.05). In both of the ketamine pre-
treatment groups, both the 0.05 and 0.1mg/kg doses had a significant effect with the 
0.1mg/kg dose producing the most significant enhancement in OST performance (p<0.05) 
(figure 4.1). 
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Figure 4.1: Administration of nicotine (n=8) enhanced OST performance in both control 
and ketamine treated animals in a dose-dependent manner. The 0.1mg/kg nicotine dose 
achieved full reversal of ketamine-induced deficits to baseline and the 0.05mg/kg nicotine 
dose improved performance in control animals. * denotes statistical significance from 
vehicle-treated control animals (p<0.05). # denotes statistical significance from vehicle 
treated animals with ketamine-induced deficits (p<0.05) 
Figure 4.1: Broad spectrum nAChR agonist nicotine dose-dependently enhanced OST performance  
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4.3.2. Clozapine had no effect on ketamine-induced deficits in the OST and impaired 
control animals 
A two-way repeated measures ANOVA revealed clozapine had an overall significant effect 
on OST performance, (F(3,30)=6.20, p<0.01), along with a significant interaction with 
ketamine (F(3,30)=4.55, p<0.05). When further analysed with a one way ANOVA, 
clozapine had no significant effect on OST performance in animals previously exposed to 
ketamine, (F(3,23)=0.10, p=0.96 n.s.), but caused a dose dependent impairment in 
performance of control animals, F(3,23)=10.91, p<0.001) (figure 4.2).   
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Figure 4.2: Clozapine had an overall effect on OST performance with a significant 
interaction between dose of clozapine and ketamine pre-treatment (n=6) (p<0.01: p<0.05, 
respectively). Further analysis determined that acute administration of clozapine had no 
effect on ketamine-treated animals, but caused a dose dependent impairment in 
performance of control animals (p=0.96, p<0.001 respectively).  *denotes statistical 
significance from vehicle treated animal where p<0.001. 
Figure 4.2: Atypical antipsychotic clozapine had no effect on ketamine-induced deficits 
in the OST and impaired control animals 
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4.3.3 LY404039 had no effect on ketamine-induced deficits in the OST and impaired 
control animals 
A two-way repeated measures ANOVA revealed LY404039 had an overall significant 
effect on OST performance, (F(4,40)=12.28, p<0.001), along with a significant interaction 
with ketamine (F(4,40)=3.52, p<0.01). Further analysis using a one way ANOVA has 
shown LY404039 impaired in performance of control animals (F(4,29)=5.55, p<0.01), and 
had a small but significant overall effect in animals treated with ketamine (F(4,29)=3.76, 
p<0.05). However, Bonferroni post-hoc analysis did not reveal any individual dose of 
LY404039 to have a significant effect on OST performance in ketamine treated animals 
when compared to vehicle treatment (figure 4.3).  
 
  
 96 
0 
2 
4 
6 
8 
10 
12 
Vehicle 0.3 1 3 10 
Vehicle 
Ketamine (10mg/kg) 
Figure 4.3: LY404039 had an overall effect on OST performance with a significant 
interaction between dose of LY404039 and ketamine pre-treatment (n=6) (p<0.001: 
p<0.01, respectively). Further analysis determined that acute administration of LY404039, 
like clozapine, caused an impairment in control animals (p<0.01). LY404039 also had an 
overall significant effect on ketamine-treated animals (p<0.05) but post-hoc analysis 
revealed that no individual dose was able to produce a statistically significant 
improvement. *denotes statistical significance from vehicle treated animal where p<0.01 
Figure 4.3: Novel mGlu2/3 agonist LY404039 had no effect on ketamine-induced deficits 
in the OST and impaired control animals 
 
 
 
 
 
 
 
 
 
 
 
  
S
p
a
n
 ±
 S
E
M
 
LY404039 mg/kg  
* 
 
 97 
4.4 Discussion 
Administration of clozapine had no effect on the performance of ketamine treated animals 
in the OST whilst, at the highest dose, also causing a significant impairment in the 
performance of vehicle-treated animals. This lack of improvement in impaired animals, is 
in contrast to studies such as that by Grayson et al (2007) who demonstrated that clozapine 
can reverse a phencyclidine- (PCP-) induced deficit in the novel object recognition (NOR) 
task (Grayson et al, 2007). However, Levin et al (2006) support the findings of this study 
by demonstrating that clozapine potentiated hippocampal lesion-induced deficits the radial 
arm maze (RAM) (Levin and Christopher, 2006a). Clinical data also supports these 
findings: McGurk et al (2005) examined the effect of clozapine on spatial working memory 
in patients with schizophrenia using a computerised delayed response test whereby 
treatment with clozapine lead to a significant impairment in performance on the task 
(McGurk et al, 2005). Melzer and McGurk (1999) also reviewed 12 studies investigating 
the effect of clozapine on cognition. They concluded that whilst clozapine was effective in 
measures of attention and verbal fluency, results were inconclusive when considering 
outcome in tasks involving working memory (Meltzer and McGurk, 1999). The findings of 
the current study are in line with clinical data but there are alternative explanations for 
these results: The dose of ketamine used in these studies may maximally reduce cognitive 
performance to a point where any subtle effects of antipsychotic treatment are lost. This 
theory is supported by the fact that both 10 and 30mg/kg doses reduced OST task 
performance to a similar degree (Chapter 3). Clinically, clozapine is also given repeatedly 
and takes several weeks before showing significant effects on cognitive performance, it 
may be that chronic or sub-chronic administration is necessary in order to see significant 
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results. A study carried out by Gray et al (2009) however, does not support this theory; 
mGluR5 knockout (KO) mice were treated with 5mg/kg clozapine (i.p.) daily for 8 weeks 
but still failed to show any improvement in Y-maze performance (Gray et al, 2009). Whilst 
the efficacy of clozapine in restoring compromised animals is not conclusive, the impairing 
effect on the performance of control animals is a well documented effect (Addy and Levin, 
2002; Levin and Rezvani, 2007; Pocivavsek et al, 2006). This effect has been replicated in 
various studies and has been attributed to the potent anti-muscarinic activity of this 
compound (McGurk et al, 2005). Overall, these data provide a meaningful point of 
reference when considering novel compounds in the OST task for the treatment of 
ketamine-induced deficits. 
LY404039 (10mg/kg) impaired control animal performance, possibly as a result of 
significant motor effects observed at this dose. This could prevent normal completion of the 
OST task and the poor performance may not therefore reflect impairments in cognition per 
se. At lower doses, where no motor disturbance was observed, LY404039 has no effect in 
control animals and was ineffective in restoring performance in animals with ketamine-
induced working memory deficits, although a significant overall effect of LY404039 was 
found in ketamine-treated animals. 
mGluR2/3 are primarily localised presynaptically where they are negatively coupled via Gi 
proteins to adenylate cyclase. LY404039 acts as an agonist at the mGluR2/3 which 
functions to inhibit glutamate release, reducing postsynaptic excitability (Manzoni et al, 
1997). This, in theory, should function to normalise the excessive glutamatergic tone found 
in patients with schizophrenia and thus improve associated deficits. In this study, 
LY404029 showed an overall trend towards improvement but no singular dose of this 
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compound significantly enhanced OST performance. As with clozapine, the effect of 
ketamine treatment on the OST may be so marked that it may be masking a significant 
effect of LY404039. In addition, chronic treatment may be more beneficial in reversing 
these deficits: The 2007 clinical trial by Patil and colleagues report a significant effect of 
LY404039 in treating positive symptoms at week four of treatment, suggesting acute doses 
may be insufficient to see significant changes although the effects of this compound 
specifically on cognition are not discussed in their report (Patil et al, 2007a). In addition 
further clinical trials have since been carried out which did not find any significant effect of 
LY404039 in patients due to an overwhelming effect of placebo (Kinon et al, 2011). 
Despite this, it is possible that this compound may prove useful with further investigation 
but too few clinical or pre-clinical studies on the effects of this compound on cognition 
exist to make full conclusions at this stage. 
In contrast, nicotine has been well characterised, showing a significant, and in most cases 
enhancing, effect on cognition in smokers, non-smokers, laboratory animals previously 
exposed to nicotine, and nicotine naϊve animals (Levin et al, 2006b). This supports the 
finding in this study that nicotine (0.025, 0.05 and 0.1mg/kg) dose-dependently enhances 
OST working memory performance in both control and ketamine treated animals in 
comparison to vehicle-treated controls. This is in addition to previous findings from our 
laboratory indicating nicotine improved task performance in normal animals. 
Uncompromised male hooded Lister rats treated acutely with nicotine (0.05 or 0.1mg/kg) or 
vehicle 10 minutes prior to testing on the OST task demonstrated enhanced performance in 
comparison to vehicle-treated controls (Rushforth et al, 2010) 
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Ketamine-treated animals improved significantly following nicotine treatment but did not 
perform as well as control animals given the same dose of nicotine. Newhouse et al (2004) 
proposed that nicotine has differential effects, depending on both the state of the subject 
undergoing tests and also the nature of the task used. If a subject is cognitively impaired 
and thus exhibiting sub-optimal performance, performance is enhanced by nicotine 
administration. However, if the subject is performing optimally, nicotine will have no effect 
or may even impair performance. Similarly, if the subject has no impairment but the task is 
particularly demanding, this effectively puts the subject in a sub-optimal state and therefore 
nicotine administration in this situation will also have beneficial effects (Newhouse et al, 
2004a). This explains the data observed in our research on several levels:  Firstly, because 
the OST is a highly demanding task, nicotine is beneficial in normal uncompromised rats 
and dose-dependently improves performance. Secondly, because rats treated sub-
chronically with ketamine perform sub-optimally, nicotine also enhances performance here. 
Furthermore, rats treated with ketamine only return to control baseline performance upon 
nicotine administration. Thus, is it proposed that nicotine can only compensate for either 
the impairment or the high demands of the task and thus nicotine will only restore impaired 
individuals to a normal level of performance. 
The nAChR is the primary target responsible for mediating the diverse actions of nicotine 
on behaviour (Wonnacott et al, 2005). Nicotine elicits the release of a multitude of 
neurotransmitters crucial to cognition, including acetylcholine (ACh), dopamine (DA), 
glutamate, serotonin (5-HT, 5-hydroxytryptamine) and gamma-aminobutyric acid (GABA) 
(Decker and McGaugh, 1991; ED Levin and BB Simon, 1998; Wonnacott et al, 1989). The 
exact mechanism by which nicotine mediates improved cognition is still unknown but is it 
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likely that the α7 and α4β2 nAChR subtypes have a significant role in this process. This is 
supported by Young et al (2007) who demonstrated that α7 KO mice demonstrated 
impaired performance in comparison to wild-type controls (Young et al, 2007a). Moreover, 
previous work in our laboratory using the OST has shown that both α7 specific agonist (R)-
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide (Compound A)  and 
α4β2 specific agonist metanicotine could significantly improve OST performance in normal 
animals (Rushforth et al, 2010).  In the next study, the effect of selective nAChR 
antagonists on OST performance in ketamine-treatmed animals was therefore examined. 
This allowed further insight into relevant nAChR targets for the development of novel 
compounds for treating cognitive deficits but also furthered our mechanistic understanding 
of nicotine’s effect on cognition. 
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4.5 Conclusions 
Neither clozapine nor LY404039 restored performance in ketamine treated rats tested on 
the OST. This replicates data found in the literature and serves as a comparison point to 
other cognitive tasks. In contrast, nicotine administration fully reversed ketamine-induced 
OST deficits as well as improving performance in uncompromised subjects. However, 
future work must be carried out to elucidate the nAChR subtypes which mediate this effect. 
Taken together, these data support the use of ketamine in the OST to model cognitive 
deficits in schizophrenia and indicate that nAChRs may be useful targets for the 
development of novel targets for their treatment. 
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Chapter 5 
Examining the effect of α7 and 
α4β2 nAChR agonists on ketamine- 
induced deficits in the OST 
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5.1 Introduction 
Acute administration of nicotine improves the performance of control animals in the Odour 
Span Task (OST) in addition to restoring impairments in rats following ketamine-treatment. 
The nicotinic acetylcholine receptor (nAChR) subtype mediating this process is yet to be 
fully elucidated as nicotine is known to activate multiple nAChR subtypes. There is 
however likely to be a role for α7 and α4β2 nAChRs in working memory tasks as rats 
treated with α4β2 and α7 nAChR selective agonists show improved performance 
(Buccafusco et al, 2007; Chan et al, 2007; Rushforth et al, 2010). In addition, 
administration of selective nAChR antagonists impairs performance in working memory 
tasks and transgenic knockout (KO) mice lacking either the β2 or α7 nAChR subunits also 
exhibit impaired performance on the radial arm maze (RAM); a well-established measure 
of spatial working memory in the rat (Chan et al, 2007; Levin et al, 2009).  
 
The α4β2 nAChR agonist metanicotine is highly selective for the α4β2 nAChR and has 
been shown to improve performance in cognitive tasks (For review see: Bencherif et al, 
1996; Lippiello et al, 1996). Lippiello et al (1996) demonstrated that metanicotine 
improved performance in rats showing cognitive deficits in the RAM following ibotenic 
acid lesions to the nucleus basilis and medial septal area (Lippiello et al, 1996). Rushforth 
et al (2010) have also shown that metanicotine can enhance performance in the OST in 
uncompromised animals, but whether this compound is effective in improving OST 
performance in compromised animals is currently unknown. 5-Iodo-A-85380 (5IA) is also 
a selective agonist for the α4β2 nAChR with additional secondary affinity for the α6β2 
nAChR, and is thus considered as a beta2* agonist. This compound has yet to be fully 
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examined behaviourally, but Livingstone et al (2009) have demonstrated that 5IA is able to 
elicit dopamine (DA) overflow in the prefrontal cortex (PFC), which may represent a 
mechanism by which α4β2 nAChR activation is able to improve performance in cognitive 
tasks (Livingstone et al, 2009). 5IA also exhibits rapid blood-brain barrier penetration, low 
toxicity and a high degree of specificity for β2* nAChRs versus the α7 nAChR (Mukhin et 
al, 2000). PHA-543613 (PHA), in contrast, is highly selective for the α7 nAChR. Like 5IA, 
PHA has demonstrated efficacy in-vitro, but this compound is also effective in-vivo: 
Wishka et al (2006) found that PHA ameliorated sensory gating deficits induced by acute 
exposure to amphetamine as well as enhancing cognitive performance in the Novel Object 
Recognition (NOR) task (Wishka et al, 2006). This suggests there may be a significant 
contribution from both the α4β2 and/or α7 nAChRs to memory processes and that either or 
both of these receptors may contribute to the enhancing effect of nicotine in the OST. 
 
This study therefore aims to assess the effects of α4β2 and α7 nAChR selective agonists on 
OST performance in normal and compromised rats to elucidate the contribution of these 
nAChR subtypes to the cognitive enhancing effects of nicotine in the OST task. 
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5.2 Methods 
Two cohorts (n=12, n=24 respectively) of male hooded Lister rats (125-150g; Harlan UK) 
were trained in the OST until demonstration of asymptotic performance. Cohort one was 
trained and tested in Newcastle University by research associate Emma Malcolm 
(Newcastle Upon Tyne, UK). I trained and tested cohort two in Janssen Pharmaceutical 
Companies of Johnson and Johnson (Beerse, Belgium). Once trained, animals were pseudo-
randomly assigned to treatment groups and treated with ketamine (10mg/kg, i.p.) or vehicle 
daily for 5 consecutive days. Following a two day washout, animals were tested on the OST 
task to assess deficits. Once the ketamine-induced deficits were stable, animals were 
pseudo-randomly allocated to treatment groups (n=6/group). Animals were then tested in a 
two day testing, one day washout routine whereby baseline was measured on day one, on 
day two animals were treated with either α7 agonist PHA (cohort one; 0.3, 1 and 3mg/kg 
i.p.), α4β2 agonists metanicotine (0.03, 0.1 and 0.3mg/kg i.p.) or 5IA (1, 3 and 6 µg/kg i.p.) 
(Cohort two), or vehicle and then tested on the OST. Day three was a washout day with no 
testing. In this design, each animal received all doses of the respective compounds or 
vehicle and thus served as his own control. Animals in cohort one were treated according to 
procedures outlined in the UK Animals (Scientific Procedures) Act 1986 and in cohort two 
according to procedures outlined in the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC). 
  
 107 
5.3 Results 
5.3.1 The α7 nAChR agonist PHA improved OST performance in compromised animals 
Acute administration of PHA at doses of 0.3, 1 and 3mg/kg produced contrasting effects in 
normal and compromised animals. This was evident from the significant interaction 
obtained between sub-chronic ketamine treatment and dose (F(3,21) = 5.40, p<0.01), 
suggesting that PHA treatment caused differing effects in control and ketamine-treated rats. 
Further analysis was carried out in the form of separate one-way ANOVAs, examining 
vehicle-treated and ketamine-treated animals as separate groups. This analysis revealed that 
PHA had no effect on uncompromised animals (F(3,3) = 18.11, p=0.61 n.s.) when 
compared to vehicle-treated controls. Conversely, PHA improved overall performance in 
ketamine-treated animals when compared to the vehicle-treated control subjects (F(3,20) = 
10.46, p<0.001). Bonferroni post-hoc comparisons revealed that the 3mg/kg doses to be the 
most effective (p<0.05). Pairwise comparisons revealed the performance of ketamine-
treated animals following the 3mg/kg dose of PHA was no different from vehicle-treated 
controls, suggesting a full restoration (p=0.54 n.s.) (figure 5.1).  
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Figure 5.1: The α7 nAChR agonist PHA improved OST performance in compromised animals 
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Figure 5.1: This figure demonstrates that the group of animals with ketamine-induced 
impairments in OST performance (n=6) were significantly improved following PHA 
administration to a point where performance of ketamine-treated and vehicle treated 
animals was insignificantly different (p<0.01; p=0.54 ns, respectively). The seeming 
impairment caused by PHA in control animals was not statistically significant (P=0.061 
n.s). * denotes statistical significance from vehicle treatment (p<0.05). 
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5.3.2 Acute administration of metanicotine improved performance in the OST 
Acute administration of metanicotine dose-dependently enhanced OST task performance 
(F(3,23) = 9.70 p<0.01). There was no interaction between the two factors (F(3,18)= , 
p=0.69, n.s.), suggesting  that metanicotine was able to enhance OST performance 
irrespective of ketamine pre-treatment. One way ANOVAs conducted for each group 
revealed that metanicotine treatment significantly enhanced performance in both vehicle-
treated and ketamine-treated animals (F(3,14) = 6.54 p<0.01, F(3,11) = 4.75 p<0.05).  
Bonferroni post-hoc analysis revealed the 0.1mg/kg dose of metanicotine to be the most 
effective dose in both groups (figure 5.2) (p<0.05). 
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Figure 5.2: Acute administration of α4β2 agonist metanicotine improved performance in 
the OST 
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Figure 5.2: Animals with ketamine-induced impairments in OST performance (n=6) were 
significantly improved following metanicotine (p<0.05). Metanicotine also significantly 
enhanced performance in control subjects (p<0.01). * denotes statistical significance from 
vehicle treatment where p<0.05 in control subjects and # denotes statistical significance 
from vehicle treatment where p<0.05 in ketamine-treated subjects. 
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5.3.3 Acute administration of 5IA improved performance in the OST 
A two way ANOVA revealed a significant overall effect of 5IA in the OST (F(3, 20) = 
9.16, p<0.01). There was however, no interaction between pre-treatment and 5IA indicating 
that the effects were similar in both groups (F(3,3) = 2.32, p = 0.29, n.s). Individual one 
way ANOVAs for each group, separated by pre-treatment, revealed that administration of 
5IA produced a dose-dependent increase in task performance in ketamine-treated animals 
(F(3,19) = 8.5, p<0.01), with Bonferroni post-hoc analysis showing the 6µg/kg dose to be 
most effective (p<0.001). This was not observed in control subjects with no overall effect 
of treatment in this group alone (F(3, 4) = 1.5, p = 0.25 n.s.). Pairwise comparisons within 
ketamine–treated and vehicle-treated groups given 5IA at 6µg/kg demonstrated full 
restoration of OST performance as there was no significant difference between these two 
groups (p = 0.25, n.s.). 
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Figure 5.3: Acute administration of α4β2 agonist 5IA improved performance in the OST 
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Figure 5.3: Animals with ketamine-induced impairments in OST performance (n=6) were 
improved following 5IA (p<0.01) to a point where full restoration was seen and 
performance of control animals and ketamine-treated animals were insignificantly 
different (p=0.25, n.s.). 5IA had no statistically significant effect on control subjects 
(p=0.25, n.s.). * denotes statistical significance from vehicle treatment where p<0.01.  
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5.4 Discussion 
The α7 nAChR selective agonist PHA dose-dependently enhanced OST performance in 
ketamine-treated rats, suggesting α7 nAChRs may mediate the improvements observed 
with nicotine in the OST task (Chapter 3). However, in contrast to the effect seen with 
systemic nicotine treatment, performance was not improved to baseline control animal level 
by PHA administration. Additionally, although a small impairment seems evident, PHA 
had no statistically significant effect on the performance of control animals on the OST. 
This result was unexpected because PHA has previously been shown to improve 
performance in the NOR task (Wishka et al, 2006) and other agonists selective for the α7 
nAChR have also been shown to improve cognition. Pichat et al (2007) showed that a 
selective α7 nAChR agonist SSR180711 was able to reverse impairments in the Morris and 
Linear maze (Pichat et al, 2007). Meyer et al (1997) also used the Morris maze to 
demonstrate that rats impaired by means of bilateral ibotenic acid lesions of the nucleus 
basalis made fewer errors following acute administration of the α7 agonist 3-(2,4-
dimethoxybenzylidine) anabaseine (DMXBA) (Meyer et al, 1997). In addition, previous 
work in the present laboratory has shown another α7 nAChR agonist, Compound A, to be 
effective in enhancing the performance of uncompromised animals in the OST task 
(Rushforth et al, 2010). 
Mechanistically, activation of α7 nAChRs located on glutamatergic terminals facilitates the 
release of glutamate and subsequent activation of ionotropic glutamate receptors in various 
neuronal networks (Livingstone et al, 2010). Gamma-aminobutyric acid (GABA)ergic 
activity is influenced by metabotropic glutamate receptor (mGluR) activation, subsequently 
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mediating the synchrony, power and duration of gamma frequency oscillations which are 
central to working memory processes (Traub et al, 2004; Whittington et al, 1995). Howard 
et al (2003) provide clinical evidence; they  demonstrated that gamma frequency 
oscillations increased linearly with cognitive load (Howard et al, 2003). Tallon-Baudry et 
al (1998) also observed that gamma frequency oscillations were induced during the delay 
period of the delayed-matching-to-sample task where, in order to complete the task 
successfully, the memory of the original stimulus must be maintained. Conversely, this 
induction was not found when memory maintenance was not required, suggesting the 
involvement of gamma frequency oscillations in the maintenance of information in working 
memory (Tallon-Baudry et al, 1998).  
This suggests that α7 nAChR activation is able to modulate working memory through 
regulation of gamma frequency oscillations. However, glutamate release induced by α7 
nAChR activation also activates mGluRs on dopaminergic neurons, facilitating DA release 
(Livingstone et al, 2010). This can also shape working memory processes by influencing 
the fidelity of synaptic transmission and facilitating long term potentiation (LTP). The α7 
nAChR is central to these processes as demonstrated by Ondrejcak et al (2012) who found 
that α7 nAChR agonist Compound A was able to persistently enhance synaptic 
transmission in the hippocampus and that this effect was blocked by α7 antagonist 
methyllycaconitine (MLA) (Ondrejcak et al, 2012). Welsby et al (2006) was also able to 
show that MLA prevented nicotine–induced enhancement of LTP induction in the rat 
dentate gyrus, providing further evidence of a role for the α7 nAChR in these processes 
(Welsby et al, 2006).  
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This overwhelming evidence of α7 nAChR involvement in memory processes, along with 
previous work demonstrating that selective α7 nAChR agonist Compound A is able to 
improve OST performance in control animals, suggests that the impairment induced by 
PHA administration is not necessarily representative of α7 nAChR agonism in this task 
(Rushforth et al, 2010). The results seen here may instead be as a result of unknown non-
specific effects of PHA, particularly as this compound has not been tested extensively in-
vivo. However, it is also possible that PHA rapidly desensitises the α7 nAChR, functioning 
to reduce transmission in the relevant neuronal networks and thus causing cognitive 
impairments. Support for this theory comes from Seipel and Yakel (2010) who demonstrate 
that PHA is able to cause inhibition of dopaminergic neurons through desensitisation of α7 
nAChRs following high frequency stimulation (Seipel and Yakel, 2010). They also show 
that this effect is similar to that produced by selective antagonism of the α7 nAChR with 
MLA. Rapid desensitisation of the α7 nAChR following PHA administration may explain 
why PHA treatment did not restore ketamine-treated animals to their baseline level of 
performance. It is however unlikely that the complete α7 nAChR population were 
desensitised as control animals were still able to perform the task to a higher standard than 
compromised animals, and PHA treatment was also able to enhance OST performance in 
ketamine-treated animals. It may be that ketamine-treated animals present such a low 
baseline that even minimal activation of α7 nAChRs has a beneficial effect, especially if 
this results in modulation of aberrant gamma frequency oscillations, which may not be 
present in animals without ketamine-induced deficits. 
In contrast to treatment with α7 agonists, both α4β2 agonists were effective in fully 
restoring OST performance in ketamine-treated animals.  This supports findings by 
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Lippiello et al (1996) who profiled metanicotine in comparison to nicotine using the RAM. 
They found that metanicotine administration reduced the number of errors made by 
compromised animals but that metanicotine was not as efficacious as nicotine in improving 
task performance (Lippiello et al, 1996). Metanicotine at a dose of 0.3µmol/kg was also 
effective in improving performance of control animals in the cued RAM, which supports 
our earlier data with metanicotine in the OST (Rushforth et al, 2010). The β2* nAChR 
agonist 5IA has not been tested extensively in-vivo but the results in this study complement 
neurochemical findings:  Livingstone et al (2009) demonstrated that 5IA was able to elicit 
dopamine release in the rat PFC; an effect that was blocked by α4β2 antagonist dihydro-
beta-erythroidine (DHβE) (Livingstone et al, 2009). This may explain how α4β2 nAChRs 
mediate the enhanced OST performance seen in this study, although glutamate has also 
been implicated in this process: Lambe et al (2003) demonstrated that nicotine was able to 
induce glutamate release from thalamocortical axons onto layer V pyramidal neurons in the 
PFC, increasing spontaneous excitatory postsynaptic currents (sEPSCs). Induction of 
sEPSCs can strengthen thalamocortical connections which are essential to working memory 
processes. They determined the involvement of α4β2 nAChRs by demonstrating that both 
β2 KO mice and animals treated with α4β2 antagonist DHβE did not demonstrate this 
increase in sEPSCs. Conversely, an agonist of the α7 nAChR did not cause any induction of 
sEPSCs (Lambe et al, 2003).  This is a potential mechanism by which activation of α4β2 
nAChRs may enhance PFC activity. This activity strengthens cortical networks which are 
weakened in patients with schizophrenia (Krystal et al, 2003; Pinault, 1995). 
Activation of the α4β2 nAChR has also been shown to enhance GABAergic inhibition in 
pyramidal neurons; more so than through activation of α7 nAChRs (Alkondon and 
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Albuquerque, 2004; Aracri et al, 2010). It is this disinhibition of GABA signalling that is 
thought to be responsible for the cognitive deficits induced by N-methyl-D-aspartate 
receptor (NMDAR) antagonists such as ketamine that model those deficits seen in patients 
with schizophrenia (Alkondon et al, 2004; Krystal et al, 1994b; Moghaddam et al, 1997). It 
may be that normalising GABA signalling compensates for the disruption following 
ketamine treatment, which could explain the greater efficacy of both metanicotine and 5IA 
in comparison to PHA in enhancing OST performance in compromised animals. 
Despite these improvements neither α7 nor α4β2 agonist treatment was as effective as 
systemic nicotine treatment in enhancing OST performance (Rushforth et al, 2010). Since 
nicotine acts at several nAChRs, this may indicate a potential synergistic effect of 
activating more than one nAChR subtype is necessary for the full agonist effect of 
activating nAChRs to be realised. 
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5.5 Conclusions 
α4β2 nAChR agonists metanicotine and 5IA are more effective in enhancing OST task 
performance in both compromised and control animals than α7 agonist PHA. This may 
suggest that the α4β2 nAChR is the prominent receptor mediating the effect of nicotine on 
OST performance. However, since the maximal effect of nicotine OST performance could 
not be fully replicated by α4β2 nAChR agonists alone, optimal performance is more likely 
to be achieved by co-activation of this receptor along with the α7 nAChR subtype. An 
alternative explanation is that the α7 nAChR is being rapidly desensitised with an agonist 
present and so the next chapter examines the effects of α7 positive allosteric modulators 
which should increase the activity of the α7 nAChR as well as negating any desensitisation 
effects.  
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Chapter 6 
Allosteric modulators for the α7 
nAChR improve OST performance: 
An effect blocked by α7 antagonist 
methyllycaconitine 
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6.1 Introduction 
Nicotine fully reverses working memory deficits in the Odour Span Task (OST) caused by 
sub-chronic ketamine exposure, as well as improving performance in uncompromised 
animals (See chapter 3, 4, and Rushforth et al, 2011). The selective α4β2 nicotinic 
acetylcholine receptor (nAChR) agonists 5-Iodo-A-85380 (5IA) and metanicotine were also 
able to improve OST performance. This effect was not however, observed with 
administration of α7 nAChR agonist PHA-543613 (PHA). PHA was only able to modestly 
enhance performance in compromised animals and impaired performance of control 
animals. The author proposed this was as a result of the α7 nAChRs becoming desensitised, 
thus ultimately reducing nAChR-induced neurotransmitter output (Chapter 5). Treatment 
with α7 allosteric modulators may present a viable alternative to treatment with α7 nAChR 
agonists as they can reduce desensitisation and convert already desensitised receptors to an 
active state, as well as lowering the threshold at which the receptor is stable in an open 
conformation (Hurst et al, 2005). More specifically, receptors exist in multiple states and 
allosteric modulators are able to change the overall properties of the receptor by modifying 
the isomerisation coefficients between these states. Positive allosteric modulators (PAMs) 
lower the energy barrier between resting and active states, increasing the effect produced by 
an agonist or endogenous ligand (Monod et al, 1965). There are two types of PAM: Type I, 
which increase the peak current across the current and Type II, which act by both 
increasing the peak current as well as changing the point at which the receptor becomes 
desensitised. 
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Steroids, such as 17-β-estradiol, have been shown to act allosterically at the α4β2 nAChR 
but in some cases demonstrate differing actions in rat and human: Paradiso et al (2001) 
demonstrated that 17-β-estradiol was unable to increase acetylcholine (ACh) currents in 
rodent α4β2 nAChRs but it was able to do so in human α4β2 nAChRs (Paradiso et al, 
2001). The metallic chemical element zinc is also able to modulate the α4β2 nAChR, 
increasing ACh-induced currents at α4β2 receptors. It is however, non-selective; also acting 
positively at α7 nAChRs, negatively at α3β2 nAChRs as well as having activity at the 5-
hydroxytryptamine (serotonin, 5-HT)1A receptor (Barrondo and Salles, 2009; Hsiao et al, 
2001). As a result of limited development of selective α4β2 nAChR PAMs, most are non-
selective; providing few useful pharmacological tools for allosteric modulation of the α4β2 
nAChR. The only current compound of interest which has been reported is α4β2 PAM 
NS9283, which was recently shown by Timmermann and colleagues (2012) to improve 
performance in the 5-Choice-Serial-Reaction-Time-Test (5-CSRTT) and the Morris Water 
Maze (MWM) (Timmermann et al, 2012). This is the first study to examine the effect of 
NS9283 on cognition and so further work is necessary. 
In contrast, development of PAMs for the α7 nAChR has been more favourable: 
Ivermectin, an antihelminthic agent and a Type I PAM, was identified as the first selective 
α7 nAChR PAM. Krause et al (1998) demonstrated that ivermectin was able to enhance 
ACh-evoked currents in both human and chick α7 nAChRs (Krause et al, 1998). NS-1738 
also belongs to the Type 1 PAM class and has been shown to enhance the potency of ACh 
in-vitro. In addition, NS-1738 improves recognition memory and is able to reverse 
scopolamine-induced impairment in the MWM (Timmermann et al, 2007). Compound T is 
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a novel Type I PAM in development by Janssen Pharmaceutical Companies of Johnson and 
Johnson that is yet to be examined in a working memory task.  
Of the Type II class of α7 nAChR PAMs, the best characterised is PNU-120596 (PNU). 
Hurst et al (2005) demonstrated that this compound was able to increase ACh-induced 
signals and reduce the level of receptor desensitisation as well as improving cognitive 
processes. PNU therefore may be useful in assessing the whether the α7 nAChR is involved 
in mediating improvements in OST performance (Hurst et al, 2005).  
One of the most frequently used compounds to assess the contribution of the α7 nAChR in 
a given task is the selective α7 nAChR antagonist methyllycaconitine (MLA). MLA has 
been shown to impair performance in the radial arm maze (RAM), a test of spatial working 
memory, where the involvement of the α7 nAChR has been well characterised (Felix and 
Levin, 1997). However, it is yet to be determined whether MLA causes impairment in the 
OST or prevents any α7 nAChR PAM-induced enhancements in OST performance.  
This study will assess the effect of  Type I and Type II PAMs compound T and PNU on 
improving OST performance in both control animals and those with ketamine-induced 
deficits, as well as whether MLA is able to block these effects. This should further our 
knowledge on the contribution of the α7 nAChR to performance in the OST and contribute 
to the development of novel compounds for the treatment of cognitive deficits associated 
with schizophrenia (CDS).  
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6.2 Methods 
Male hooded Lister rats (n=24) initially weighing 125-150g (Harlan UK) were trained in 
the OST until demonstration of asymptotic performance. They were then pseudo-randomly 
assigned to treatment groups and administered ketamine (10mg/kg i.p.) or vehicle daily for 
five consecutive days. Following a two day washout, animals were then tested to assess 
deficits. Once deficits were evident and stable, animals were pseudo-randomly allocated to 
one of four treatment groups (n=6/group). Animals were then tested in a two day testing, 
one day washout routine whereby day one measured baseline OST performance and day 
two measured OST performance following treatment with either α7 nAChR PAM PNU 
(0.03, 0.1, 0.3, 1 and 3mg/kg), compound T (0.1, 0.3, 1, 3 and 9mg/kg) or vehicle. Day 
three was a washout day with no testing or training. In this design, each animal received all 
doses of the respective compounds as well as vehicle and thus served as his own control. 
The difficulty of getting PNU into solution should be noted: All doses of this compound 
were sonicated to assist solubility but the 1 and 3mg/kg doses of this compound remained 
in suspension which was taken into consideration when interpreting results.  
Following the conclusion of this experiment, all animals were given maintenance training 
every other day for a period of one week to ensure a stable baseline. They were then tested 
on the OST task following administration of the most effective dose of PNU (0.3mg/kg) or 
compound T (1mg/kg) in conjunction with MLA (2, 6mg/kg). Animals were treated 
according to procedures outlined in the UK Animals (Scientific Procedures) Act 1986. 
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6.3 Results 
  6.3.1 Acute administration of α7 allosteric modulator PNU improved OST 
performance 
A two way repeated measures analysis of variance (ANOVA) revealed a significant overall 
effect of PNU administration (F(3,29) = 5.99, p<0.01) . There was also a significant 
interaction between PNU treatment and ketamine pre-treatment suggesting that PNU had 
differing effects dependent upon ketamine or vehicle pre-treatment (F(3,29) = 3.84, 
p<0.05). One-way ANOVA analysis examining vehicle-treated and ketamine-treated 
animals as separate groups revealed that acute administration of PNU had no significant 
effect on OST performance of control animals (F(5,35) = 0.94,  p=0.47 n.s.). In contrast, 
ketamine-treated animals displayed a dose-dependent improvement in performance 
(F(5,35) = 8.86, p<0.01), with Bonferroni post-hoc tests confirming that the 0.1 and 
0.3mg/kg PNU were the most effective doses when compared to vehicle treated controls 
(p<0.05, p<0.01 respectively). At this dose, pairwise comparisons revealed that the 
performance of ketamine-treated animals was not significantly different from vehicle-
treated controls (p=0.33 n.s.) (figure 6.1). 
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Figure 6.1: Acute administration of α7 allosteric modulator PNU improved OST 
performance 
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Figure 6.1: PNU administration improves performance in ketamine-treated animals (n=6) 
with both 0.1 and 0.3mg/kg doses being most effective (p<0.05, p<0.05 respectively). At 
the 0.3mg/kg dose, the performance of ketamine treated animals and control animals in 
the OST task was insignificantly different (p=0.33). PNU also had no discernible effect on 
the OST performance of control animals (p=0.47). * denotes statistical significance from 
vehicle treatment (p<0.05) 
* 
* 
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6.3.2: The α7 allosteric modulator Compound T improved OST performance 
A two way repeated measures ANOVA demonstrated that Compound T had a significant 
overall effect on OST performance (F(3,26)=5.85, p<0.01). A significant interaction 
between Compound T administration and pre-treatment was also observed (F(3,26)=3.68, 
p<0.05), suggesting that Compound T had differing effects dependent upon ketamine or 
vehicle pre-treatment.  
Further analysis using a one-way ANOVA that examined vehicle-treated and ketamine-
treated groups individually revealed that acute administration of Compound T had no 
significant effect on OST performance of control animals (F(5,35) = 0.35, p=0.88 n.s.). 
However, the performance of ketamine-treated animals was significantly improved 
following compound T administration (F(5,35) = 6.13, p<0.01), with Bonferroni post-hoc 
analysis indicating the 1, 3 and 9mg/kg doses to be most effective (p<0.05, p<0.01 p<0.01 
respectively). 
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Figure 6.2: The α7 allosteric modulator Compound T improved OST performance 
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Figure 6.2: Administration of Compound T was able to improve performance in 
ketamine-treated animals (n=6) with the 1, 3 and 9mg/kg doses being effective (p<0.05, 
p<0.01 p<0.01 respectively). Compound T had no discernible effect on the OST 
performance of control animals (p=0.88). # denotes statistical significance from vehicle 
treatment (p<0.05) and * denotes statistical significance from vehicle treatment (p<0.01) 
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6.3.3: The a7 antagonist MLA blocked α7 PAM-induced improvements in OST 
performance and also impaired uncompromised animals 
 
A one way ANOVA demonstrated that, in control subjects, a significant impairment of 
OST performance was induced by MLA administration (F(2,17) = 15.14, p<0.001). 
Bonferroni post-hoc tests revealed this impairment in response to both the 2mg/kg and 
6mg/kg doses of MLA (p<0.01, p<0.001) (figure 6.3). 
Prior to treatment with MLA, baseline OST performance following the most effective dose 
of PNU (0.3mg/kg) was re-examined in both control and ketamine treated animals. When 
the same animals were then given this dose of PNU in conjunction with prior MLA, an 
overall significant effect of MLA was observed (F(2,20) = 10.18, p<0.01). There were no 
interaction effects between the two factors F(2,20) = 2.54, p=0.10 n.s.) suggesting that 
treatment had the same effect irrespective of ketamine or vehicle pre-treatment. Further 
analysis using one way ANOVAs in both control and ketamine groups demonstrated that 
MLA treatment had no significant effect on the performance of control animals (F(2,17) = 
2.72, p=0.12 n.s). However, MLA was able to block the enhancing effects of PNU 
0.3mg/kg on ketamine-treated animals: Following administration of MLA at 2 or 6mg/kg, 
no significant difference seen between when those given vehicle and those given PNU 
0.3mg/kg (F(2,17) = 2.72, p=0.12 n.s.) (figure 6.4). 
As before, prior to treatment with MLA, the baseline performance and OST performance 
following the most effective dose of Compound T (1mg/kg) in both control and ketamine-
treated animals was re-examined. 
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When MLA was administered prior to Compound T treatment, no main effect of MLA was 
noted (F(2,20) = 2.21, p=0.14). One way ANOVAs were carried out on both ketamine and 
control groups. In control subjects, Compound T administration in conjunction with MLA 
had no significant effect on OST performance (F(2,17) = 3.24, p=0.07 n.s.). In ketamine-
treated animals, MLA blocked a Compound T-induced improvement in performance so that 
these subjects were no different from controls ((F(2,17) = 3.61, p=0.05 n.s.) (figure 6.5).  
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Figure 6.3: The a7 antagonist MLA impaired uncompromised animals 
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Figure 6.3: Administration of MLA was able to impair the performance of control 
animals (n=6) at both 2mg/kg and 6mg/kg (p<0.01, p<0.001) # denotes statistical 
significance from vehicle treatment (p<0.01) and * denotes statistical significance from 
vehicle treatment (p<0.001) 
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Figure 6.4: The a7 antagonist MLA blocked PNU-induced improvements in OST 
performance 
 
S
p
a
n
 ±
 S
E
M
 
Figure 6.4: Administration of MLA was able to block the PNU-induced improvement in 
the OST performance of ketamine treated animals(n=6), so that performance was no 
different to controls (p<0.01, p=0.12, respectively). PNU administration also failed to 
prevent an MLA induced impairment in OST performance. * denotes statistical 
significance from vehicle treatment (p<0.01) 
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Figure 6.5: The a7 antagonist MLA blocked Compound T-induced improvements in OST 
performance 
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Figure 6.5: Administration of MLA was unable to block the Compound T-induced 
improvement in the OST performance of control animals(n=6) (p=0.14). Compound T 
administration also failed, in control animals, to prevent an MLA induced impairment in 
OST performance (p=0.07). MLA blocked the enhancing effect of Compound T on OST 
performance in ketamine-treated animals (p<0.05) * denotes statistical significance from 
vehicle treatment (p<0.01) 
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6.4 Discussion 
Both allosteric modulators were able to improve the performance of ketamine-treated 
animals in a dose-dependent manner. However, in contrast to results seen with nicotine 
treatment, neither PNU nor Compound T was able to enhance the performance of control 
animals in the OST task. 
Allosteric modulation of the α7 nAChR using PNU has been shown to enhance 
transmission at the α7 nAChR without causing desensitisation (Hajos et al, 2005). Sitzia et 
al (2011) have also shown that PNU is able to reduce the likelihood of nAChR 
desensitisation as well as being able to recover nAChR from a desensitised to active state 
even in the continued presence of an agonist (Sitzia et al, 2011). Despite this enhanced 
transmission and lack of desensitisation, acute PNU treatment did not enhance performance 
in control animals. This is in contrast to the effect of acute nicotine administration which 
did improve the performance of control subjects in the OST task (Chapter 4). This implies a 
lesser role for the α7 nAChR in mediating the enhancing effects of nicotine in control 
animals tested with the OST.  Similar effects of PNU treatment have been seen before, as 
shown by Thomsen et al (2011) using the social discrimination test as a measure of 
working memory. This study demonstrated that uncompromised rats did not show any 
improvement in performance following acute or chronic PNU treatment (Thomsen et al, 
2011). An alternative explanation to a lack of α7 nAChR involvement is that there is a 
strong correlation between temperature and the ability of PNU to enhance ACh-induced 
transmission: Using a patch-clamp measure of ACh current, Sitzia et al (2011) have been 
able to demonstrate that PNU is most effective at room temperature and that this effect is 
significantly reduced as the temperature is increased to near-physiological levels (Sitzia et 
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al, 2011). This means the effect of PNU in-vivo may be much less than previously indicated 
by in-vitro studies, although it is unlikely that physiological temperature completely 
attenuated the effects of PNU as there was significant recovery observed in ketamine-
treated animals in the OST task. It may instead be that modest enhancements in ACh 
transmission at the α7 nAChR did not confer any phenotypic advantage in control animals 
or perhaps that this improvement was beyond the sensitivity of the OST task. 
However, this study also provides evidence for the involvement of the α7 nAChR, as PNU 
was able to restore OST performance in animals with ketamine-induced deficits. PNU 
increases the probability of the α7 nAChRs being in an active state whilst also preventing 
desensitisation of these nAChRs in addition to de-desensitising any α7 nAChRs that are 
currently in the desensitised state. This results in increased ACh transmission both pre and 
post-synaptically. Post-synaptic α7 nAChRs are present on interneurons and their activation 
mediates fast cholinergic excitatory synaptic transmission which in turn facilitates cortical 
strengthening and long term potentiation (LTP) (Alkondon et al, 1998; Frazier et al, 1998). 
Presynaptic activation of α7 nAChRs on glutamatergic neurons increases intraterminal Ca2+ 
levels, facilitating glutamate release (Gray et al, 1996). Becker et al (2003) have shown that 
rats exposed to a sub-chronic ketamine regime have been shown to have 25% less 
glutamate binding in the prefrontal cortex (PFC) when compared to vehicle treated controls 
(Becker et al, 2003b).   Presynaptic activation of α7 nAChRs on glutamatergic neurons may 
therefore serve to compensate for the reduced level of glutamate found following exposure 
to sub-chronic ketamine treatment and restore normal functioning. In addition, this release 
of glutamate has follow-on effects: Livingstone et al (2010) have shown that glutamate acts 
at metabotropic glutamate receptors (mGluRs) on dopaminergic terminals, facilitating 
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dopamine (DA) release. Increased DA has been shown to increase the efficiency of 
processing within cortical networks, ultimately resulting in a short term enhancement of 
synaptic plasticity (Gonzalez-Burgos et al, 2005; Kroener et al, 2009). DA is also able to 
modulate GABAergic input which is involved in the regulation, synchrony and amplitude 
of gamma frequency oscillations that are known to be essential to the normal functioning of 
working memory (Seamans et al, 2001). Further evidence for this mechanism as an 
explanation for the effects of PNU in this study comes from an in-vivo microdialysis study 
by Livingstone et al (2010). They demonstrated that reverse dialysis of PNU was able to 
augment DA release in the medial PFC (mPFC) in-vivo in the presence of α7 agonist (R)-
N-(1-azabicyclo[2.2.2]oct-3-yl)(5-(2-pyridyl)thiophene-2-carboxamide (Compound A) 
(Livingstone et al, 2010). 
Relatively little is known about Compound T, as it is a novel compound in development by 
Janssen Pharmaceutical Companies of Johnson and Johnson. It is classed as a Type I PAM 
which means that Compound T is able to increase peak amplitude at the α7 nAChR but has 
little or no effect on desensitisation.  Both the Type I and Type II PAMs used in this study 
demonstrate similar effects on OST performance. As PNU is a Type II PAM which 
increases peak amplitude but also reduces desensitisation, it may be expected to improve 
OST performance to a greater degree than a Type I PAM which improves peak amplitude 
alone. This is because α7 nAChRs rapidly desensitise and so Type II allosteric modulation 
would be expected to confer greater transmission in comparison to Type I allosteric 
modulation.  It may be that the full effect of PNU was somewhat attenuated as a result of 
in-vivo physiological temperature which Sitzia et al (2011) demonstrate reduced the effect 
of PNU (Sitzia et al, 2011). Alternatively, it may be that the improvement in performance 
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seen in ketamine-treated animals is as a result of an increase in peak amplitude and not as a 
result of any reduction in desensitisation.  
 
These data serve to demonstrate an involvement of the α7 nAChR in enhancing the 
performance of ketamine-treated animals but does not necessarily implicate these receptors 
as being involved in mediating the performance of control animals in the OST task. Neither 
PNU nor Compound T were able to confer any protection against an MLA-induced 
impairment in OST performance when administered prior to treatment with selective α7 
nAChR antagonist MLA in control animals, although a trend towards significance was 
observed in animals pre-treated with Compound T prior to MLA administration. In 
ketamine-treated animals, MLA prevented both Compound T and PNU-induced 
improvements in performance. This is similar to results seen with α7 nAChR selective 
PAM JNJ-1930942 in a study by Dinklo et al (2011), who demonstrated that this 
compound was able to reverse a deficit in sensory gating and that this effect was blocked by 
MLA treatment (Dinklo et al, 2011).  MLA has been long since been shown to antagonise 
the α7 nAChR (Macallan et al, 1988; Ward et al, 1990). Mechanistically, MLA 
competitively binds to α7 nAChRs and preferentially stabilises the receptor in a closed 
state. This prevents activation by endogenous ligands such as ACh, reducing 
neurotransmission and thus no enhancing effect is seen. A study by Livingstone et al 
(2010) provides further evidence for this mechanism as MLA was able to prevent α7 
nAChR agonist-induced DA overflow in the PFC (Livingstone et al, 2010).  
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In control animals, MLA treatment was also able to impair performance on the OST task. 
This is supported by Levin et al (2002) who demonstrated that MLA was able to impair 
working memory in both the 8 and 16-arm RAM (Levin et al, 2002).  
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6.5 Conclusions 
These data suggest a role for the α7 nAChR in mediating the restoration of baseline 
performance in ketamine-compromised subjects. It is also evident that normal functioning 
of the α7 nAChR is required for uncompromised subjects to complete the task but that 
increasing transmission at this receptor when no deficit is present confers no advantage in 
the task. As nicotine is able to elicit improvements in OST performance of uncompromised 
animals, it is likely that the α7 nAChR does not mediate the full effect of nicotine on this 
task. This suggests involvement of other nAChRs such as the α4β2 nAChR in mediating 
the effects of nicotine on OST performance of control animals. To further investigate 
potential mechanisms by which these receptors may mediate the effects of nicotine, the 
next chapter examines the effect to nicotine and nicotinic agonists on gamma frequency 
network oscillations in the PFC. 
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Chapter 7 
Nicotine enhances gamma frequency 
oscillations in the PrL region of the 
PFC: An effect blocked by 
mecamylamine 
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7.1 Introduction 
 
Fast network oscillations such as beta (15-30 Hz) and gamma (30-80 Hz) are essential for 
higher cognitive processes such as attention and working memory, where synchronous 
oscillations correlate with improvement in cognitive tasks (Jensen et al, 2007). Roux et al 
(2012) have demonstrated that gamma frequency oscillations in the prefrontal cortex (PFC) 
contribute significantly to the maintenance of behaviourally relevant information during 
working memory (Roux et al, 2012). Mainy et al (2007) further support this, demonstrating 
that human subjects tasked with remembering a series of letters, exhibited higher gamma 
frequency activity in several brain regions including the PFC and hippocampus (Mainy et 
al, 2007).  
Gamma oscillations are initiated by excitation and firing of pyramidal neurons and 
controlled by parvalbumin-(PV)-positive interneurons through gamma-aminobutyric acid-
(GABA)-induced inhibition (Mann et al, 2005; Whittington et al, 2001; Whittington et al, 
2000). Following decay of this inhibition, pyramidal cells have a window within which 
they can fire, initiating the next oscillation. Pyramidal cells involved in the same set of 
neural codes become synchronised and the stronger the input, the more cells are entrained 
into the same oscillation (Bartos et al, 2007). Therefore, when working memory load is 
increased, gamma frequency oscillations increase in power and synchrony in order to 
maintain information (Howard et al, 2003; Tallon-Baudry et al, 1998). Cho et al (2006) 
have shown that this ability to increase induced gamma band activity is aberrant in patients 
with schizophrenia and may therefore explain the presence working memory deficits in this 
disorder (Cho et al, 2006). This abnormality in gamma frequency oscillations is also 
evidenced by Lee et al (2003) who replicated the finding that gamma frequency oscillations 
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are reduced in schizophrenia and furthermore, demonstrated that the degree to which this 
reduction occurs correlates to negative symptoms of the disease (Lee et al, 2003).  
Mechanistically, several studies have confirmed a reduction in PV-expression and glutamic 
acid decarboxylase 67 (GAD67), the enzyme which synthesises GABA, in patients with 
schizophrenia (Volman et al, 2011). GABA is inextricably linked to gamma frequency 
oscillations as the timescale of inhibition generated by GABAA receptor activation matches 
the 40Hz gamma frequency oscillations (Tiesinga et al, 2004). Thus, a potential mechanism 
for disrupted cognition in schizophrenia is a malfunction of PV-positive interneurons, 
which results in impaired function of these interneurons and therefore impaired generation 
of gamma frequency activity (For review see Lewis and Moghaddam, 2006; Lisman et al, 
2008). 
Nicotine improves performance in cognitive tasks in control subjects and subjects with 
schizophrenia and has also been shown to enhance gamma frequency oscillations in the 
hippocampus (Featherstone et al, 2012b; Song et al, 2005). In the hippocampus, application 
of nicotine depolarises interneurons as well as inhibiting the inhibitory synapses onto 
interneurons (Wanaverbecq et al, 2007). This leads to excitation of interneurons and 
enhanced GABA release thus increasing inhibitory output (Hulo and Muller, 2001; 
Wanaverbecq et al, 2007). The α7 nicotinic acetylcholine receptor (nAChR) subtype has 
been implicated in this process in the hippocampus as α7 nAChRs have been shown to be 
expressed in interneurons in this region (Hulo et al, 2001; Wanaverbecq et al, 2007). 
However, the contribution of the α4β2 nAChR to inhibitory function and gamma frequency 
oscillations in the hippocampus is yet to be elucidated.  
Few studies have examined the effect of nicotine in the PFC, and it is possible that different 
nAChR subtypes mediate the actions of nicotine to those in the hippocampus. This is 
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pertinent with regard to the PFC as there are significantly more α4β2 nAChRs in the PFC 
than in the hippocampus and also significantly more α4β2 nAChRs than α7 nAChRs in the 
PFC (Poorthuis et al, 2013). Despite this, very little work exists in the literature examining 
the effect of nicotine on gamma frequency oscillations in the PFC and the different 
nAChRs which may mediate nicotine’s effect. This means that the overall notion of 
whether nicotine can enhance gamma frequency network oscillations in the PFC is still 
unknown.  
This investigation therefore aims to address whether nicotine is able to increase gamma 
frequency oscillations in the prelimbic regions of the PFC in-vitro and whether there is any 
involvement of the α7 or α4β2 nAChR in mediating the effect of nicotine. 
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7.2 Methods  
Slices were prepared as described in Chapter 2. Persistent gamma oscillations were 
generated by co-application of carbachol (10µM) and kainate (200nM). Following 
application of carbachol and kainate, gamma frequency oscillations increase in size; 
stabilising after 2 to 3 hours. Upon establishing a stable baseline, defined as three 
consecutive area readings with no more than 10% change in area power, test compounds 
were delivered via the circulating bath artificial cerebrospinal fluid (ACSF).  The peak 
effect of agonist was measured at 15 minutes post- application or 15 minutes post-washout. 
Nicotine (1 and 10µM) were examined in individual slices (n=6, n=8 respectively) from 
different rats. The effect of the nicotinic antagonist mecamylamine was also investigated 
alone and in combination with nicotine (n=7). Following these results, α7 and α4β2 nAChR 
selective agonists PHA-543613 (PHA) and 5-iodo-A-85380 (5IA), respectively, were 
examined individually, (n=7, n=2) and in combination (n=4).  
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7.3 Results 
7.3.1. Nicotine increases gamma frequency oscillations 
Extracellular field recordings from the PrL region of the mPFC demonstrate that bath 
application of a 1µM concentration of nicotine did not increase the power of gamma 
frequency oscillations in this region (figure 7.1, A (trace) and B (power spectra)). However, 
when the concentration of nicotine was increased to 10µM, the power of gamma frequency 
oscillations in the PrL region was enhanced (figure 7.1, A (trace) and B (power spectra)), 
increasing in size by approximately 70% (figure 7.2). 
One way analysis of variance (ANOVA) on group data revealed a significant overall effect 
of nicotine on the percentage increase in the size of gamma network oscillations (p<0.001). 
Holm-Sidak post-hoc analysis further demonstrated that nicotine at a dose of 10µM but not 
1µM was able to significantly enhance the area power of gamma network oscillations 
(p<0.05) (figure 7.2).  
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Figure 7.1: Nicotine increased percentage change in size of gamma frequency oscillations  
  
 
 
 
 
  
Figure 7.1: This figure shows an example of extracellular field recordings of PrL region gamma 
frequency oscillations at baseline (black), following bath application of nicotine 1µM (n=6) (A) 
and 10µM (n=8) (B) (green) and following washout (blue): With increasing time into bath 
application of nicotine, the power of the oscillation is significantly increased following 
application of the 10µM nicotine concentration (D) but not the 1µM nicotine concentration (C). 
These readings are taken 15 minutes after drug application and represent the peak response. 
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Figure 7.2: Nicotine increased percentage change in power of gamma frequency oscillations. 
  
Figure 7.2: Group data (n=6) show that the 1µM nicotine did not significantly 
enhance the power of gamma frequency oscillations. However, the 10µM (n=8) 
concentration of nicotine produced a significant increased in power (p<0.05). These 
readings are taken 15 minutes after drug application and represent the peak response. 
* denotes significance where p<0.05. 
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7.3.2. The enhancing effect of nicotine was blocked by mecamylamine 
Extracellular field recordings from the PrL region of the mPFC demonstrate that bath 
application of a 10µM concentration of mecamylamine did not increase the power of 
gamma frequency oscillations in this region. Bath application of nicotine at a concentration 
of nicotine 10µM following one hour exposure to mecamylamine caused a significantly 
attenuated response of gamma frequency oscillations in comparison to bath application of 
nicotine 10µM alone (figure 7.1, A (trace) and B (power spectra)).  
One way ANOVA on group data revealed a significant overall effect of drug treatment on 
gamma frequency oscillations (p<0.05). Paired T-tests examining the effect of 
mecamylamine alone and mecamylamine plus nicotine in comparison to their respective 
baselines however revealed no significant difference at either point (p=0.16, p=0.71, 
respectively) (figure 7.3, C). 
 
 
  
 
 
 
 
 
 
 
 148 
-20.00 
0.00 
20.00 
40.00 
60.00 
80.00 
100.00 
Mecamylamine 
10µM 
Mecamylamine 
10µM + Nicotine 
10µM 
Figure 7.3: The enhancing effect of nicotine was blocked by broad spectrum nicotinic 
antagonist mecamylamine 
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Figure 7.3: (A) This figure shows an example of extracellular field recordings of PrL region gamma 
frequency oscillations at baseline (black), following bath application of mecamylamine (red),  following 
bath application of mecamylamine plus nicotine (10 μM) (green) and following washout (blue). (B) Power 
spectra demonstrating mecamylamine (10μM) application for one hour had no effect alone and was also 
able to prevent any effect from the subsequent application of nicotine (10μM) on gamma frequency 
oscillations. (C) Group data (n=7) show that the 10µM mecamylamine has no significant effect on the 
power of gamma frequency oscillations (p=0.16). Application of 10µM mecamylamine also prevented the 
10µM concentration of nicotine from producing a significant increased in gamma oscillation power 
(p=0.71). These readings are taken 15 minutes after drug application and represent the peak response. 
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7.3.3. Neither α7 or α4β2 nAChR agonists significantly increased gamma frequency 
oscillations 
Extracellular field recordings from the PrL region of the mPFC demonstrate that bath 
application of neither 5IA at a concentration of 3µM (figure 7.1, A (trace) and C (power 
spectra)) or PHA at a concentration of 10µM (figure 7.1, B (trace) and D (power spectra)) 
were able to increase the power of gamma frequency oscillations in this region.  
Group data was not normally distributed so a Wilcoxon Signed Rank Test was carried out 
to examine the effect of PHA on baseline gamma frequency oscillations, revealing no 
significant effect of dose at 10μM (p=0.94). Similarly, 5IA demonstrated no significant 
effect on gamma frequency oscillations (p=0.33). As nicotine acts at many nAChRs, co-
application of both PHA and 5IA was also examined for any synergistic effects on gamma 
frequency oscillations: This also had no effect on gamma frequency oscillations (p<0.85). 
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Figure 7.4: Neither α7 or α4β2 nAChR agonists significantly increased gamma 
frequency oscillations 
Figure 7.4: This figure shows an example of extracellular field recordings of PrL region 
gamma frequency oscillations at baseline (black), following bath application of α4β2 nAChR 
agonist 5IA 3µM (n=2) (A) and α7 nAChR agonist PHA 10µM (n=7) (B) (green) and 
following washout (blue). Neither 5IA 3 3µM or PHA 10µM significantly increased the 
power of gamma frequency oscillations. These readings are taken 15 minutes after drug 
application and represent the peak response.  
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Figure 7.5: Neither α7 or α4β2 nAChR agonists were able to significantly increase 
gamma frequency oscillations 
 
  
Figure 7.5: Group data show that the 10µM PHA (n=7) had no significant effect on 
gamma frequency oscillations (p=0.938). No significant increased in gamma 
frequency oscillation power was also found with 3µM 5IA (n=2) (p=0.33). 
Combination of 5IA and PHA (n=4) also failed to have any significant effect on the 
power of gamma frequency oscillations (p<0.85). Nicotine alone at 10µM, from the 
previous experiment is provided for reference. * denotes significance at the level of 
p<0.05. These readings are taken 15 minutes after drug application and represent the 
peak response.  
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7.4 Discussion 
Acute bath application of nicotine enhanced gamma frequency oscillations in the prelimbic 
(PrL) region of the PFC when examined in an in-vitro brain slice preparation. This 
enhancing effect of nicotine was blocked by pre-application of broad spectrum nAChR 
antagonist mecamylamine. This indicates that the enhancing effect of nicotine is likely to 
be as a result of action at the nAChRs as opposed to non-specific effects.  
These results correlate with findings from behavioural studies where nicotine was able to 
enhance performance in the Odour Span Task (OST) (Chapter 4) and may therefore provide 
a mechanism behind the nicotine-induced enhanced OST performance observed in control 
subjects.  However, the enhancing effect of nicotine on gamma frequency oscillations is in 
contrast to the findings of Mansvelder et al (2005) who showed that application of nicotine 
in the PrL region of the PFC in an in-vitro brain slice preparation completely attenuated the 
carbachol-induced oscillatory state (Mansvelder et al, 2006). Two main explanations exist 
for this dichotomy: The rats used in Mansvelder’s study may not have had fully developed 
inhibitory interneuron networks as the rats were only three weeks old (Mansvelder et al, 
2006). Significant development of inhibitory networks occurs during adolescence in rats 
between 28 and 55 days of age (Spear, 2000).  As the mechanism by which nicotine 
increases gamma frequency oscillations is proposed to be via modulation of inhibitory 
interneurons, these effects may not be seen immature brain network.  Aracri et al (2010) 
examined the effect of nicotine on oscillatory activity and demonstrated that the level of 
glutamatergic tone determines whether nicotine will inhibit GABAergic neurons or excite 
them (Aracri et al, 2010).  Application of nicotine following blockade of ionotropic 
glutamate receptors in the PFC inhibited inhibitory postsynaptic potentials (IPSPs). This is 
in contrast to nicotine alone which increased IPSP output (Aracri et al, 2010).  This means 
that the lack of effect seen in the study by Mansvelder and colleagues could be as a result of 
reduced glutamatergic tone, which would cause nicotine to inhibit inhibitory neurons and 
C. 
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thus reduce IPSPs; resulting in a state whereby oscillatory drive is impaired. In the current 
study, gamma frequency oscillations are induced through co-application of carbachol and 
kainate, as opposed to carbachol alone as used by Mansvelder et al (2005). Thus, in our 
experimental conditions, with kainate receptor activation, we may have a greater 
glutamatergic tone that could enable nicotine to elicit increased GABA release.  
Aracri et al (2010) further demonstrated that the α7 nAChR specific antagonist 
methyllycaconitine (MLA) and α4β2 nAChR specific antagonist dihydro-beta-erythroidine 
(DHβE) could reverse the effect of ionotropic glutamate receptor blockade on nicotine 
induced IPSP reduction (Aracri et al, 2010). This indicates that both the α7 and α4β2 
nAChRs are involved in mediating both excitation and inhibition of interneurons depending 
on the overall glutamatergic drive although the involvement of these receptors was not 
confirmed by in the current study: Application of either α7 nAChR agonist PHA, or α4β2 
nAChR agonist 5IA did not enhance gamma frequency network oscillations either alone or 
in combination. Co-application of both PHA and 5IA was not examined in the OST, but the 
application of these agonists alone also replicates what is seen behaviourally whereby 5IA 
and PHA were only able to enhance performance in ketamine-treated animals (Chapter 5). 
These findings indicate that another receptor subtype may be responsible for nicotine’s 
enhancing effect on the OST in normal animals or that synergistic activation of an 
alternative combination of nAChR subtypes mediates the effect of nicotine in normal 
subjects.  
However, it must also be noted than α4β2 nAChR selective agonist metanicotine did 
improve performance in control subjects behaviourally and that studies such as that by 
Featherstone et al (2012) have shown that α4β2 nAChR subtype-selective agonist 
AZD3480 can enhance gamma frequency oscillatory activity in the hippocampus 
(Featherstone et al, 2012b). The α7 nAChR subtype has historically been implicated in this 
process in the hippocampus as α7 nAChRs are expressed in interneurons in this region 
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(Hulo et al, 2001; Wanaverbecq et al, 2007).   However, Featherstone et al (2012) 
demonstrate that the enhancing effect of nicotine on hippocampal oscillations is blocked by 
α4β2 antagonist DHβE but not α7 nAChR antagonist MLA, indicating a selective effect of 
nicotine at α4β2 nAChR in the hippocampus (Featherstone et al, 2012b). Aracri (2010) also 
support a role for the α4β2 nAChR over the α7 nAChR in the PFC as they have shown that 
it is mainly α4β2 nAChRs which are present on GABAergic interneurons in this region, 
although there is little direct evidence for selective α4β2 nAChR involvement at this stage 
(Aracri et al, 2010). This is further supported by Tsutsui-Kimura et al (2010) who 
demonstrate that nicotine stimulates α4β2 nAChRs in the infralimbic (IL) region but not the 
PrL region of the PFC. This suggests that whilst the current in-vitro findings correlate with 
behavioural work, it may be other brain medial prefrontocortical (mPFC) brain regions, 
such as the IL or anterior cingulate cortex (Cg1) which mediate the effect of nicotine on the 
OST (Tsutsui-Kimura et al, 2010). These inconsistencies mean that further work is needed 
to elucidate the role for α4β2 nAChRs in mediating the effect of nicotine on gamma 
frequency oscillations and that conclusions from the current work must be drawn cautiously 
at this stage. 
In the hippocampus, application of nicotine exerts its enhancing effects on gamma 
frequency oscillations through depolarising interneurons as well as by inhibiting the 
inhibitory synapses onto interneurons; enhancing GABA release and thus enhancing 
excitation of interneurons and increasing inhibitory output (Hulo et al, 2001; Wanaverbecq 
et al, 2007). Aracri et al (2010) have also shown that nicotine (1-100 µM) is able to 
increase GABAergic IPSPs onto pyramidal neurons in layer V of the PFC (Aracri et al, 
2010). This increase in IPSPs is due to a nAChR-dependent stimulation of glutamate 
release from thalamocortical afferents acting at PV-positive interneurons (Aracri et al, 
2010; Gioanni et al, 1999; Kruglikov and Rudy, 2008; Lambe et al, 2003). This means that 
the processes mediating a nicotine-induced increase in network oscillations may be similar 
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in the hippocampus and PFC, but the nAChRs involved in this process in each region need 
to be examined further.  
Although further work is needed, these initial findings provide a proof of concept that the 
OST may be frontally mediated, as nicotine was able to improve gamma frequency activity.  
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7.5 Conclusions 
A mechanism for nicotine’s positive effects on control animals in the OST may be as a 
result of enhanced gamma frequency oscillations, as these are increased upon application of 
nicotine in the PrL region of the PFC. It is possible that the PrL region specifically may not 
mediate OST response but these data indicate there is a potential role for this region in 
mediating the enhancing effects of nicotine. Further work is needed to address the 
contribution of specific nAChRs involved as well as examining the effect on nicotine in a 
network model of cognitive impairment. This work also indicates that it will be useful to 
understand the contribution of the mPFC to the OST task and whether local application of 
nicotine replicates systemic findings; this will be discussed in the following chapter. 
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8.1 Introduction 
Zola-Morgan and colleagues (1986) identified the hippocampus as having an individual 
role in memory when studying Patient R.B. who had developed anterograde amnesia 
following an ischemic episode. The bilateral lesion caused by the ischemia was limited to 
the CA1 field of the hippocampus and demonstrated for the first time that damage to the 
hippocampus alone could cause impairments in memory (Zola-Morgan et al, 1986). 
Pre-clinically there have been many studies examining the role of the hippocampus in 
working memory using tasks such as the Radial Arm Maze (RAM) and Morris Water Maze 
(MWM). These studies indicate that the hippocampus has a significant role in spatial 
working memory (For review see Jarrard, 1993). Spatial working memory is disordered in 
patients with schizophrenia: Pisculic and colleagues (2007) conducted meta-analyses on 33 
studies examining spatial working memory deficits in these patients which revealed a 
consistently greater spatial working memory deficit in patients with schizophrenia in 
comparison to control subjects (Piskulic et al, 2007). 
However, Perlstein et al (2003) have shown that patients with schizophrenia also have 
significant impairments in non-spatial working memory. The n-back task is a sequential 
letter memory task with varying memory load conditions, requiring a subject to match a 
singular letter (0-back), or a letter identical to that presented in the one or two trials 
preceding (1-back, 2-back). Perlstein and colleagues (2003) found that patients with 
schizophrenia made significantly more errors in the high memory load condition than 
control subjects. In addition, fMRI analysis also demonstrated that when completing this 
task, patients with schizophrenia showed a significant reduction in the activation of the 
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dorsolateral prefrontal cortex (DLPFC) in comparison to control subjects (Perlstein et al, 
2003). Barch et al (2003) also found that patients with schizophrenia did not show 
activation of the DLPFC in response to the n-back task in contrast to both control subjects 
and patients with major depression who both demonstrated activation of this area (Barch et 
al, 2003). This demonstrates a significant role for the PFC in the working memory deficits 
present in schizophrenia. This is supported by lesion work in both monkeys and humans 
which demonstrates a role for the PFC in memory (Mishkin and Pribram, 1955; Sakurai 
and Sugimoto, 1985). 
The brain regions involved in the OST are yet to be fully elucidated: Dudchenko et al 
(2000) have demonstrated that hippocampectomised rats are still able to complete the OST 
indicating that it is unlikely that the hippocampus has a significant role in mediating the 
OST (Dudchenko et al, 2000). As the literature indicates a significant role for the DLPFC 
in human working memory, it may be that in rats the OST task is mediated by the mPFC, 
the rodent functional homologue of the human DLPFC region (Seamans et al, 2008; 
Uylings et al, 2003). Nicotine has been shown to be effective in the OST when given 
systemically (Chapter 4). Local administration of nicotine to the mPFC is therefore likely 
to improve OST performance if there is a significant contribution of the PFC in mediating 
this task.  
To confirm the contribution of the PFC, the effect of local administration of GABA 
antagonist muscimol will also be examined in the OST. Local injection of muscimol into 
the nucleus basalis has been shown to impair working memory on the double Y maze 
(Beninger et al, 1992). Additionally, intracerebroventricular (ICV) administration of 
muscimol also impair rodent working memory in a matching-to-position task (Ramirez et 
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al, 2005). Sawaguchi and Iba (2001) have also examined the performance of monkeys on a 
visual working memory task following local administration of muscimol to the DLPFC, 
demonstrating significant muscimol-induced impairments in performance (Sawaguchi and 
Iba, 2001). The effect on OST performance following nicotine or muscimol administration 
should give a good indication of the involvement of the PFC in this task. 
 
 
 
  
 161 
4.2 Methods 
Twenty-four male hooded Lister rats were trained in the OST. On establishing stable 
performance, animals were pseudo-randomised into two treatment groups (n=12) and 
administered vehicle or ketamine (10mg/kg i.p.) for 5 consecutive days. They were given 2 
days wash out, then tested on the OST to establish baseline performance. Following stable 
performance, all 24 animals underwent stereotactic surgery to implant bilateral cannulae 
into the medial prefrontal cortex (for details of exact methodology see Chapter 2).  
Following recovery from surgery and familiarisation with handling for local injections, as 
well as a preliminary baseline saline injection, rats were given local injection of nicotine (1, 
2 or 4 µg/side) or vehicle (ACSF) in the procedure as outlined in chapter two and 
immediately tested on the OST. As with previous studies, this was a within-subjects, 
repeated measures design where each rat received each dose in a pseudo-randomised 
fashion with a day washout and a drug-free baseline testing day between doses.  
All animals were treated in accordance with procedures outlined in the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC) with additional 
advice from the in-house animal welfare and veterinary team. 
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8.3 Results 
8.3.1 Local administration of nicotine dose-dependently enhanced OST performance in 
control subjects and ketamine-treated animals 
A repeated measures ANOVA revealed an overall effect of local nicotine administration on 
OST performance (F(3,54)=9.40, p<0.001).  No significant interaction between ketamine 
pre-treatment and nicotine was found (F(3,54)=0.25 p=0.86 n.s.), indicating that nicotine 
had the same effect regardless of whether subjects had previously received ketamine or 
vehicle treatment. Pairwise comparisons showed that local administration of 2µg  nicotine 
was the most effective dose in enhancing overall OST performance when compared to 
vehicle-treated controls (p<0.001). 
One way ANOVAs were carried out examining control animals and ketamine-treated 
animals individually. Nicotine had an overall significant effect on OST performance of 
control animals (F(3,35)=3.15, p<0.05) with Bonferroni post-hoc analysis revealing the 2µg 
dose significantly enhanced performance when compared to vehicle treated controls. 
Ketamine-treated animals also improved overall following local administration of nicotine 
(F(3,43)=23.49, p<0.001): In this case, both the 2 and 4µg doses significantly improved 
OST performance in comparison to vehicle-treated controls (p<0.001, p<0.001). 
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Figure 8.1: Local administration of broad spectrum nAChR agonist nicotine dose-
dependently enhanced OST performance in control subjects and ketamine-treated 
animals 
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Figure 8.1: Local administration of nicotine was able to enhance the performance of 
ketamine treated animals (n=11) in the OST at both 2µg and 4µg doses. The 2µg dose 
also improved the performance of control animals (n=9). * denotes statistical significance 
from vehicle treatment (p<0.001) in control animals. # denotes statistical significance 
from vehicle treatment (p<0.001) in ketamine-treated animals. 
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8.3.2: Local administration of muscimol dose-dependently impaired OST performance in 
control subjects but not ketamine-treated animals 
A repeated measures ANOVA revealed an overall effect of local muscimol administration 
on OST performance (F(2,36)=7.48, p<0.01).  No significant interaction between pre-
treatment and muscimol treatment was found (F(2,36)=1.57, p=0.22 n.s) indicating that 
muscimol had the same effect regardless of whether subjects had previously received 
ketamine or vehicle treatment.  
One way ANOVA on control animals alone determined that the there was an overall 
significant effect of muscimol of OST performance (F(2, 26)=6.00, p<0.01) with 
Bonferroni post-hoc analysis showing the 2µg dose to be most effective in impairing 
performance in control animals (p>0.01). The overall effect of muscimol on ketamine-
treated animals, as shown by one way ANOVA, was not significantly different to vehicle-
treated subjects (F(2,32) = 1.53, p=0.23 n.s.). 
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Figure 8.2: Local administration of GABA antagonist muscimol dose-dependently 
impaired OST performance in control subjects but not ketamine-treated animals 
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Figure 8.2: Local administration of 2µg muscimol impaired the performance of control 
animals (n=9) (p>0.01). Muscimol had no effect of the performance of ketamine-treated 
animals at any of the doses tested (n=11) (p=0.23). * denotes statistical significance from 
vehicle treatment (p<0.01) in control animals.  
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8.4 Discussion 
Local administration of nicotine into rat mPFC enhances performance in both control and 
ketamine-treated animals. This suggests a significant contribution of the mPFC to the OST 
task and is supported by data from Dade et al (2001) who used fMRI to determine the brain 
regions activated in human subject during an olfactory working memory task. They found 
that regions involved in this task include the polar frontal cortex, the DLPFC and the 
ventrolateral frontal cortex (Dade et al, 2001). As the DLPFC in humans is thought to be 
functionally homologous to the rodent mPFC, the finding of Dade and colleagues supports 
the findings in this study implicating the rodent mPFC in working memory (Uylings et al, 
2003). Tsukada et al (2005) provide further support, demonstrating that chronic systemic 
MK-801 administration to non-human primates reduced D1 receptor binding in the PFC. 
This effect was normalised following intravenous nicotine administration which was 
additionally able to elicit a significant increase in DA release into PFC extracellular fluid.  
These findings also correlated with improved performance following MK-801 induced 
deficits in a working memory task (Tsukada et al, 2005).  
The findings of Tsukeda et al (2005) suggests that nAChR mediated activation of 
dopaminergic neurons may have a role in mediating improvements in working memory. 
This is supported by Marshall et al (1997) who demonstrated, using microdialysis, that 
nicotine elicits DA release in the PFC of freely moving rats (Marshall et al, 1997). In terms 
of receptor subtype, Livingstone et al (1997) demonstrate that the ability of nicotine to 
elicit DA in the PFC can be blocked by administration of α4β2 nAChR antagonist dihydro-
beta-erythroidine (DHβE). In future studies, it may therefore be useful to examine whether 
local administration of selective α4β2 nAChR agonists into the PFC also enhances OST 
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performance. This may help to elucidate the mechanism by which nicotine elicits an effect 
on the OST. 
The consequences of increased DA are yet to be fully elucidated, however Kolomiets et al 
(2009) demonstrate in-vitro that prefrontal DA functions to increase ERK phosphorylation, 
increasing neurotransmitter release and in turn inducing LTP. This may provide a 
mechanism by which nicotine elicits improvements in working memory (Kolomiets et al, 
2009). Lambe et al (2003) have also shown that nicotine induces glutamate release onto 
layer V pyramidal neurons of the PFC via thalamo-cortical afferents (Lambe et al, 2003). 
This may also increase LTP in the PFC and thus improve cognitive performance. In 
contrast, work by Couey et al (2007) describes a mechanism for the action of nicotine on 
cognition whereby nAChR activation increases GABAA output onto layer V pyramidal 
neurons in mouse PFC and thus increases the threshold for spike-timing dependent 
potentiation (STDP). This in turn decreases LTP and may account for why, in some tasks, 
nicotine can cause cognitive impairment. However, as discussed by Newhouse et al (2004), 
the baseline activity and the nature of the task can determine the ability of nicotine to 
enhance performance: Thus, it may be that an increased threshold for STDP allows the 
signal to noise ratio to be improved, enhancing task performance (Newhouse et al, 2004c). 
The effects seen with local administration of nicotine are not dissimilar to that seen with 
systemic nicotine administration (Chapter 4; Rushforth et al, 2010; Rushforth et al, 2011). 
This suggests that the PFC is also likely to play a significant role in mediating the 
cognitive-enhancing effects of systemic nicotine on OST performance. However, ketamine-
treated animals were not fully restored to baseline performance following local nicotine 
administration as was found with systemic nicotine. There could be further contribution 
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from other brain regions, although this is difficult to interpret for this data as the brain 
concentration of systemically dosed nicotine is unknown so a conclusive comparison 
cannot be made. However, if there was a contribution from another brain region, the first 
likely candidate would be the hippocampus given that this brain region has well 
documented involvement in working memory. However, Dudchenko et al have shown that 
hippocampectomised rats can still complete the OST task and recent data from our 
laboratory also supports this finding. Rats implanted with bilateral cannulae into the 
hippocampus were examined on the OST: Local administration of nicotine (2, 4 or 8µg) 
failed to improve OST performance in both control and ketamine-treated animals. 
Performance was, however, improved with systemic nicotine administration in the same 
subjects, suggesting that there is a lack of hippocampal contribution to mediating the OST 
and that the systemic effect of nicotine on OST performance is unlikely to be mediated by 
this region (Mitchelmore et al, 2012, unpublished data). This does not rule out any 
contribution of the hippocampus but indicates that it is unlikely to be the main brain region 
mediating this effect.   
Evidence that the PFC may instead play a significant role comes from Enomoto et al 
(2009). They examined the effect of sub-chronic ketamine treatment on working memory 
performance using the delayed spatial win-shift radial arm maze which is dependent on a 
neural circuit containing the mPFC and hippocampus along with dopaminergic inputs. 
They found that 10-day ketamine treatment impaired performance on the PFC-dependent 
task but not a hippocampally dependent random foraging task (Enomoto and Floresco, 
2009). These findings suggests a contribution of the PFC to non-spatial working memory 
and supports the outcomes of the current study: Data presented here demonstrates that local 
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administration of GABAA antagonist muscimol could impair the OST performance of 
control subjects. However, Horst et al (2009) also discovered that local muscimol into the 
PFC can impair spatial working memory. As Dudckenko et al (2000) have shown that 
activation of the hippocampus is needed in order to complete a spatial version of the OST, 
it may be that there is a combined role for both the hippocampus and PFC in spatial 
working memory tasks. This is supported by Yoon et al (2008) who examined the effect of 
both dorsal-hippocampal and mPFC inactivation, using muscimol, on the ability of rats to 
successfully complete a delayed alternation task. This was a figure 8 maze requiring the 
animals to alternate arms for a food reward. They found that inactivation of either brain 
region resulted in task impairments but that the nature of these impairments was different: 
Inactivation of the mPFC caused impairment of working memory but not reference memory 
compared to dorso-hippocampal inactivation which impaired both memory functions. This 
demonstrates that both regions are involved in working memory and indicates a synergistic 
effect of having both regions intact (Yoon et al, 2008). 
The fact that the hippocampus and mPFC contribute to differing memory functions may 
serve to explain the effects of local muscimol administration to the mPFC of ketamine-
treated subjects: These animals did not show any significant deficits in OST performance 
indicating that basal performance of the OST for animals treated with ketamine is not PFC 
dependent. Therefore, another brain region, such as the hippocampus, may be mediating 
low level working memory performance. However, Mitchelmore (2012) demonstrate that 
rats with ketamine-induced deficits that were administered muscimol directly into the 
hippocampus, did not display any reduction in OST performance (Mitchelmore et al, 2012). 
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This indicates that other brain regions may be involved or that local muscimol 
administration may not have fully inactivated the PFC, leaving basal function intact.  
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8.5 Conclusions 
The data presented in this chapter indicate a significant role for the PFC in mediating OST 
performance. There are significant deficits in PFC-dependent memory in patients with 
schizophrenia and MRI studies also demonstrate that patients have reduced PFC volume 
(Volpe et al, 2012): The OST in rodents may therefore provide a translational model for the 
development of novel compounds to treat neuropsychiatric disorders such as schizophrenia.   
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Chapter 9 
General Discussion 
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9.1 Main Findings 
The overarching outcome of this research indicates that nAChRs do represent viable targets 
for the treatment of cognitive deficits in schizophrenia with a potential role for both the α7 
and α4β2 nAChRs in reversing impaired cognitive performance. The use of the sub-
chronic, sub-anaesthetic 10mg/kg ketamine dosing regimen has repeatedly been shown to 
induce stable and long-lasting deficits in the OST. These cognitive deficits translate to 
those seen in patients with schizophrenia, as they are not ameliorated following treatment 
with currently used or novel antipsychotics. Acute local injection of nicotine has 
demonstrated that the nAChRs in the mPFC mediate improvements in OST performance. 
Contribution of the mPFC region was further supported by local administration of 
muscimol to the mPFc which induced impairment in the OST. A neural correlate model of 
fast network oscillations was developed, providing a potential mechanism behind the 
behavioural data: Activation of nAChRs in the PrL region of the mPFC mediated 
enhancement of gamma frequency oscillations. Compounds which target nAChRs in the 
PFC may therefore prove to be a useful adjunct therapy in combination with current 
treatments, providing more targeted relief for the heterogeneous symptoms seen in this 
disorder. 
9.1.1 Sub-anaesthetic, sub-chronic ketamine in the OST as a model of cognitive 
deficits 
This body of work has demonstrated that a sub-anaesthetic, sub-chronic ketamine dosing 
regimen in the OST may be a useful tool for examining novel compounds for the treatment 
of CDS. The ketamine-induced deficits were dose-dependent and the 10mg/kg dose was 
chosen since it produced a marked deficit and thus provided a window to observe cognitive 
enhancement by psychoactive drugs.   
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The ketamine dosing regimen described in this body of research may prove to be a valuable 
alternative to the commonly used PCP treatment. The use of ketamine is advantageous in 
that it only needs to be given once daily for 5 days in comparison to the twice daily for 7 
days regimen commonly used in sub-chronic PCP dosing. From an animal welfare 
perspective, the ketamine regimen presents more than a 60% reduction in the number of 
injections the animals receive: This aligns well with the aims of the 3 Rs to reduce the 
suffering of animals used in experimental procedures, without compromising on research. 
In addition, the 5 day regimen logistically fits in better to the normal working week, and 
working day.  
9.1.2 PCP as an alternative to ketamine: Differences pre-clinically in response to 
antipsychotic treatment. 
The PCP model has been repeatedly shown to induce cognitive deficits in a wide range of 
tasks (For review see Neill et al, 2010). In order to assess whether the sub-chronic, sub-
anaesthetic 10mg/kg ketamine regimen is more reliable in producing deficits than the sub-
chronic PCP regimen, it would be necessary to examine the PCP regimen in the OST. 
Comparison of the sub-chronic ketamine and PCP regimens on the OST would be useful as 
although one of the significant advantages of using ketamine pre-clinically is that it is also 
used in the clinic, the 5 day regimen may be more similar to studies examining people who 
abuse ketamine rather than the single acute dose which is licensed for use in clinical 
experiments with healthy subjects. However, (Javitt et al 2012) report that whilst acute 
ketamine administration does not induce auditory hallucinations, behaviours associated 
with such phenomena in monkeys, including increased scanning behaviour, were observed 
during sub-chronic but not acute ketamine administration (Javitt et al, 2012). In addition, 
the sub-chronic, sub-anaesthetic ketamine regimen has been shown to induce deficits in the 
OST that are not reversed with either acute clozapine or LY404039 treatment. This is in 
line with clinical findings where several weeks of treatment are needed before any changes 
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are noted, but in contrast to other preclinical models where atypical antipsychotics are often 
effective after a single dose: Atypical antipsychotics such as clozapine and olanzapine have 
been shown to be effective in reversing cognitive deficits in models using PCP which is 
also in contrast to the clinic where patients often gain little improvement after a single dose 
(Abdul-Monim et al, 2006; Dunn and Killcross, 2006; Grayson et al, 2007). This suggests 
that the sub-chronic ketamine regimen may provide improved predictive validity for the 
development of novel compounds in that false positives are less likely. This being said only 
clozapine and LY404039 have been examined to date and thus further examination of other 
typical and atypical antipsychotics is necessary for this finding to be confirmed. In addition, 
it would be useful to determine whether the effect of chronic exposure to antipsychotic 
treatment also follows typical clinical outcomes in the OST.  
9.1.3 Nicotine as a treatment for CDS: Ethical considerations? 
The finding that systemic and local administration of nicotine directly into the mPFC was 
able to reverse the deficits induced by ketamine is indicative of nAChRs as viable targets 
for the treatment of CDS. As nicotine has such a profound effect, it could be argued that an 
effective and low-cost option could be to prescribe nicotine patches or gum as an adjunct 
therapy for the treatment of CDS. However, nicotine has dependence-producing effects and 
additionally is able to improve the performance of control subjects: Both of these factors 
raise ethical considerations, although restrictions over use could control the latter. This 
means that the development of a non-addictive compound, which targets the specific 
nAChRs involved in mediating enhanced cognition, is more favourable.  
9.1.4 Enhanced gamma oscillations as a mechanism of cognitive enhancement in the 
OST 
Local administration of nicotine to the mPFC induced similar levels of enhanced OST 
performance to systemic administration, indicating that there is a significant contribution of 
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nAChRs in this region. This was further confirmed by the fact that local administration of 
muscimol into the mPFC impaired task performance. When nicotine was applied to the PrL 
region of the PFC in an in-vitro brain slice preparation, gamma frequency oscillations were 
significantly increased. Gamma frequency oscillations increase with increased working 
memory load and are impaired in patients with schizophrenia. Therefore it may be that the 
mechanism by which nicotine is mediating improved performance in the OST is through 
enhancing gamma frequency oscillations, although this has only been examined in normal 
subjects thus far. The fact that application to the PrL region improved gamma oscillations 
also correlates with the behavioural findings that the PFC is heavily involved in the 
mediation of the OST task. 
9.1.5 The α7 nAChR as a drug target for treatment of CDS 
It is likely that there is a role for the α7 nAChR in mediating the effect of nicotine on OST 
performance as the α7 agonist PHA and allosteric modulators PNU and Compound T were 
able to improve performance in the OST. The α7 nAChR antagonist MLA also impaired 
performance in ketamine treated animals. This would indicate that the α7 nAChR is a 
viable target in terms of developing novel compounds for CDS. Both type I and type II 
allosteric modulators were able to restore performance to baseline levels where as PHA did 
improve OST performance but did not fully restore to baseline. 
This suggests that in terms of drug development, allosteric modulation which incorporates 
lowering the activation threshold of the α7 nAChR, may be more effective than direct 
agonism. This is supported by McLean and colleagues (2011, 2012) who demonstrate that 
PNU-282297 and PNU-120506 can reverse deficits in cognitive tasks such as reversal 
learning, novel object recognition and the attentional set shifting task (McLean et al, 2011; 
McLean et al, 2012). However, it would be useful to examine other α7 agonists in the OST 
to confirm the findings with PHA120596. In terms of mechanism, α7 nAChR activation by 
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endogenous or exogenous agonists causes calcium influx and in turn the induction of 
calcium induced calcium release (CICR). This in turn activates the ERK1/2-dependent 
pathways, leading to the phosphorylation and activation of synapsin-1, a key protein in the 
synaptic neurotransmitter vesicle release machinery (figure 9.1) (Dickinson et al, 2008). 
The α7 nAChR does not appear to mediate the enhancing effect of nicotine on control 
subjects as neither systemic administration of agonists or allosteric modulators for this 
receptor improved performance in the OST. In addition, bath application of α7 nAChR 
agonist PHA was also unable to enhance gamma frequency oscillations. However, there is 
clearly some contribution of the α7 nAChR as MLA was able to induce deficits in control 
animals. Ethically, it may be beneficial that compounds targeting this receptor are unlikely 
to enhance cognition in control subjects as there is significant controversy surrounding the 
widespread use of cognitive enhancers. For example, does a student who revises and takes 
an exam with a cognitive enhancer on board have an unfair advantage over a student who 
does not? Similarly, will employees feel under pressure to take such compounds if they 
were available over the counter, in order to keep ahead of their peers or competitors? If 
compounds for CDS were only effective in those with deficits, this problem would be 
avoided. Having said that, if a drug which has cognitive enhancing effects in the normal 
population has appropriate restrictions, this should not be a problem. Ultimately, 
compounds which target the α7 nAChR may prove to be a useful adjunct therapy for CDS, 
as well as other disorders which feature cognitive deficits. 
9.1.5 The α4β2 nAChR as a drug target for treatment of CDS 
Restoration of ketamine-induced deficits on the OST by nicotine is also likely to be 
mediated by the α4β2 nAChR, as the α4β2 nAChR agonist’s metanicotine and 5IA were 
both able to fully reverse ketamine-induced deficits. As these agonists were able to fully 
restore baseline performance, it may be that the α4β2 nAChRs are more involved that α7 
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nAChR, or this may simply be because there are higher numbers of α4β2 nAChRs in the 
PFC than α7 nAChRs in the PFC: The region where local injection work indicates the OST 
is likely to be mediated. The α4β2 nAChR is therefore another viable drug development 
target for the treatment of CDS. However, the α4β2 nAChR may also have a role in 
mediating the enhancing effect of nicotine in control animals as in contrast to agonists for 
the α7 nAChR, the α4β2 nAChR agonist metanicotine was able to improve the performance 
in control animals. This means that there could be ethical concerns in the development of 
cognition-enhancing compounds which target this receptor as they could improve 
performance in those with no clinical deficit. Despite this, further clarification is needed, as 
another α4β2 nAChR-specific agonist, 5IA, failed to enhance performance of control 
subjects. In addition, application of 5IA to the PrL region of the rat mPFC did not improve 
gamma frequency oscillations in an in-vitro brain slice model, which may be explained by 
Tsutsui-Kimura et al (2010) who found that nicotine stimulates α4β2 nAChRs in the IL 
region but not the PrL region of the PFC. This further suggests that whilst the current in-
vitro findings correlate with behavioural work, it may be other brain mPFC brain regions, 
such as the IL or Cg1 which mediate the effect of nicotine on the OST (Tsutsui-Kimura et 
al, 2010).  
Mechanistically, the α7 nAChR and the α4β2 nAChR elicit their effects through differing 
processes: Although the exact mechanism for α4β2-induced neurotransmitter release is not 
yet known, the α4β2 nAChR has low calcium ion permeability in comparison to the α7 
nAChR. In addition, Dickinson et al (2008) have shown that activation of α4β2 nAChRs by 
5IA does not induce neurotransmitter release through CICR and activation of the ERK1/2-
synapsin-1 pathway as is the case for α7 nAChRs (figure 9.1). Despite these clear 
mechanistic differences, activation of both the α7 and α4β2 nAChRs has been shown to 
enhance GABAergic inhibition onto pyramidal neurons, as well as increasing DA release in 
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the PFC. This means that the net effects of activation at both of these receptors are similar, 
which may give further insight into the mechanisms behind improving cognition. 
Taken together the research undertaken for this thesis indicates that sub-chronic, sub-
anaesthetic administration of ketamine in the OST is a useful model of CDS in a 
prefrontally-driven task. Additionally, the α7 and α4β2 nAChRs are both viable targets for 
the development of novel compounds to treat CDS and may elicit their enhancing effects 
through enhanced gamma frequency network oscillations. 
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Figure 9.1: The downstream effects of α7 nAChR activation  
 
  
Figure 9.1 A: α7 nAChR activation by endogenous or exogenous agonists causes calcium influx and in turn 
the induction of calcium induced calcium release (CICR). This in turn activates the ERK1/2 pathways, 
phosphorylating synapsin 1 which induces vesicle binding to the synaptic membrane and neurotransmitter 
release. B: Glutamate acts at ionotropic receptors on DA neurons, increasing DA release which can shape 
working memory processes by influencing the fidelity of synaptic transmission and facilitating long term 
potentiation. In addition, activation of metabotropic receptors on GABAergic interneurons facilitates GABA 
release, increasing the synchrony and size of gamma oscillations which are also central to working memory 
processes and aberrant in patients with schizophrenia 
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9.2 How will these results impact on patients? 
This body of research demonstrates that nicotine is able to improve cognition in animals 
that were impaired on a prefrontally–driven cognitive task. This supports findings with 
patients who have schizophreniethicala who are proposed to treat their cognitive deficits by 
tobacco smoking.  This research found that α7 nAChRs are likely to be involved in 
mediating positive effects of nicotine on and are thus a viable target for the development of 
novel compounds. Partial α7 nAChR agonist DMBX-A has been clinically tested in 
patients with schizophrenia by Olincy et al (2006). They found that on the Repeatable 
Battery for the Assessment of Neuropsychological Status total scale score, patients treated 
with DMXB-A demonstrated significant neurocognitive improvement in comparison to 
placebo treatment (Olincy et al, 2006).  
However, the study by Olincy and colleagues (2006) was in a small group of non-smoking 
patients (Olincy et al, 2006). Freedman et al (2008) examined DMXBA in a larger group of 
patients using the MATRICS test battery. Patients were tested over 3 treatment arms. 
Overall, DMXB-A was not found to have any significant effect on cognitive measures but 
this was, in part, attributed to strong effects of test repetition where it was observed that 
subjects improved markedly in their performance over 4 months. When the initial treatment 
arm was examined individually, a significant improvement in both attention/vigilance and 
working memory was seen with DMXB-A treatment compared to placebo (Freedman et al, 
2008). However, other cognitive measures still failed to demonstrate any improvement. In 
the current work, PHA did improve cognitive performance of ketamine subjects but this 
was not as significant as when treated with nicotine (Chapter 5).  In contrast, both α7 
nAChR PAMs, PNU-120596 and Compound T, produced robust improvements when 
examined in the OST (Chapter 6). Thus, it may be useful to examine the effect of α7 
nAChR PAM in a clinical setting, as this may provide a superior outcome in comparison to 
α7 nAChR agonism. 
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This study also found that α4β2 nAChRs might prove to be valuable targets for the 
treatment of CDS. The results presented here demonstrated the enhancing effects of α4β2 
nAChR agonists but promising work has recently been published by Timmerman and 
colleagues (2012) using NS9283, an α4β2 nAChR PAM. They found that NS9283 
improved social recognition as well as performance in the 5CSRTT and MWM 
(Timmermann et al, 2012). These positive findings regarding the α4β2 nAChR means that 
preclinical as well as clinical studies are warranted in order to develop new treatments for 
CDS which target this receptor. 
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9.3 Limitations of the OST 
Whilst the OST may have been successfully used for the purposes of this research, there are 
several shortcomings which could be addressed. The main concern is that measurement of 
performance in this task is subjective: It is the decision of the investigator as to what 
constitutes a ‘dig’ and what is simply sampling. This concern was overcome in these 
experiments by experimenter blinding, as well as strictly defining a dig as the displacement 
of digging media. However, although these measures go a significant way to ensuring that 
the results of these experiments are consistent, it is likely that there will be slight 
differences in scoring between different laboratories. There is also the issue of training 
methods: As with people, different rats learn the task at different rates and how these rats 
are trained may also differ slightly from person to person and laboratory to laboratory.  In 
our laboratory, rats consistently plateau at a span score between 6 and 8, but other 
laboratories train animals to a point where they can achieve span scores of 20 and above. 
When our animals were trained to this level by an undergraduate student, it was found that 
ketamine did not impair their performance on the task. This illustrates that training 
technique and individual judgement are significant factors in this task and make extensive 
handover training essential for any new person running the task in order for results to be 
comparable.  
Although every care was taken to prevent scent marking, this is still a mechanism by which 
rats could successfully discriminate between novel bowls, and those previously sampled. 
This was controlled for by changing bowls for new ones with the same odour at random 
points during training as well as replacing any bowls that were obviously marked.  
Animals were exposed to all 24 scents in a short period of time, the order of which was 
pseudo-randomised for each testing and training session using a random letter chart: 
However even though a ratio of 3g of scent to every 100g of woodchip was used, there was 
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no easy way to control for the individual strength or appeal of each scent. For example, 3g 
of cumin has a significantly stronger odour than 3g of cocoa powder. Despite this, each 
animal received the odours in the same order within each trial and so any effect this may 
have had would be consistent across the group, though scores may have been affected from 
day to day. 
The OST is a very time consuming task: It takes between 4 and 5 months to complete the 
training of one cohort of 24 animals and test one set of compounds. Each animal receives 
several doses of the test compound as well as vehicle. Repeated testing with several 
compounds in a single animal was avoided to prevent previous treatment from confounding 
findings. This approach is therefore costly in both time and money.  
The OST is also still a relatively new task and with each laboratory training their animals in 
a slightly different way, time frame and even apparatus, significant further research using 
this task is needed in order to refine the protocol.  
In order to improve the efficiency of the OST, an automated OST could be developed. An 
initial prototype could be built using three nose-poke walls from a standard skinner box 
(figure 9.2).   Animals would be presented with increasing set of odours as in the OST. 
However, these odours could be sampled through a hole in the test wall, similar to a nose-
poke space. Odours behind each slot could be in moveable, cylindrical holding pots with 
small holes on the side so the spice can be scented by the rat.  Instead of digging in bowls 
for a food reward, animals therefore learn to nose poke to indicate a choice. If this choice is 
correct, a pellet is dispensed on the other side of the arena. Retrieval of the pellet then 
triggers the start of the next trial. During pellet collection and consumption, a pick and 
place robot could move the various odours to new slots. This ensures that, as with the 
manual OST, the automated task is not reliant upon spatial working memory.  
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There are a number of benefits to automating the OST, the main benefit being that this test 
would then be standardised between laboratories. Animals would also be less able to scent 
mark and as the experimenter is only required to place, or remove animals from the 
experimental apparatus; one experimenter could essentially train as many animals as 
apparatus was available. The development of the automated OST would increase the level 
of throughput which means that this task would be a more viable option for the 
pharmaceutical industry. If the OST can be used in the industrial as well as academic 
environment, the yield in the development of novel compounds for CDS is likely to be 
significantly higher. 
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Figure 9.2: The automated OST 
 
 
  
A 
B 
Figure 9.2 A: A diagrammatic representation of the automated OST. The animals would sample 
the odours from the top hole and nose poke in the bottom hole to indicate a choice. An incorrect 
choice would signify the end of the test, or retrial, and a correct choice would trigger a food pellet 
reward. Retrieval of the reward would then trigger the start of the next trial. Automating the OST 
would provide a way of both standardising OST training and testing between laboratories as well 
as increasing the efficiency of the task with regard to testing novel compounds. 
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9.4 Weaknesses of this research 
 
In the body of this research, the aim has been to draw the most logical conclusions based on 
what is presented within the current literature. However, there are other possibilities and 
more abstract explanations for these findings. For example, there is the possibility that 
ketamine could alter blood/brain barrier permeability or have a direct impact on the 
mechanism by which nicotinic agonists work, although we are yet to find evidence for such 
explanations. Additionally, there is the possibility that ketamine and indeed nicotine could 
simply be affecting smell. If ketamine impaired smell and nicotine enhanced smell, this 
could explain the findings that we are interpreting as impaired and enhanced OST 
performance. However, the finding that local administration of nicotine into the PFC 
(which should leave olfaction unaffected) improves OST performance supports the theory 
that it is memory specifically which is being affected. Also, if ketamine treated animals are 
given a trial of many sets of just two odours to choose from, they can achieve a normal 
span score. It is when this is increased to more than two that errors are made. In addition, 
the sub-chronic ketamine regimen used in this task does not affect the simple 
discrimination or compound discrimination of set shifting (Shoaib, 2013). This supports the 
idea that both of these compounds are affecting cognitive processes as opposed to olfaction.  
Local injection of nicotine cannot be directly compared to the systemic administration of 
nicotine as the brain concentration of the systemic nicotine is unclear. In addition, the 
intracerebral distribution over time is unknown as one dose of methylene blue was given 
and brains taken at approximately 5 minutes. This means that it is possible that the OST 
was carried out at a point where the drug was still very local or widely distributed and 
affecting other brain regions. One way to overcome this would be to give several groups of 
rats methylene blue and cull at differing time point to assess brain distribution over time. 
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This could then be correlated with the time course for completion of the OST which would 
give a more accurate picture of drug distribution. 
Another weakness is that only one behavioural test was used as a result of the time 
consuming nature of the OST. In addition the OST has only one outcome measure in the 
testing phase. This is because any error in performance indicates the end of the task. Other 
factors which could be measured such as search strategies would be useful and could be 
accomplished perhaps by using a camera and behavioural tracking software such as that 
used in the open field test. It would be prudent in future to directly test for non-specific 
effects such as motor function. This could be achieved by running additional tests alongside 
the OST such as the open field test, rotarod task and attentional set shifting task. That being 
said, the OST is very time consuming and so additional tasks would need to be chosen 
carefully. 
The gamma frequency network oscillation data was only carried out on brain tissue from 
uncompromised animals. A significant strengthening of this data would have come from 
also carrying out these experiments in animals which had been treated with ketamine. 
Unfortunately this was not completed as there was a limited amount of time available in the 
electrophysiology lab. In addition, another student whose complete project surrounded the 
effects of ketamine on gamma oscillations was due later on to carry out similar experiments 
and so it was felt that it was inappropriate for them to be carried out twice or for me to 
complete these studies first.  
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9.5 Future research 
In the PrL region of the PFC, which has been described as the most morphologically 
similar region to the primate DLPFC, gamma frequency oscillations can be generated in an 
in-vitro brain slice model. McNally et al (2011) have shown that in the PrL, the NMDA 
antagonist ketamine can increase the area power of gamma frequency oscillations. This is a 
conflicting finding in that NMDA antagonism is often used to model CDS and increasing 
gamma frequency oscillations is associated with improved cognition. However, it may be 
that acute NMDA antagonism, which produces many of the positive symptoms of 
schizophrenia, does not induce cognitive deficits with the drug on board.  Instead, it may be 
that repeated exposure to NMDA antagonists is required to induce a reduction in gamma 
frequency oscillations. Work by Gilloughley et al (2012) however found that acute 
application of ketamine reduced gamma frequency oscillations in the Cg1 regions of the 
PFC. It would therefore be a logical next step to examine the effect of the sub-chronic-sub-
anaesthetic 10mg/kg ketamine regimen in the in-vitro brain slice model. Animals would be 
treated in the same way as for the OST, including a 6 day wash-out, the point at which 
deficits are evident behaviourally. If a reduction in gamma oscillations was evident, then 
nicotine and subtype-selective nAChR agonists could be examined. If these results were 
found to correlate with behavioural data, it may provide a reasonably high-throughput 
method for screening novel compounds before testing them in the full behavioural model.  
It would also be interesting to assess the effect of nicotine and ketamine treatment on the 
generation of oscillatory activity in both the anterior cingulate and infralimbic regions: This 
would give further insight as to whether the mPFC as a whole is involved in mediating the 
effect of nicotine on gamma oscillations or whether this process is sub-region specific. 
Knowledge of which brain regions mediate the effects of nicotine may help in the 
development of novel compounds that target nAChRs. In addition, further examination of 
the contribution of α4β2 nAChRs in mediating gamma frequency oscillations in all regions 
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of the mPFC would be useful in order to elucidate their contribution to the effect of nicotine 
on gamma frequency oscillations and also on OST performance.  
In line with this, it would also be important to examine the effect of a sub-chronic, sub-
anaesthetic ketamine regimen on the expression of PV positive neurons in the PFC. Carlen 
et al (2012) demonstrate a critical role for NMDA receptors in PV positive interneurons by 
selectively knocking out these receptors in PV positive neurons alone. Although baseline 
oscillations were increased, the induction of gamma frequency oscillatory activity was 
impaired following optogenetic drive onto PV positive neurons, which correlated with 
animals exhibiting significant cognitive impairments (Carlen et al, 2012). McKibben et al 
(2010) have also demonstrated that PV positive interneurons in the PFC are reduced 6 
weeks after sub-chronic treatment with NMDA antagonist phencyclidine. This was 
specifically observed in the PrL region but not the IL or cingulate cortices (McKibben et al, 
2010). Examination of a sub-chronic, sub-anaesthetic ketamine regimen would compliment 
these studies and further our understanding of the brain regions involved in mediating the 
effect of ketamine on the OST. Taken together, these studies may help to determine the 
sub-region of the mPFC where ketamine is likely to be exerting an effect, along with 
whether nicotine or nicotinic agonist treatment is mediating restoration through the same, 
different or a combination of sub-regions.  It could then be established whether or not the 
effect of ketamine and subsequent restoration by nAChR activation correlates to the size 
and synchrony of gamma frequency oscillations. 
As all of the electrophysiological studies so far have examined extracellular field potentials, 
it would be useful to examine the effect of acute and sub-chronic ketamine, nicotine, 
selective nAChR agonists, antagonists and allosteric modulators intracellularly. This would 
help to further determine the cellular processes involved in the changes induced by these 
compounds which in turn may lead to novel targets for the treatment of CDS. 
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Behaviourally, one option would be to examine the effect of local administration of 
selective nAChR agonists and PAMs in the mPFC to see whether this replicates systemic 
administration. Additionally, as it would also be useful to explore the contribution of other 
brain regions to the OST through local administration of nAChR agonists or area specific 
lesions. Recent work by our group has established that local administration of nicotine to 
the hippocampus has no effect on the OST, which in contrast, significantly improves 
performance when given systemically to the same subjects. This means that there is 
unlikely to be a significant contribution of the hippocampus in mediating the OST, but the 
contribution of other regions with input to the PFC such as the entorhinal cortex or the 
ventral tegmental area (VTA) is yet to be elucidated.  
It would also be valuable to explore the possibility of automating the OST, as described 
above although this is potentially a PhD thesis project in itself. 
Overall, this thesis has discovered that nAChRs are viable targets for the development of 
novel drugs for the treatment of CDS. These findings may help to progress development of 
compounds which target these receptors and help to improve the lives of patients suffering 
with this disorder.  
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